Führend in Alzheimer Forschung! PRANA Biotech.

Beiträge: 150
Zugriffe: 28.638 / Heute: 4
Prana Biotechnolo.
kein aktueller Kurs verfügbar
 
Prana Biotechnolo.
kein aktueller Kurs verfügbar
 
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Führend in Alzheimer Forschung! PRANA Biotech.

2
15.04.04 20:24
#1
PRANA BIOTECHNOLOGY LTD PRAN an der Nasdaq zu ordern!

ein Biotechnologie Wert aus Australien,

In Deutschland wird der Wert auch gehandelt und als ADR Wert, an der Nasdaq!

Empfhele den Wert in großen Mengen an der Nasdaq zu ordern. Das Handelvolumen übersteigt, das der Heimatbörse, und das will was heißen!  

Werbung

Entdecke die beliebtesten ETFs von Xtrackers

Xtrackers MSCI Japan UCITS ETF 1D
Perf. 12M: +155,87%
Xtrackers MSCI Pakistan Swap UCITS ETF 1C
Perf. 12M: +64,68%
Xtrackers Artificial Intelligence and Big Data UCITS ETF 1C
Perf. 12M: +52,81%
Xtrackers MSCI USA Communication Services UCITS ETF 1D
Perf. 12M: +48,05%
Xtrackers S&P 500 2x Leveraged Daily Swap UCITS ETF 1C
Perf. 12M: +45,34%

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Drugs to watch!

 
15.04.04 20:27
#2
MELBOURNE, Australia, Mar 25, 2004 /PRNewswire-FirstCall via COMTEX/ -- Prana
Biotechnology Limited (ASX: PBT; Nasdaq: PRAN) today announced that Forbes.com
has added Prana to its list of "neurological drugs to watch," highlighting the
most promising experimental drugs to treat diseases of the brain and nervous
system.

Harvard University's Professor Ashley Bush, M.D., Ph.D., is described as a
"provocative scientist", whose approach to treating Alzheimer's Disease is
distinct from that of most big drug companies. Dr. Bush argues that copper and
zinc interact with proteins in the brain (beta-amyloid) to make them toxic.

Professor Bush has recently entered into a 10-year extension consultancy
agreement with Prana.

To obtain the article of Forbes 'Neurological Drugs to Watch', please go to:
www.forbes.com/2004/01/26/cx_mh_rl_neurotearsheet_print.html

About Prana:

Prana is a Melbourne-based biotechnology established in 1997 to commercialize
research into Alzheimer's disease and other major age-related degenerative
disorders (ASX: PBT; Nasdaq: PRAN). Prana's technology was discovered by the
company's researchers at prominent international institutions including
Massachusetts General Hospital at Harvard Medical School, the University of
Melbourne and the Mental Health Research Institute in Melbourne.

SOURCE Prana Biotechnology Limited



CONTACT:          Media: Ivette Almeida of The Anne McBride Co., +1-212-983-1702,

                 ext. 209, ivette.almeida@annemcbride.com, or Investor: Steven Silver of The

                 Anne McBride Co., +1-212-983-1702, ext. 212, silver@annemcbride.com, both for

                 Prana; or Company: Geoffrey Kempler, Executive Chairman, Prana Biotechnology

                 Limited, +61-3-9690-7892, gkempler@pranabio.com



URL:              www.pranabio.com

www.prnewswire.com


Copyright (C) 2004 PR Newswire.  All rights reserved.

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

An der Heimatbörse AUS heute 9 % Plus!

 
16.04.04 05:47
#3
Nachdem die Vorgaben in USA schon positiv waren!

PBT Kürzel an der ASX

www2.tradingroom.com.au/apps/qt/quote.ac?section=chart&code=PBT
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Es gibt News!

 
16.04.04 06:02
#4

www2.tradingroom.com.au/news_research/index.jsp?
section=news_search&page=http%3A%2F%2Fnewsstore.f2.com.au%2Fapps%2FviewDocument.
ac%3Fsy%3Dtpl_nws%26ss%3DTPL%26docID%3DGCA00429396PBT%26backTo%3Dhttp%3A%2F%2Fwww2.
tradingroom.com.au%2Fapps%2Fqt%2Fquote.ac%3Fcode%3DPBT%26sy%3Dtpl­%26section%3Dca

Medikament zeigt Erfolge in 2. Klinischer Phase!
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Mein Tip! Heute noch ordern!

 
16.04.04 13:48
#5
In Berlin oder USA PRAN ADR WERT

in USA ist noch Kurspotential heute drin von 6.20 auf 6.80 mind. da austr. Kurs!

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Keiner interessiert? Tja heute Plus 50 %!!! o. T.

 
16.04.04 16:55
#6
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Weil ich nicht Grenke und Co heiße kein Interese?

 
19.04.04 10:04
#7
Interesse mit zwei ss ging nicht mehr rein!

Braucht euch nicht wundern, warum ich interessante
Werte nicht mehr poste!
Interessiert hier sowieso keinen!

Grenke und andere bekannte Namen sind hier im forum beliebter!

Und meine Werte sind auf Pushen nicht angewiesen, da meist an der Nasdaq notiert!

Da bringen die paar Umsätze aus Deutschland gar nichts.

Heute In australien 8,8 Mio
in USA am Freitag umgerechnet auf die ADRS waren es
6,11 Mio bzw. 611 TSD in 10 er Stückelung!

Führend in Alzheimer Forschung! PRANA Biotech. Optimal
Optimal:

hups ... laß dich nicht verunsichern

 
19.04.04 14:09
#8
lesen bestimmt mehr Leute - lagst doch ziemlich gut in lezter Zeit

hätt ich mal auch ein paar deiner Empfehlungen kaufen sollen ... aber ich hab immo eine kleine Blockade - außerdem lese ich das Hot Stocks Forum nicht mehr besonders

RIM ist ja auch noch gut weitergelaufen


Grüßle :-)
Führend in Alzheimer Forschung! PRANA Biotech. pebi
pebi:

Prana Biotech ist

 
19.04.04 14:30
#9
in Deutschland ein sehr marktenger Wert mit geringen Umsätzen. Nicht jeder hat die Möglichkeit, direkt an den Heimatmärkten zu ordern (ich z.B.). Ich lese trotzdem deine Empfehlungen !!  
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

an der Nasdaq zu kaufen! @pebi

 
19.04.04 15:52
#10
Prana Biotech kauft man an der Nasda, Kürzel PRAN und ist nicht tuer in USA bei den Banken uzu ordern!

Kurs aktuell!

PRANA BIOTECHNOLOGY LTD - Nasdaq SmallCap Market: PRAN

Real-time ECN Quote*
Last Change (%) After Hours Chg (%)** Trade Time Bid Ask
7.80  0.98 (11.16) N/A 09:50 7.80 (2) 7.90 (4)

--------------------------------------------------
Exchange QuoteLast Change (%) Trade Time Bid (size) Ask (size)
8.27  0.51 (5.81) 09:30 8.61 (4) 8.69 (50)
Latest Ticks Prev Close Open Low High
==-- 8.78 8.74 8.27 9.09
Day Volume Avg Day Vol VWAP 52 Wk Low 52 Wk High
52,015 210,800 8.7174 2.95 10.50
# of Trades Last Size Avg Trade Size P/E Ratio Market Cap (mil)
69 1,000 754 0


WKN in Deutschland für Nasdaq ist 753907
Führend in Alzheimer Forschung! PRANA Biotech. pebi
pebi:

Danke, gs

 
19.04.04 17:08
#11
sind ja tolle Umsätze in NJ, in Berlin aber noch keine einzige Aktie gehandelt heute
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Aktuelle Analyse!

 
23.04.04 13:55
#12

VectorVest Stock Analysis of Prana BiotchADR as of 4/22/2004

 
Business: PRANA BIOTECHNOLOGY LTD -ADR, (PRAN) Seeks to commercialize research into Alzheimer's disease and other major age-related degenerative disorders. The company's mission is to develop diagnostic and therapeutic drugs to treat the central disease pathways that cause degeneration of the brain
 
Price: PRAN closed on 4/22/2004 at $7.39 per share  
 
Value: Value is a measure of a stock's current worth.  PRAN has a current Value of $1.04 per share. Therefore, it is overvalued compared to its Price of $7.39 per share.  Value is computed from forecasted earnings per share, forecasted earnings growth, profitability, interest, and inflation rates. Value increases when earnings, earnings growth rate and profitably increase, and when interest and inflation rates decrease. VectorVest advocates the purchase of undervalued stocks. At some point in time, a stock's Price and Value always will converge.  
 
RV (Relative Value): RV is an indicator of long-term price appreciation potential. PRAN has an RV of 0.15, which is very poor on a scale of 0.00 to 2.00. This indicator is far superior to a simple comparison of Price and Value because it is computed from an analysis of projected price appreciation three years out, AAA Corporate Bond Rates, and risk. RV solves the riddle of whether it is preferable to buy High growth, High P/E stocks, or Low growth, Low P/E stocks. VectorVest favors the purchase of stocks with RV ratings above 1.00.
 

RS (Relative Safety): RS is an indicator of risk. PRAN has an RS rating of 0.85, which is fair on a scale of 0.00 to 2.00. RS is computed from an analysis of the consistency and predictability of a company's financial performance, debt to equity ratio, sales volume, business longevity, price volatility and other factors. A stock with an RS rating greater than 1.00 is safer and more predictable than the average stock in the VectorVest database. VectorVest favors the purchase of stocks of companies with consistent, predictable financial performance.
 
RT (Relative Timing): RT is a fast, smart, accurate indicator of a stock's price trend. PRAN has a Relative Timing rating of 1.40, which is excellent on a scale of 0.00 to 2.00.  RT is computed from an analysis of the direction, magnitude, and dynamics of a stock's price movements over one day, one week, one quarter and one year time periods. Once a stock's price has established a strong trend, it is expected to continue in that trend for the short-term. If a trend dissipates, RT will gravitate toward 1.00. RT will explode from bottoms, dive from tops, and reflect changes in price momentum. VectorVest favors the purchase of stocks with RT ratings above 1.00.  
 
VST (VST-Vector):  VST is the master indicator for ranking every stock in the VectorVest database. PRAN has a VST rating of 1.00, which is fair on a scale of 0.00 to 2.00. VST is computed from the square root of a weighted sum of the squares of RV, RS, and RT. Stocks with the highest VST ratings have the best combinations of Value, Safety and Timing. These are the stocks to own for above average, long-term capital appreciation. VectorVest advocates the purchase of safe, undervalued stocks rising in price. The efficacy of this indicator was demonstrated in a study conducted at the University of Chicago which showed that high VST stocks outperformed the S&P 500 by 583.1% over the six year period from 1996 through 2002.  
 
CI (Comfort Index): CI is an indicator which reflects a stock's ability to resist severe and/or lengthy price declines. PRAN has a CI rating of 1.26, which is very good on a scale of 0.00 to 2.00. CI is quite different from RS in that it is based solely upon a stock's long-term price history. VectorVest advocates the purchase of high CI stocks.  
 
GRT (Earnings Growth Rate): GRT reflects a company's one to three year forecasted earnings growth rate in percent per year. PRAN has a forcasted Earnings Growth Rate of -7.00%, which VectorVest considers to be very poor. GRT is computed from historical, current and forecasted earnings data. It is updated each week for every stock in the VectorVest database. GRT often foretells a stock's future price trend. If a stock's GRT trend is upward, the stock's price will likely rise. If GRT is trending downward, the stock's Price will probably fall. VectorVest favors the purchase of stocks whose GRT is rising and is greater than the sum of current inflation and interest rates, (7.54%).  
 
Recommendation (REC): VectorVest gives a Buy, Sell, Hold recommendation on every stock, every day. PRAN has a Hold recommendation. REC reflects the cumulative effect of all the VectorVest parameters working together. These parameters are designed to help investors buy safe, undervalued stocks rising in price. They also help investors avoid or sell risky, overvalued stocks falling in price. VectorVest recommends that investors buy high VST-Vector, Buy-rated stocks in rising markets.  
 
Stop (Stop-Price): Stop is an indicator of when to sell a long position or cover a short position.  PRAN has a Stop of $5.56 per share. This is $1.83 below PRAN's current closing Price. A stock's Stop is computed from a 13 week moving average of its closing prices, and is fine-tuned according to the stock's fundamentals. High RV, high RS stocks have lower Stops, and low RV, low RS stocks have higher Stops. In the VectorVest system, a stock gets a 'B' or 'H' recommendation if its Price is above its Stop and an 'S' recommendation if its Price is below its Stop.
 
EPS (Earnings per Share):  EPS stands for leading 12 months Earnings Per Share.  PRAN has a forecasted EPS of $-1.02 per share. VectorVest determines this forecast from a combination of recent earnings performance and traditional fiscal and/or calendar year earnings forecasts.  
 
P/E (Price to Earnings Ratio): P/E is a popular measure of stock valuation which shows the dollars required to buy one dollar of earnings.  PRAN has a P/E of -7.25. This ratio may be deemed to be high or low depending upon your frame of reference. The average P/E of all the stocks in the VectorVest database is 36.63. P/E is computed daily using the formula: P/E = Price/EPS.  
 
EY (Earnings Yield): EY reflects earnings per share as a percent of Price. EY is related to P/E via the formula, EY = 100 / (P/E), and may be used in place of P/E as a measure of valuation. EY has the advantages that it is always determinate and can reflect negative earnings. PRAN has an EY of -13.83 percent. This is below the current average of 2.74% for all the stocks in the VectorVest database. EY equals 100 x (EPS/Price).  
 
GPE (Growth to P/E Ratio): GPE is another popular measure of stock valuation. It compares earnings growth rate to P/E ratio. PRAN has a GPE rating of -0.97.  High growth stocks are believed to be able to justify high P/E ratios. A stock is commonly considered to be undervalued when GPE is greater than 1.00 and overvalued when GPE is below 1.00. Unfortunately, this rule of thumb does not take into account the effect of interest rates on P/E ratios. The operative GPE ratio of 1.00 is valid when and only when interest rates equal 10%. With long-term interest rates currently at 5.84%, the operative GPE ratio is 0.34. Therefore, PRAN may be considered to be overvalued.  
 
DIV (Dividend): VectorVest reports annual, regular, cash dividends as indicated by the most recent payments. Special distributions, one-time payments, stock dividends, etc., are not generally included in DIV. PRAN does not pay a dividend.  
 
DY (Dividend Yield): DY reflects earnings per share as a percent of Price. PRAN does not pay a dividend, so it does not have a Dividend Yield rating. . DY equals 100 x (DIV/Price). It is useful to compare DY with EY. If DY is not significantly lower than EY, the dividend payment may be in jeopardy.  
 
DS (Dividend Safety): DS is an indicator of the assurance that regular cash dividends will be declared and paid at current or at higher rates for the foreseeable future. PRAN does not pay a dividend, so it does not have a Dividend Safety rating . Stocks with DS values above 75 typically have RS values well above 1.00 and EY levels that are much higher than DY.

 
DG (Dividend Growth Rate): Dividend Growth is a subtle yet important indicator of a company's financial performance. It also provides some insight into the board's outlook on the company's ability to increase earnings. PRAN does not pay a dividend, so it does not have a Dividend Growth rating .  
 
YSG (YSG-Vector): YSG is an indicator which combines DIV, DY and DG into a single value, and allows direct comparison of all dividend-paying stocks in the database. PRAN does not pay a dividend, so it does not have a YSG rating . Stocks with the highest YSG values have the best combinations of Dividend Yield, Safety and Growth. These are the stocks to buy for above average current income and long-term growth.  
 
Open: PRAN opened trading at a price of $7.45 per share on 4/22/2004.
 
High: PRAN traded at a High price of $8.27 per share on 4/22/2004.
 
Low: PRAN traded at a Low price of $7.18 per share on 4/22/2004
 
Close: PRAN closed trading at price $7.39 per share on 4/22/2004. (Close is also called Price in the VectorVest system)
 
Range: Range reflects the difference between the High and Low prices for the day. PRAN traded with a range of $1.09 per share on 4/22/2004.  
 
$Change: PRAN closed down 0.21 from the prior day's closing Price.  
 
%PRC: PRAN's Price changed -2.76% from the prior day's closing price.
 
Volume: PRAN traded 131,900 shares on 4/22/2004.
 
AvgVol: AvgVol is the 50 day moving average of daily volume as computed by VectorVest. PRAN has an AvgVol of 105,100 shares traded per day.
 
%Vol: %Vol reflects the percent change in today's trading volume as compared to the AvgVol. %Vol equals 100 x (Volume/AvgVol). PRAN had a %Vol of 25.50% on 4/22/2004
 
Sales: PRAN has annual sales of $
 
Sales Growth: Sales Growth is the Sales Growth Rate in percent over the last 12 months. PRAN has a Sales Growth of 177.00% per year. This is excellent. Sales Growth is updated each week for every stock. It is often useful to compare Sales Growth to Earnings Growth to gain an insight into a company's operations.  
 
Sales Per Share (SPS): PRAN has annual sales of $0.05 per share. SPS can be used as a measure of valuation when comparing stocks within an Industry Group.  
 
Price to Sales Ratio (P/S): PRAN has a P/S of 135.33. This ratio is also used as a measure of valuation. Here, too, it is useful when comparing stocks within an Industry Group.
 
Shares: PRAN has 5,000,000 shares of stock outstanding.
 
Market Capitalization: PRAN has a Market Capitalization of $43,000,000. Market Capitalization is calculated by multiplying price times shares outstanding.
 
Industry Group: PRAN has been assigned to the Drug (Biomedical\Genetic) Industry Group. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.
 
Business Sector: PRAN has been assigned to the Drug Business Sector. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.
 
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Kurs heute ausgesetzt

 
26.04.04 16:16
#13
laut Austr. Börse kommen news. und wird erst wieder am Mittwoch eingesetzt, oder wenn die Nachricht füher da ist. Wird also heute nacht was kommen!

die Amis haben es heute nacht nicht mitbekommen, obgleich es beie denen ja noch abends war, zu Austr. Börsenzeit.

Es gibt aber keine anhaltspunkte was es für eine Nachricht sein kann?

Nun machen kann man ohnedies nichts, weil Handel überall ausgesetzt ist! auch in USA!

schätze von der Company wird man auch nichts in Erfahrung bringen können! Noch dazu, wenn man vom Ausland aus anruft.

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

capital raising! Kapital Erhöhung!

 
26.04.04 17:10
#14
Fand ich als Erklärung in einem austr. Börsenboard!


"capital raising... typical process after share price rise, issue more shares to capitilize. Find out tomorrow, just hoipng for an issue price above .95 so as not to depress share price."

Das wäre eine plausible Erklärung!

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Oder ein Fond investiert 20 Mill. US $!

 
28.04.04 07:41
#15
Nun ist die Nachricht raus!

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Fond investiert in ADR' 20 Mio US $

 
28.04.04 07:47
#16
www2.tradingroom.com.au/news_research/...%3Dtpl%26section%3Dca

Außerdem kann er Optionen erwerben zu 8 US $

Ich hoffe der Link läßt sich aufrufen, weil diese Seite nur mit Anmeldung funktioniert
Austr. Börse!


Ist doch eine sensationelle Nachricht, der Kurs dürfte hochschießen!
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Sensationelle Nachricht !

 
28.04.04 08:03
#17
   Latest News  

--------------------------------------------------
(Printer friendly version) Prana Biotechnology $US20m placement to US health funds  


Sydney, Apr 28, 2004 (RWE via COMTEX) -- Prana Biotechnology Ltd has entered
definitive agreements with new American institutional investors for a $US20
million placement of 4 million ADRs at $US5 each.

The agreements also involved the acquisition by the investors of five-year
warrants to buy an additional 3 million ADRs at an exercise price of $US8 each,
which would raise a further $US24 million.

The transaction is to close upon shareholder approval, which is expected to be
obtained promptly.

Executive chairman Mr Geoffrey Kempler said, "These additional funds will allow
us to independently fund further trials of our MPAC technology, which has shown
early promise as a potential treatment for Alzheimer's disease in clinical
trials.

"We intend to accelerate the development of PBT-2, our 'second-generation'
product, into clinical trials planned for later this year."

Shares in Prana fell 18c to 82c today before improving to 93c.

The shares had risen from 48c last month to as high as $1.18 in April.


RWE Australian Business News

URL:              rweabn.com.au


Copyright 2004 RWEABN





SUBJECT CODE:     Australian Equities



 
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Die Amis haben die Nachricht noch nicht entdeckt

 
28.04.04 16:08
#18
Haben den Kurs der Austr. Börse genommen, aber die Nachricht kam erst heute nach Börsenschluss!

Und die Kursausssetzung hat wohl Einige nervös gemacht und gingen lieber raus!
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Oh mein Gott! Die Amis haben überhaupt keineAhnung

 
29.04.04 14:28
#19
von den News!

Dabei habe ich die Nachrichten außer von der austral. Börse auch auf der US Seite,. sogar zum Kopieren gesucht!

na dann gute NachT!

die diskutieren über die alten Nachrichten noch!

Können die nicht Nachrichten lesen?
Muß doch auffallen, wenn ein Kurs 3 Tage ausgestzt wurde!!

Gruß
GS
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Und noch ne News!

 
29.04.04 14:37
#20
Prana to Present at Citigroup Smith Barney Biotech Showcase  


MELBOURNE, Australia, Apr 29, 2004 /PRNewswire-FirstCall via Comtex/ -- Prana
Biotechnology Limited (Nasdaq: PRAN, ASX: PBT), today announced that the Company
has been invited to present later today at Citigroup Smith Barney's second
biannual "Medtech and Biotech Bullring," in Sydney, Australia.

Geoffrey Kempler, Prana's Executive Chairman, will provide an update of Prana's
scientific and commercial milestones, including forthcoming clinical trials for
its MPAC technology, which has shown early promise as a potential treatment for
Alzheimer's disease. Mr. Kempler will highlight recent data from an extended
Phase II trial in patients with Alzheimer's disease, which was presented earlier
this month at the 8th International Springfield/Montreal Symposium on Advances
in Alzheimer's Disease.

About Prana

Prana is a Melbourne-based biotechnology established in 1997 to commercialize
research into Alzheimer's disease and other major age-related degenerative
disorders (Nasdaq: PRAN; ASX: PBT). Prana's technology was discovered by the
company's researchers at prominent international institutions including
Massachusetts General Hospital at Harvard Medical School, the University of
Melbourne and the Mental Health Research Institute in Melbourne. For more
information about Prana, please visit www.pranabio.com

SOURCE Prana Biotechnology Limited



CONTACT:          Geoffrey Kempler of Prana, +61-3-9690-7892, or

                 gkempler@pranabio.com; Media and Investor, US: Ivette Almeida,

                 ivette.almeida@annemcbride.com, or Steven Silver, silver@annemcbride.com, both

                 of Anne McBride, +1-212-983-1702 ext. 209; Media, Australia: Kate Mazoudier,

                 +61-1-3-866-4722, or kmazoudier@bcg.com.au, all for Prana Biotechnology

                 Limited



URL:              www.prnewswire.com

                 www.pranabio.com


Copyright (C) 2004 PR Newswire.  All rights reserved.




Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Kurs zieht an! Habe gestern nachgelegt!

 
29.04.04 17:59
#21
Und zwar kräftig!
Führend in Alzheimer Forschung! PRANA Biotech. Mr Fragezeichen
Mr Fragezeich.:

Leute lasst blos die Finger von

 
30.04.04 09:43
#22
dieser Aktie. Das Ding ist hoch spekulativ. Hier kommt in den nächsten Tagen der Absturz schlecht hin.
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Toll Fragezeichen, lass Deine störenden

 
30.04.04 09:59
#23
Beiträge, das machst du doch nur, weil ich aus GPC ausgestiegen bin!!

Was soll das! Mach nur weiter so, wenn du nichts vernünftiges zu sagen hast, dann bleibe hier weg!

Du Frusti!  
Führend in Alzheimer Forschung! PRANA Biotech. Nussriegel
Nussriegel:

Wieso sollte man auch mit GPC Geld verlieren?

 
30.04.04 12:17
#24
bzw. sauer sein, weil andere das nicht tun und einfach schlauer sind?
Geteilter Verlust ist in dem Fall ja nicht halber Verlust :)
Hat Mr.Grenke-Zeichen eigentlich auch mal irgendwen auf das Risiko bei seiner
GPC 200 hingewiesen?
Oder macht man das nur bei Aktien, die andere Leute vorstellen?
Führend in Alzheimer Forschung! PRANA Biotech. Optimal
Optimal:

irgendwo wird er das schon mal geschrieben

 
30.04.04 12:44
#25
haben ... denk ich

aber ehrlich gesagt halte ich das Kursziel für absolut übertrieben

Führend in Alzheimer Forschung! PRANA Biotech. Nussriegel
Nussriegel:

@ optimal

 
30.04.04 13:46
#26
muss ja vielleicht auch nicht jedesmal extra dazu gesagt werden, weils eben selbstverständlich ist.
aber diese Spielchen "schreibst du `risikoreich` in meinen Thread, schreib ich es in deinen"
und "ich mach dich fertig, weil ich mehr IDs hab als Du"
sind doch Kindergartenkram.
Das könnte man doch unter Erwachsenen OPTIMALer lösen, oder?
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

An Kindergarten hab` ich auch gedacht

 
01.05.04 18:22
#27
als ich die Beiträge von Fragezeichen las!
Nur habe ich gar nichts von risikoreich geschrieben, sondern  nur das ich froh bin, nicht beim Down dabei zu sein  und das Geld von GPC und mehr nochmal in Prana investiert habe, und dass ich es gut finde, wenn Forst Falkenau, die Begeisterung für GPC mal bremst!

Das hat ihn so geärgert, dass er nun meinen Wert überall niedermacht!

da konnte ich nicht umhin auch bei GPC darauf aufmerksam  zu machen, dass schließlich alle Biotech Aktien sehr spekulativ sind!

Denn GPC ist mit dem einen Medikament in der Pipeline, nicht sehr stabil, aber doch schon sehr teuer!

Wer sich für biotech interessiert, der sollte auf mehrere biotech-Werte setzen und vor allem auf welche, die noch mehr Kurschancen aufweisen, wie ich das bei Prana Biotech sehe!

Und in der Krebs-Forschung sind eine Unmenge an Firmen tätig, aber Alzheimer ist eine Erkrankung, die nicht wie Krebs zum Tode führt sondern zu einem Pflegefall und einer langsamen aber sicheren VErblödung führt, deshalb finde ich die Forschung in diesem Bereich sehr wichtig, weil es wie Parkinson, eine sehr häufige Alterserkrankung ist!

Meine Großmutter hat unter ihrer Parkinson-Erkrankung sehr gelitten und sie wäre froh gewesen, wenn sie nicht mehr hätte weiterleben müssen! Außer mir hat das niemand gewußt, weil ihre Söhne mit ihr gar nicht mehr kommunzieren konnten, weil sie sehr lange brauchte, bis sie wußte wer der Besucher war! Mein Onkel (ihr Sohn) erzählte, er könne mit ihr nichts mehr anfangen, weil sie nicht wüßte wer er sei!!

Ich hoffe dass Prana, ERfolg mit diesem Medikament hat, und dass es zugelassen wird!!

Es würde vielleicht manche vor einem Pflegeheim bewahren!

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Neues Research über Alzheimer Erkrankung

 
15.05.04 16:54
#28
Welche Rolle Prana spielt, bei der Behandlung von Alzheimer??  

Latest News  

--------------------------------------------------
(Printer friendly version) New Research Suggests Additional Role for Prana Technology Against Alzheimer's Disease  


MELBOURNE, Australia, May 3, 2004 /PRNewswire-FirstCall via COMTEX/ -- The
Journal of Biological Chemistry has published findings by researchers for Prana
Biotechnology Limited (Nasdaq: PRAN; ASX: PBT) suggesting an additional
mechanism for the action of Prana's technology in delaying the progress and
severity of Alzheimer's disease.

Prana's MPACs (metal protein attenuating compounds) have previously been shown
to lower the levels of beta-amyloid in the brain -- the main component of
amyloid plaques that are a feature of Alzheimer's disease. The new research
suggests that that these MPACs may also be effective in preventing beta-amyloid
from attaching itself to and damaging COX-2, the key enzyme that mediates
inflammation in the brain often associated with Alzheimer's disease. Levels of
beta amyloid/COX-2 complexes were found to be elevated significantly in the
brains of patients with Alzheimer's disease.

Professor Ashley Bush of Harvard Medical School and Chief Scientific Consultant
to Prana was the senior author on the paper: "COX-2 has been implicated in
Alzheimer's disease, but studies of COX-2 inhibitors (anti- inflammatory drugs)
have been disappointing. Our current findings explain how the interaction of
beta-amyloid with brain copper corrupts the normal metabolism of COX-2 in
Alzheimer's disease. These findings further validate Prana's MPAC drug approach,

which targets the adverse metal interaction with amyloid. MPACs stop the
beta-amyloid/metal complex from damaging COX-2. These findings also may explain
why anti-inflammatory drugs would not be effective in Alzheimer's disease."

An abstract of the article can be read online at
www.jbc.org/cgi/content/abstract/279/15/14673

About Prana Biotechnology Limited

Based in Australia, incorporated in 1997 and listed on the Australian Stock
Exchange in March 2000, Prana Biotechnology (NASDAQ: PRAN; ASX: PBT) was
established to commercialize research into Alzheimer's disease and other major
age-related degenerative disorders. Its mission is to develop diagnostic and
therapeutic drugs to treat the central disease pathways that cause degeneration
of the brain as the aging process progresses. Prana's technology has emerged
from its researchers at prominent international institutions such as
Massachusetts General Hospital at Harvard Medical School and the University of
Melbourne. For further information, please visit our web site at
www.pranabio.com.

This press release contains "forward looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995 regarding the Company's
business strategy and future plans of operation. Forward-looking statements
involve known and unknown risks and uncertainties; both general and specific to
the matters discussed in this press release. These and other important factors,
including those mentioned in various Securities and Exchange Commission filings
made by the Company, may cause the Company's actual results and performance to
differ materially from the future results and performance expressed in or
implied by such forward-looking statements. The forward-looking statements
contained in this press release speak only as of the date hereof and the Company
expressly disclaims any obligation to provide public updates, revisions or
amendments to any forward-looking statements made herein to reflect changes in
the Company's expectations or future events.

SOURCE Prana Biotechnology Limited



CONTACT:          Geoffrey Kempler of Prana Biotechnology Limited,

                 +61-3-9690-7892, gkempler@pranabio.com; or Media and Investor, US - Ivette

                 Almeida, ivette.almeida@annemcbride.com, or Steven Silver,

                 silver@annemcbride.com, both of the Anne McBride Company, +1-212-983-1702,

                 ext. 209, for Prana; or Media, Australia - Kate Mazoudier, +61-1-3-9866-4722,

                 kmazoudier@bcg.com.au, for Prana



URL:              www.pranabio.com

www.prnewswire.com


Copyright (C) 2004 PR Newswire.  All rights reserved.





KEYWORD:          Australia

INDUSTRY KEYWORD: MTC

                 HEA

                 BIO


So vor lauter GPC Streit, habe ich vergessen die News reinzustellen, würde mich aber mal freuen, wenn andere auch mitachen würden!

Wenn Alzheimer nicht wichtig erscheint, dann kannich es ja bleiben lassen!

Die Einmann Show liegt mir nicht!
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Prana wurde in London vorgestellt!

 
15.05.04 17:00
#29
In London gab es ein Treffen von vielen bekannten Biotech Frimen, darunter auch Prana!
Ich hatte auch eine Einladungskarte bekommmen, konnte aber nicht teilnehmen.



MELBOURNE, Australia, May 5, 2004 /PRNewswire-FirstCall via COMTEX/ --
Executive Chairman of Prana Biotechnology Limited (Nasdaq: PRAN; ASX: PBT), Mr
Geoffrey Kempler, has been invited to brief UK investors at the Rodman & Renshaw
Techvest Global Healthcare Conference at Claridge's Hotel in London on Wednesday
May 12, 2004 at 8:40 AM local time.

Prana is an Australian-based biotechnology company focusing on technology that
has shown early promise as a potential treatment for Alzheimer's disease and
other age-related disorders. At the conference, Mr Kempler will provide an
update of Prana's scientific and commercial milestones, including forthcoming
clinical trials for its MPAC technology.

Rodman & Renshaw, a leading investment bank dedicated to emerging growth
companies, was recently agent for Prana Biotechnology's US $20 million placement
to US institutions and professional investors.

To arrange a one-on-one meeting with representatives of Prana Biotechnology
during the conference, please contact Steven Silver at The Anne McBride Company,
tel. 212-983-1702, ext 212, or silver@annemcbride.com.

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Prana am 20 Mai in Las VEGAS Healthcare Conference

 
15.05.04 17:04
#30
 

(Printer friendly version) Prana's Founding Scientist to Present at Banc of America 2004 Healthcare Conference  


MELBOURNE, Australia, May 11, 2004 /PRNewswire-FirstCall via COMTEX/ -- Prana
Biotechnology Limited (Nasdaq: PRAN, ASX: PBT) today announced that its founding
scientist Dr. Ashley Bush, of Harvard Medical School, will present at the Banc
of America 2004 Healthcare Conference at The Four Seasons Hotel in Las Vegas on
Thursday, May 20th, 2004, at 8:00 AM PDT.

Dr. Bush's theories concerning the interaction between metals and the protein
beta-amyloid in the brain are the basis of Prana's treatments for Alzheimer's
and other neurodegenerative diseases.

The conference will include both a company presentation and a moderated
discussion between management and institutional investors.

To arrange a one-on-one meeting with Dr. Bush during the conference, please
contact Steven Silver at The Anne McBride Company, tel. 212-983-1702, ext 212,
or silver@annemcbride.com.

About Prana

Prana is a Melbourne-based biotechnology established in 1997 to commercialize
research into Alzheimer's disease and other major age-related degenerative
disorders (Nasdaq: PRAN; ASX: PBT). Prana's technology was discovered by the
company's researchers at prominent international institutions including
Massachusetts General Hospital at Harvard Medical School, the University of
Melbourne and the Mental Health Research Institute in Melbourne. For more
information about Prana, please visit www.pranabio.com

This press release contains "forward looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995 regarding the Company's
business strategy and future plans of operation. Forward-looking statements
involve known and unknown risks and uncertainties; both general and specific to
the matters discussed in this press release. These and other important factors,
including those mentioned in various Securities and Exchange Commission filings
made by the Company, may cause the Company's actual results and performance to
differ materially from the future results and performance expressed in or
implied by such forward-looking statements. The forward-looking statements
contained in this press release speak only as of the date hereof and the Company
expressly disclaims any obligation to provide public updates, revisions or
amendments to any forward-looking statements made herein to reflect changes in
the Company's expectations or future events.

SOURCE Prana Biotechnology Limited

Ich sehe, dass prana seinen Weg machen wird!

Nach den Presentationen, werden noch mehr Fonds einsteigen!


 
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Die Kapitalerhöung drückt auf den Kurs

 
15.06.04 11:54
#31
Latest News  

--------------------------------------------------
(Printer friendly version) Prana Biotechnology $US20m capital raising goes ahead  


Sydney, Jun 02, 2004 (RWE via COMTEX) -- Shareholders in Prana Biotechnology
Ltd have approved the issue of securities worth $US20 million to institutional
and professional investors, led by New York-based healthcare fund managers
OrbiMed Advisors and XMark Funds.

The transaction was originally announced on April 28.

Prana executive chairman Mr Geoffrey Kempler commented: "This substantial
support shown by leaders in the healthcare investment community reflects the
progress and strength of Prana's technology.

"With this offering, we have been able to enhance shareholder value by
increasing our access and exposure to the vast US capital markets and broaden
our base of US institutional investors, complementing our traditional Australian
shareholder base."

"This capital raising will provide the funds to progress PBT-2, our proprietary
MPAC for Alzheimer's disease, into clinical trials in Australia through 2005 and
2006," said Mr Kempler.

Investors also bought five-year warrants to purchase an additional 3 million
ADRs at an exercise price of $US8 per ADR.

If exercised, this would raise an additional $US24 million for the company.

Prana shares today rose 3c to 68c.


RWE Australian Business News

URL:              rweabn.com.au


Copyright 2004 RWEABN





SUBJECT CODE:     Australian Equities




 

DJIA  10,334.70   75.40

Nasdaq  1,969.99   29.88

S&P 500  1,125.29   11.18

30 Yr Bond  5.53   0.06

10 Yr Bond  4.87   0.08



$7 Trades, Fast Executions & Real-Time Balances. Go!

Keyword Search  
Enter Keyword
 





--------------------------------------------------


Exchange market data provided by DTN Market Access. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither FreeRealTime.com nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the FreeRealTime.com site, a member has agreed to the FreeRealTime.com Member Agreement.

Copyright © 1998-2004 FreeRealTime.com, Inc. All rights reserved.
User Agreement, Privacy Statement, Version 3.50


In Australien heute unverändert bei 0,7 das sind o,48 us $

Nachbörslich in USA gestern bei 4,71 (x 10)


gruß
gs



Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Prana hat die Patentrechte für USA und Japan

 
10.08.04 13:00
#32

 

 while
PNG will hold the rights for European and other territories.

Prana settles patents dispute
Sydney, Aug 09, 2004 (RWE via COMTEX) -- Prana Biotechnology Ltd says it andMassachusetts General Hospital have agreed to settle all outstanding litigationwith PN Gerolymatos SA (PNG) regarding the exploitation rights to certainpatents relating to pharmaceutical compositions and uses of clioquinol (alsoknown as PBT-1).Accordingly, all patent oppositions in Europe and Austra lia are being withdrawnand the law suits pending before the US District Court for the District ofColumbia and the Court of Athens in Greece are being dismissed.As a result of the settlement, Prana and PNG have agreed to recognise the rightsof each other to develop clioquinol in their respective territories.Prana will hold the rights to clioquinol in the United States and Japan, whilePNG will hold the rights for European and other territories.RWE Australian Business NewsURL:              rweabn.com.auCopyright 2004 RWEABNSUBJECT CODE:     Australian EquitiesPRANA BIOTECHNOLOGY LTD - Nasdaq SmallCap Market: PRAN
Führend in Alzheimer Forschung! PRANA Biotech. 1603741quotes.freerealtime.com/gra/p.gif" style="max-width:560px" >
Chart Options    1 Day2 Day5 Day10 Day1 Month6 Month1 Year2 Year5 Year10 YearMax  BarDotLineMountain  Führend in Alzheimer Forschung! PRANA Biotech. 1603741host.wallstreetcity.com/frti/...91311-4-1-0-5-400-211-_-0.gif" style="max-width:560px" > Charts provided by Telescan
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Auf Forbes Liste: neurolog. drugs to watch!

 
10.08.04 13:13
#33
Prana Biotechnology Added To Forbes Neurological Drug Watch List

MELBOURNE, Australia, Aug 9, 2004 /PRNewswire-FirstCall via COMTEX/ -- PranaBiotechnology Limited (Nasdaq: PRAN; ASX: PBT) today announced that Forbes.comhas once again added Prana to it's list of "neurological drugs to watch",highlighting the most promising experimental drugs to treat diseases of thebrain and nervous system.To obtain the web link of Forbes 'Neurological Drugs to Watch', please go to:http://www.forbes.com/sciencesandmedicine/2004/01/26/cx_mh_rl_neurotearsheet htmlAbout PranaPrana is a Melbourne-based biotechnology established in 1997 to commercializeresearch into Alzheimer's disease and other major age-related degenerativedisorders (Nasdaq: PRAN; ASX: PBT). Prana's technology was discovered by thecompany's researchers at prominent international institutions includingMassachusetts General Hospital at Harvard Medical School, the University ofMelbourne and the Mental Health Research Institute in Melbourne. For moreinformation about Prana, please visit http://www.pranabio.comThis press release contains "forward-looking statements" within the meaning ofthe Private Securities Litigation Reform Act of 1995 regarding the Company'sbusiness strategy and future plans of operation. Forward-looking statementsinvolve known and unknown risks and uncertainties; both general and specific tothe matters discussed in this press release. These and other important factors,including those mentioned in various Securities and Exchange Commission filingsmade by the Company, may cause the Company's actual results and performance todiffer materially from the future results and performance expressed in orimplied by such forward-looking statements. The forward-looking statementscontained in this press release speak only as of the date hereof and the Companyexpressly disclaims any obligation to provide public updates, revisions oramendments to any forward-looking statements made herein to reflect changes inthe Company's expectations or future events.SOURCE Prana Biotechnology LimitedCONTACT:          Jonas Alsenas, CEO of Prana, +1-203-328-3097,                  jalsenas@pranabio.com; or Media Relations, Ivette Almeida, +1-212-983-1702,                  ext. 209, ivette.almeida@annemcbride.com; or Investor Relations, Rachel                  Levine, +1-212-983-1702, ext. 207, rlevine@annemcbride.comURL:              http://www.pranabio.com http://www.prnewswire.comCopyright (C) 2004 PR Newswire.  All rights reserved.KEYWORD:          AustraliaINDUSTRY KEYWORD: MTC                  HEASUBJECT CODE:     SVY
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Prana erhält 1 % von PNG´s Einkommen bezügl.

 
10.08.04 13:47
#34

des Verkaufes  von PBT 1

 

Prana Settles Clioquinol Patent Litigation Conference Call To Be Hosted  


MELBOURNE, Australia, Aug 9, 2004 (PRNewswire-FirstCall via COMTEX) -- Prana
Biotechnology Limited today announced that Prana and Massachusetts General
Hospital have agreed to settle all outstanding litigation with P.N Gerolymatos
S.A. (P.N.G.) regarding the exploitation rights to certain patents relating to
pharmaceutical compositions and uses of clioquinol (also known as PBT-1).
Accordingly, all patent oppositions in Europe and Australia are being withdrawn
and the law suits pending before the U.S. District Court for the District of
Columbia and the Court of Athens in Greece are being dismissed.

As a result of the settlement, Prana and P.N.G. have agreed to recognize the
rights of each other to develop clioquinol in their respective territories.
Prana will hold the rights to clioquinol in the United States and Japan, while
P.N.G. will hold the rights for European and other territories. Prana has agreed
to allot 1.35 million shares which will be held in escrow for twelve months and
pay a royalty to P.N.G. on sales in the USA and Japan, Prana will receive a
percentage of PNG's income for the other territories.

Mr. Geoffrey Kempler, Executive Chairman of Prana commented, "Prana now holds
issued patents in the US on clioquinol (PBT-1), a drug which has already
demonstrated that it can slow down the progression of the disease in a group of
moderate to severe Alzheimer's disease patients. In December 2003, promising
Phase II clinical trial results evaluating clioquinol in Alzheimer's disease


were published in the Archives of Neurology. This settlement heralds a very
important opportunity for Prana, its an important part of our drug pipeline and
allows Prana to undertake further clinical development of clioquinol."

"Furthermore, the assignment of these patents also complements the position of
our newer drugs, including PBT-2, which is now in the final months of toxicology
testing before entering Phase 1 clinical trials," said Mr. Kempler.

Commenting on the settlement, Mr. Panayotis Gerolymatos, President and Chief
Executive Officer of P.N. Gerolymatos S.A. stated: "We are pleased to put this
litigation behind us. The amicable settlement makes possible the further
development of clioquinol and we look forward to working jointly with Prana in
this regard."

Unlike current approved Alzheimer's therapies that largely treat the symptoms of
the disease, clioquinol, PBT-2 and Prana's other MPAC's (Metal Protein
Attenuating Compound) hold promise to help prevent the progression of the
disease.

The Company will conduct a teleconference to discuss the patent litigation,
Monday, August 9th, at 5:00 PM US Eastern Time or Tuesday, August 10th at 7 AM
Australian Eastern Time. To participate in the call, please dial 1-800-792-0846
from the US or Canada (toll free), or +1-800-002-092 from Australia, or
+1-706-634-1485 from other locations approximately 5 minutes prior to the
starting time. A replay of the call will be available from 5:45pm ET on Monday,
August 9, 2004, until 11:59pm ET on Tuesday, August 16. To

access the replay, please dial 1-800-642-1687, or +1-706-645-9291 from Australia
or other locations.



Webcast will be available at www.pranabio.com/

  About Prana Biotechnology Limited

Prana Biotechnology was established to commercialize research into Alzheimer's
disease and other major age-related degenerative disorders. The company was
incorporated in 1997 and listed on the Australian Stock Exchange in March 2000
and listed on NASDAQ in September 2002. Researchers at prominent international
institutions including the University of Melbourne and Massachusetts General
Hospital as a teaching hospital of Harvard Medical School discovered Prana's
technology.

This press release contains "forward looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995 regarding the Company's
business strategy and future plans of operation. Forward-looking statements
involve known and unknown risks and uncertainties; both general and specific to
the matters discussed in this press release. These and other important factors,
including those mentioned in various Securities and Exchange Commission filings
made by the Company, may cause the Company's actual results and performance to
differ materially from the future results and performance expressed in or
implied by such forward-looking statements. The forward-looking statements
contained in this press release speak only as of the date hereof and the Company
expressly disclaims any obligation to provide public updates, revisions or
amendments to any forward-looking statements made herein to reflect changes in
the Company's expectations or future events.

For further information, please visit our web site at www.pranabio.com/.

SOURCE Prana Biotechnology Limited



CONTACT:          Dianne Angus, Prana Biotechnology Ltd., +61-3-9349-4906; or Ivette Almeida, Media Relations, +1-212-983-1702 ext. 209, or Rachel Levine, Investor Relations, +1-212-983-1702 ext. 207, for Prana Biotechnology Limited; or Donita Boddie, Massachusetts General Hospital, +1-617-724-5627



URL:              www.pranabio.com/

                  www.prnewswire.com


Copyright (C) 2004 PR Newswire. All rights reserved.





KEYWORD:          Australia

                  Massachusetts

INDUSTRY KEYWORD: HEA

                  BIO

                  MTC

SUBJECT CODE:     LAW

                  CCA


Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

ausführliche Analyse

 
02.09.04 17:16
#35
VectorVest Stock Analysis of Prana BiotchADR as of 9/1/2004

 
Thank you for requesting an analysis of Prana BiotchADR from VectorVest. The ticker symbol for Prana BiotchADR is PRAN.  PRAN is traded on the NASDAQ - (O)  
 
Analysis Summary
PRAN is overvalued compared to its Price of $3.90 per share, has somewhat below average safety, and is currently rated a Hold.
 
In-Depth Analysis
Business: PRANA BIOTECHNOLOGY LTD -ADR, (PRAN) Seeks to commercialize research into Alzheimer's disease and other major age-related degenerative disorders. The company's mission is to develop diagnostic and therapeutic drugs to treat the central disease pathways that cause degeneration of the brain
 
Price: PRAN closed on 9/1/2004 at $3.90 per share  
 
Value: Value is a measure of a stock's current worth.  PRAN has a current Value of $1.05 per share. Therefore, it is overvalued compared to its Price of $3.90 per share.  Value is computed from forecasted earnings per share, forecasted earnings growth, profitability, interest, and inflation rates. Value increases when earnings, earnings growth rate and profitably increase, and when interest and inflation rates decrease. VectorVest advocates the purchase of undervalued stocks. At some point in time, a stock's Price and Value always will converge.  
 

RV (Relative Value): RV is an indicator of long-term price appreciation potential. PRAN has an RV of 0.32, which is very poor on a scale of 0.00 to 2.00. This indicator is far superior to a simple comparison of Price and Value because it is computed from an analysis of projected price appreciation three years out, AAA Corporate Bond Rates, and risk. RV solves the riddle of whether it is preferable to buy High growth, High P/E stocks, or Low growth, Low P/E stocks. VectorVest favors the purchase of stocks with RV ratings above 1.00.
 
RS (Relative Safety): RS is an indicator of risk. PRAN has an RS rating of 0.85, which is fair on a scale of 0.00 to 2.00. RS is computed from an analysis of the consistency and predictability of a company's financial performance, debt to equity ratio, sales volume, business longevity, price volatility and other factors. A stock with an RS rating greater than 1.00 is safer and more predictable than the average stock in the VectorVest database. VectorVest favors the purchase of stocks of companies with consistent, predictable financial performance.
 
RT (Relative Timing): RT is a fast, smart, accurate indicator of a stock's price trend. PRAN has a Relative Timing rating of 0.73, which is poor on a scale of 0.00 to 2.00.  RT is computed from an analysis of the direction, magnitude, and dynamics of a stock's price movements over one day, one week, one quarter and one year time periods. Once a stock's price has established a strong trend, it is expected to continue in that trend for the short-term. If a trend dissipates, RT will gravitate toward 1.00. RT will explode from bottoms, dive from tops, and reflect changes in price momentum. VectorVest favors the purchase of stocks with RT ratings above 1.00.  
 
VST (VST-Vector):  VST is the master indicator for ranking every stock in the VectorVest database. PRAN has a VST rating of 0.69, which is poor on a scale of 0.00 to 2.00. VST is computed from the square root of a weighted sum of the squares of RV, RS, and RT. Stocks with the highest VST ratings have the best combinations of Value, Safety and Timing. These are the stocks to own for above average, long-term capital appreciation. VectorVest advocates the purchase of safe, undervalued stocks rising in price. The efficacy of this indicator was demonstrated in a study conducted at the University of Chicago which showed that high VST stocks outperformed the S&P 500 by 583.1% over the six year period from 1996 through 2002.  
 
CI (Comfort Index): CI is an indicator which reflects a stock's ability to resist severe and/or lengthy price declines. PRAN has a CI rating of 1.11, which is good on a scale of 0.00 to 2.00. CI is quite different from RS in that it is based solely upon a stock's long-term price history. VectorVest advocates the purchase of high CI stocks.  
 
GRT (Earnings Growth Rate): GRT reflects a company's one to three year forecasted earnings growth rate in percent per year. PRAN has a forcasted Earnings Growth Rate of -7.00%, which VectorVest considers to be very poor. GRT is computed from historical, current and forecasted earnings data. It is updated each week for every stock in the VectorVest database. GRT often foretells a stock's future price trend. If a stock's GRT trend is upward, the stock's price will likely rise. If GRT is trending downward, the stock's Price will probably fall. VectorVest favors the purchase of stocks whose GRT is rising and is greater than the sum of current inflation and interest rates, (8.72%).  
 
Recommendation (REC): VectorVest gives a Buy, Sell, Hold recommendation on every stock, every day. PRAN has a Hold recommendation. REC reflects the cumulative effect of all the VectorVest parameters working together. These parameters are designed to help investors buy safe, undervalued stocks rising in price. They also help investors avoid or sell risky, overvalued stocks falling in price. VectorVest recommends that investors buy high VST-Vector, Buy-rated stocks in rising markets.  
 
Stop (Stop-Price): Stop is an indicator of when to sell a long position or cover a short position.  PRAN has a Stop of $3.83 per share. This is $0.07 below PRAN's current closing Price. A stock's Stop is computed from a 13 week moving average of its closing prices, and is fine-tuned according to the stock's fundamentals. High RV, high RS stocks have lower Stops, and low RV, low RS stocks have higher Stops. In the VectorVest system, a stock gets a 'B' or 'H' recommendation if its Price is above its Stop and an 'S' recommendation if its Price is below its Stop.
 
EPS (Earnings per Share):  EPS stands for leading 12 months Earnings Per Share.  PRAN has a forecasted EPS of $-1.22 per share. VectorVest determines this forecast from a combination of recent earnings performance and traditional fiscal and/or calendar year earnings forecasts.  
 
P/E (Price to Earnings Ratio): P/E is a popular measure of stock valuation which shows the dollars required to buy one dollar of earnings.  PRAN has a P/E of -3.20. This ratio may be deemed to be high or low depending upon your frame of reference. The average P/E of all the stocks in the VectorVest database is 27.54. P/E is computed daily using the formula: P/E = Price/EPS.  
 
EY (Earnings Yield): EY reflects earnings per share as a percent of Price. EY is related to P/E via the formula, EY = 100 / (P/E), and may be used in place of P/E as a measure of valuation. EY has the advantages that it is always determinate and can reflect negative earnings. PRAN has an EY of -31.27 percent. This is below the current average of 3.64% for all the stocks in the VectorVest database. EY equals 100 x (EPS/Price).  
 
GPE (Growth to P/E Ratio): GPE is another popular measure of stock valuation. It compares earnings growth rate to P/E ratio. PRAN has a GPE rating of -2.19.  High growth stocks are believed to be able to justify high P/E ratios. A stock is commonly considered to be undervalued when GPE is greater than 1.00 and overvalued when GPE is below 1.00. Unfortunately, this rule of thumb does not take into account the effect of interest rates on P/E ratios. The operative GPE ratio of 1.00 is valid when and only when interest rates equal 10%. With long-term interest rates currently at 5.72%, the operative GPE ratio is 0.33. Therefore, PRAN may be considered to be overvalued.  
 
DIV (Dividend): VectorVest reports annual, regular, cash dividends as indicated by the most recent payments. Special distributions, one-time payments, stock dividends, etc., are not generally included in DIV. PRAN does not pay a dividend.  
 
DY (Dividend Yield): DY reflects earnings per share as a percent of Price. PRAN does not pay a dividend, so it does not have a Dividend Yield rating. . DY equals 100 x (DIV/Price). It is useful to compare DY with EY. If DY is not significantly lower than EY, the dividend payment may be in jeopardy.  
 
DS (Dividend Safety): DS is an indicator of the assurance that regular cash dividends will be declared and paid at current or at higher rates for the foreseeable future. PRAN does not pay a dividend, so it does not have a Dividend Safety rating . Stocks with DS values above 75 typically have RS values well above 1.00 and EY levels that are much higher than DY.

 
DG (Dividend Growth Rate): Dividend Growth is a subtle yet important indicator of a company's financial performance. It also provides some insight into the board's outlook on the company's ability to increase earnings. PRAN does not pay a dividend, so it does not have a Dividend Growth rating .  
 
YSG (YSG-Vector): YSG is an indicator which combines DIV, DY and DG into a single value, and allows direct comparison of all dividend-paying stocks in the database. PRAN does not pay a dividend, so it does not have a YSG rating . Stocks with the highest YSG values have the best combinations of Dividend Yield, Safety and Growth. These are the stocks to buy for above average current income and long-term growth.  
 
Open: PRAN opened trading at a price of $4.02 per share on 9/1/2004.
 
High: PRAN traded at a High price of $4.05 per share on 9/1/2004.
 
Low: PRAN traded at a Low price of $3.84 per share on 9/1/2004
 
Close: PRAN closed trading at price $3.90 per share on 9/1/2004. (Close is also called Price in the VectorVest system)
 
Range: Range reflects the difference between the High and Low prices for the day. PRAN traded with a range of $0.21 per share on 9/1/2004.  
 
$Change: PRAN closed down 0.10 from the prior day's closing Price.  
 
%PRC: PRAN's Price changed -2.50% from the prior day's closing price.
 
Volume: PRAN traded 7,300 shares on 9/1/2004.
 
AvgVol: AvgVol is the 50 day moving average of daily volume as computed by VectorVest. PRAN has an AvgVol of 59,800 shares traded per day.
 
%Vol: %Vol reflects the percent change in today's trading volume as compared to the AvgVol. %Vol equals 100 x (Volume/AvgVol). PRAN had a %Vol of -87.79% on 9/1/2004
 
Sales: PRAN has annual sales of $1,000,000
 
Sales Growth: Sales Growth is the Sales Growth Rate in percent over the last 12 months. PRAN has a Sales Growth of 177.00% per year. This is excellent. Sales Growth is updated each week for every stock. It is often useful to compare Sales Growth to Earnings Growth to gain an insight into a company's operations.  
 
Sales Per Share (SPS): PRAN has annual sales of $0.17 per share. SPS can be used as a measure of valuation when comparing stocks within an Industry Group.  
 
Price to Sales Ratio (P/S): PRAN has a P/S of 22.45. This ratio is also used as a measure of valuation. Here, too, it is useful when comparing stocks within an Industry Group.
 
Shares: PRAN has 6,000,000 shares of stock outstanding.
 
Market Capitalization: PRAN has a Market Capitalization of $25,000,000. Market Capitalization is calculated by multiplying price times shares outstanding.
 
Industry Group: PRAN has been assigned to the Drug (Biomedical\Genetic) Industry Group. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.
 
Business Sector: PRAN has been assigned to the Drug Business Sector. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.
 
The basic strategy of VectorVest is to buy Low risk, High reward stocks. We suggest that Prudent investors buy enough High Relative Value, High Relative Safety stocks to keep the overall RV and RS ratings of their portfolios above 1.00. As you do this, you'll find that your risk will go down and your investment performance will improve.
 
Graph
 
Prana BiotchADR
 
 
Drug (Biomedical\Genetic)
 
 






For more information, please click here.
 
 
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

chartechnisch bildet sich ein W

 
02.09.04 17:18
#36
Derzeit in richtung Spitze 2. Zacke, wird bis ca. 3,6 nach unten gehen und von da wieder nach oben, deshalb halten!
bzw. wer kann nachkaufen.
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Verstärkte Umsätze und Kaufsignal! o. T.

 
08.10.04 08:26
#37
Führend in Alzheimer Forschung! PRANA Biotech. Happy_Berti
Happy_Berti:

Kaufsignal....*ggggg* o.T.

 
08.10.04 09:32
#38
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Riesige Umsätze und News!

 
12.10.04 19:48
#39
Prana's Open Label Extension Study of PBT-1 Reinforces Positive Phase II Results - PBT-1 Slows Alzheimer's Disease Progression and Well Tolerated by Patients -

MELBOURNE, Australia, Oct 12, 2004 /PRNewswire-FirstCall via COMTEX/ -- PranaBiotechnology Limited (Nasdaq: PRAN, ASX: PBT), today announced the results ofthe open label 84-week "Extension Study" of its Phase II clinical trial of PBT-1(clioquinol) study, also known as the CQAD study. The data from the formaltreatment phase of the study was published in the December 2003 issue ofArchives of Neurology.All participants from the original 36-week blinded and placebo-controlledportion of the Phase II trial were offered the opportunity to continue the PBT-1treatment on an open label basis for an additional 48 weeks. 18 (66.7%) out of27 patients elected to start the CQADEX extension study. Nine patients completedthe full 84-week study."The Extension Study data demonstrates that PBT-1 treatment for Alzheimer'sappears to slow the expected disease progression by about half," said JonAlsenas, DVM, chief executive officer of Prana Biotechnology Limited. "The rateof decline in PBT-1 treated patients, compared to the predicted rate of decline,suggests that the drug has a disease-modifying treatment effect, not simply acognition enhancement effect. Moreover, the results show that PBT-1 is welltolerated by patients and has no increased adverse effects over those to beexpected in untreated patients suffering from Alzheimer's disease."Data from the Extension Study data revealed that Alzheimer's patients withADAS-cog scores similar to those in the CQAD and the CQADEX would have beenexpected to decline by an average of 18 points over the treatment period. Theresults showed an average decline of approximately eight points for a differenceof 10 points from that predicted without treatment in the nine patients on PBT-1for 84 weeks. Results from the MMSE (Mini Mental State Examination) were alsoencouraging, as, when compared to baseline, the patients on 84 weeks of PBT-1demonstrated no statistically significant decline."PBT-1 represents a novel approach to Alzheimer's: namely, a disease-modifier.In other words, PBT-1 targets a key feature of the underlying process thatappears to cause the destruction of nerve cells," said Sam Gandy, MD, PhD,Professor of Neurology and Director of the Farber Institute at Thomas JeffersonUniversity. "Alzheimer's is believed to begin as long as 10 years or more beforeclinical memory loss is manifested. Accordingly, disease-modifying drugs mayneed to be administered for many years. Along this line, it is extremelyencouraging to see evidence that PBT-1 is well-tolerated for extended periods."The full publication on the data from the extension study is available onPrana's website http://www.pranabio.com.Prana is currently evaluating the next potential steps in continued PBT-1clinical development and anticipates being able to announce its plans in thenear future.Company Management is hosting an Analyst Day at The Four Seasons, Salon A&B, inNew York City, on Monday, October 18, 2004. Featured speakers will include Dr.Bush, Professor Rudolph Tanzi, Neurology, Harvard Medical School, MassachusettsGeneral Hospital, Dr. Craig William Ritchie, Psychiatry, Royal Free Campus,University College London, UK and Medical Director, Clinical Trials Centre, UCLBiomedica, University College London, UK, as well as Dr. Jon Alsenas, CEO andDr. Ross Murdoch, COO of Prana.About Prana Biotechnology LimitedPrana Biotechnology was established to commercialize research into Alzheimer'sdisease and other major age-related degenerative disorders. The company wasincorporated in 1997 and listed on the Australian Stock Exchange in March 2000and listed on NASDAQ in September 2002. Researchers at prominent internationalinstitutions including the University of Melbourne and Massachusetts GeneralHospital, a teaching hospital of Harvard Medical School, discovered Prana'stechnology.This press release contains "forward looking statements" within the meaning ofthe Private Securities Litigation Reform Act of 1995 regarding the Company'sbusiness strategy and future plans of operation. Forward-looking statementsinvolve known and unknown risks and uncertainties; both general and specific tothe matters discussed in this press release. These and other important factors,including those mentioned in various Securities and Exchange Commission filingsmade by the Company, may cause the Company's actual results and performance todiffer materially from the future results and performance expressed in orimplied by such forward-looking statements. The forward-looking statementscontained in this press release speak only as of the date hereof and the Companyexpressly disclaims any obligation to provide public updates, revisions oramendments to any forward-looking statements made herein to reflect changes inthe Company's expectations or future events.For further information, please visit our web site at http://www.pranabio.com.SOURCE Prana Biotechnology LimitedCONTACT:          Jon Alsenas, CEO of Prana Biotechnology Ltd., +1-203-328-3097;                  or Media, Ivette Almeida, +1-212-983-1702 ext. 209, or Investors, Rachel                  Levine, +1-212-983-1702 ext. 207, both for Prana Biotechnology Ltd. URL:              http://www.pranabio.com http://www.prnewswire.comCopyright (C) 2004 PR Newswire.  All rights reserved.KEYWORD:          AustraliaINDUSTRY KEYWORD: HEA                  MTC                  BIOSUBJECT CODE:     SVY                  CCA
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

100 % buy

 
12.10.04 20:06
#40
Composite Indicator
   Trend Spotter TMBuy
 
Short Term Indicators
   7 Day Average Directional IndicatorBuy
   10 - 8 Day Moving Average Hilo ChannelBuy
   20 Day Moving Average vs PriceBuy
   20 - 50 Day MACD OscillatorBuy
   20 Day Bollinger BandsBuy
 
Short Term Indicators Average:  100% - Buy
20-Day Average Volume - 24545
 
Medium Term Indicators
   40 Day Commodity Channel IndexBuy
   50 Day Moving Average vs PriceBuy
   20 - 100 Day MACD OscillatorSell
   50 Day Parabolic Time/PriceBuy
 
Medium Term Indicators Average:  50% - Buy
50-Day Average Volume - 18112
 
Long Term Indicators
   60 Day Commodity Channel IndexBuy
   100 Day Moving Average vs PriceBuy
   50 - 100 Day MACD OscillatorSell
 
Long Term Indicators Average:  33% - Buy
100-Day Average Volume - 42880
 
Overall Average:  72% - Buy
 
Price Support Pivot Point Resistance
4.59 3.94 4.43 4.92


Click on the indicator for a graphical interpretation of the result
or visit the Learning Center for more information on the studies

PRAN4.76Führend in Alzheimer Forschung! PRANA Biotech. 1671353 0.17 (3.70)4.734.79464,480

 

Antatt durchschnittlich 10`Tsd sind es nun 465`Tsd heute.

 

Da geht was!

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Klinische Studie I bringt das Interesse!

 
12.10.04 20:15
#41
PRANA BIOTECHNOLOGY LTD - Nasdaq SmallCap Market: PRAN
Führend in Alzheimer Forschung! PRANA Biotech. 1671363quotes.freerealtime.com/gra/p.gif" style="max-width:560px" >
Chart Options    1 Day2 Day5 Day10 Day1 Month6 Month1 Year2 Year5 Year10 YearMax  BarDotLineMountain  Führend in Alzheimer Forschung! PRANA Biotech. 1671363host.wallstreetcity.com/frti/...0_d_d_d_d_s_213_d_d_d_d-0.gif" style="max-width:560px" >
Führend in Alzheimer Forschung! PRANA Biotech. bauwi
bauwi:

Ohne Hirn gibt's auch keine Alzheimererkrankung

 
12.10.04 21:20
#42
Führend in Alzheimer Forschung! PRANA Biotech. 1671448usuarios.lycos.es/BTT_CARDONA/images/carabela.gif" style="max-width:560px" >
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Positve Resultate bei den klin. Studien erzielt

 
12.10.04 21:21
#43
Associated Press
Prana: Extended Trial Results Positive
10.12.2004, 12:38 PM

Australian drug developer Prana Biotechnology Ltd. said Tuesday that an extended mid-stage trial of its PBT-1 Alzheimer's treatment demonstrated positive results, slowing the expected progression of the disease by about half.

Prana also said the extended Phase II trial showed the drug was well-tolerated by patients over a long period of time, an important factor for Alzheimer's patients who can expect drug regimens to last many years.

Nine patients from the original 27-patient, 36-week study completed an additional 48 weeks on the drug, for a total of 84 weeks on PBT-1.

The PBT-1 drug works by binding to zinc in the bloodstream, preventing the mineral's association with proteins that have been linked to Alzheimer's disease. Alzheimer's is a degenerative brain disease that affects about four million Americans, according to the National Institutes of Health.

Melbourne, Australia-based Prana concentrates its research on age-related diseases, focusing particularly on Alzheimer's as well as on cataracts and Parkinson's disease.

American depository receipts of Prana rose 16 cents, or 3.5 percent, to $4.75 in midday trading on the Nasdaq. The stock has stayed around $4 after hitting a 52-week high of $10.50 in April.


E-mail |-->Comments | E-Mail Newsletters | RSS Führend in Alzheimer Forschung! PRANA Biotech. 1671450
');//-->Today's Top Stories
 
Merrill Lynch Earnings Fall 8%
Associated Press - 10/12/04 9:46:08 AM ET
The company blames results on a slowdown in transactions prompted by an extremely slow summer on Wall Street.
 
Oil Prices Pass $54 Per Barrel
Associated Press - 10/12/04 10:00:07 AM ET
Crude for November delivery on the New York Mercantile Exchange reached a new high of $54.45, after settling overnight at $53.64. 
 
quelle Forbes
 
 
News Headlines | More From Forbes.com | Special Reports
 
 
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

@bauwi, dann sollten wir unser Hirn noch

 
12.10.04 21:24
#44

Führend in Alzheimer Forschung! PRANA Biotech. 1671454ausnutzen, solange es noch klar ist!  Oder?

Ich hoffe für Prana und für die Alzheimerforschung, dass es einen Erfolg gibt.

 

gruß

geldschneider

 

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Institutionelle Beteiligungen

 
14.10.04 00:24
#45
PRANA BIOTECHNOLOGY LTD ADR
Führend in Alzheimer Forschung! PRANA Biotech. 1673287     function relocate (form_object) {      var v=form_object;      if (v == 'symbol') {        window.location.href="searchresults.cfm?getcompany=739727105&smethod=cusip&search=symbol&pt_flag=1";      } else if (v == 'mutual') {        window.location.href="searchresults.cfm?getcompany=739727105&smethod=cusip&search=mutual&pt_flag=1";      } else if (v == 'edgar') {        window.location.href="searchresults.cfm?getcompany=739727105&smethod=cusip&search=edgar&pt_flag=1";      } else if (v == 'insider') {        window.location.href="searchresults.cfm?getcompany=739727105&smethod=cusip&search=insider&pt_flag=1";      } else if (v == 'combine') {        window.location.href="searchresults.cfm?getcompany=739727105&smethod=cusip&search=combine&pt_flag=1";      }    }  
Other Search Views:  Institutional Ownership View Mutual Fund Ownership View
Führend in Alzheimer Forschung! PRANA Biotech. 1673287
tablealiases.cfm template was included twice on this page. Please review your code and remove unnecessary procedures.-->
 Displaying North American Holders
Führend in Alzheimer Forschung! PRANA Biotech. 1673287
    
 
NHolder NamePositionPos Change$ Mkt Val% Port% O/SRpt Date
 1 OrbiMed Advisors, Inc. 800,000800,0003,840,0000.096.9006-30-04
 2 Highbridge Capital Management LLC 600,000600,0002,880,0000.105.1706-30-04
 3 William Harris Investors, Inc. 200,000200,000960,0000.181.7206-30-04
 4 Perceptive Advisors LLC 200,000200,000960,0000.361.7206-30-04
 5 DKR Capital Partners LP 200,000200,000960,0000.031.7206-30-04
 6 Viking Global Investors LP 200,000200,000960,0000.051.7206-30-04
 7 Neuberger Berman LLC 10,500050,4000.000.0906-30-04
 8 Marketocracy Capital Management LLC 8,2308,23039,5040.060.0706-30-04
 9 Deutsche Bank Securities, Inc. 7,6547,65436,7390.000.0706-30-04
 

recht interessant.

 

gruß

gsd

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Trend analyse

 
18.11.04 09:37
#46
Composite Indicator
   Trend Spotter TMBuy
 
Short Term Indicators
   7 Day Average Directional IndicatorSell
   10 - 8 Day Moving Average Hilo ChannelHold
   20 Day Moving Average vs PriceBuy
   20 - 50 Day MACD OscillatorBuy
   20 Day Bollinger BandsHold
 
Short Term Indicators Average:  20% - Buy
20-Day Average Volume - 32155
 
Medium Term Indicators
   40 Day Commodity Channel IndexHold
   50 Day Moving Average vs PriceBuy
   20 - 100 Day MACD OscillatorBuy
   50 Day Parabolic Time/PriceBuy
 
Medium Term Indicators Average:  75% - Buy
50-Day Average Volume - 54398
 
Long Term Indicators
   60 Day Commodity Channel IndexHold
   100 Day Moving Average vs PriceBuy
   50 - 100 Day MACD OscillatorBuy
 
Long Term Indicators Average:  67% - Buy
100-Day Average Volume - 55703
 
Overall Average:  56% - Buy
 
Price Support Pivot Point Resistance
4.75 4.60 4.72 4.84


Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

BUY

 
18.11.04 09:47
#47
Führend in Alzheimer Forschung! PRANA Biotech. 1712831
PRAN
PRANA BIOTECHNOLOGY LTD ADR
Daily Commentary

Our system posted a BUY-IF today. The previous SELL recommendation that was confirmed was made on 11.11.2004 (7) days ago, when the stock price was 4.9000. Since then PRAN has fallen -3.06% .

Is this finally a good time to buy? Well, it depends. First check what happened at after hours trading and future values. Then, follow the next session very carefully and be on your toes. This candlestick pattern is a bullish one, but we have to see whether it will be confirmed or not.

Do you see a gap-up at the market open? Do you see a white candlestick forming with a higher close at the session's end? Shortly, is it a nice bullish day? If so, place your buy orders and open new long positions. The market is now on the bull side.

But, be careful, also. If you see a gap-down when the market opens, or if the session closes with a bearish sentiment producing a black candlestick characterized by a lower close, do not challenge the market. Ignore the BUY-IF alert. Cancel the buy orders and cover any new long positions that you might have opened. Bears are still in control.

[MOTTO OF THE DAY]
Buy only if the bulls are in charge
Forget about it if the bears surge



 
BUY-IF
4.7500
-0.0400 -0.84%
Candlestick Analysis
Today’s Candlestick Patterns:

Doji
Bullish Doji Star
Führend in Alzheimer Forschung! PRANA Biotech. 1712831 Führend in Alzheimer Forschung! PRANA Biotech. 1712831 Führend in Alzheimer Forschung! PRANA Biotech. 1712831 Führend in Alzheimer Forschung! PRANA Biotech. 1712831 Führend in Alzheimer Forschung! PRANA Biotech. 1712831 Führend in Alzheimer Forschung! PRANA Biotech. 1712831 Führend in Alzheimer Forschung! PRANA Biotech. 1712831 Führend in Alzheimer Forschung! PRANA Biotech. 1712831 Führend in Alzheimer Forschung! PRANA Biotech. 1712831 Führend in Alzheimer Forschung! PRANA Biotech. 1712831 Führend in Alzheimer Forschung! PRANA Biotech. 1712831


Today a
Doji was formed. This shows indecision about the direction of the market and it represents a tug-of-war between buyers and sellers.

For more about this candlestick click here.

The last two candlesticks formed a Bullish Doji Star Pattern . This is a bullish reversal pattern that marks a potential change in trend. However, its reliability is not very high and it requires confirmation.

For more about this pattern click here.
rnum=Math.round(Math.random() * 100000);document.write('');Führend in Alzheimer Forschung! PRANA Biotech. 1712831 Führend in Alzheimer Forschung! PRANA Biotech. 1712831
 
 
Stock Quote
Day's Close4.7500
Previous Close 4.7900
Previous Open 4.9100
Change -0.0400
% Change -0.84%
Volume 27,837
 
Stock Activity
Day's Open 4.7500
Day's High 4.7700
Day's Low 4.6500
50-Day Close M.A. 4.2406
200-Day Close M.A. 4.6080
65
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Hauptversammlung 17. Nov.

 
18.11.04 09:51
#48
Prana Biotechnology Announces Results of Annual General Meeting of Shareholders

MELBOURNE, Australia, Nov 17, 2004 /PRNewswire-FirstCall via COMTEX/ -- PranaBiotechnology Limited (Nasdaq: PRAN, ASX: PBT), today announced the results ofits Annual General Meeting held on November 17, 2004. During the proceedings,the following resolutions were passed:    -- Mr. Geoffrey Kempler was re-elected to serve as a director of the       Company and Dr. Jonas Alsenas was elected to serve as a director of the       Company;    -- the approval of previous issuance of ordinary shares to P.N.       Gerolymatos S.A. and to certain consultants of the Company pursuant to       resolution of the patent dispute regarding PBT-1 that was announced in       August;    -- the adoption of the 2004 American Depositary Share (ADS) Option Plan       and the 2004 Employees, Directors' and Consultants' Share and Option       Plan, as well as the approval of up to an aggregate 12,000,000 ordinary       shares or ADS issuable under the 2004 ADS Option Plan and the 2004       Employees, Directors' and Consultants' Share and Option Plan;"Prana Biotechnology made great strides in fiscal 2004," said Geoffrey Kempler,chairman. "Our most notable achievement was advancing from a pre- clinical stagecompany to a late-stage clinical company by securing the PBT-1 intellectualproperty and announcing the planned initiation of the PII/III PLACQUE study."Other achievements for 2004 included the announcement of results PBT-1 Phase IIExtension Study of Alzheimer's disease patients. According to Extension Studyresults released in October 2004, PBT-1 was well-tolerated in up to 84 weeks oftreatment in Alzheimer's patients. When compared to a historical control, PBT-1appeared to slow the rate of disease progression by approximately half.Prana announced a US$20 million placement of shares in April 2004 with leadingUS biotechnology investors led by OrbiMed Advisors and X Mark Funds andannounced the appointment of a US based CEO in August.Dr. Jon Alsenas, CEO added, "We are excited about the opportunities that lieahead for Prana in fiscal 2005. We will soon have two very promising Alzheimer'sdrugs in the clinic, with the PBT-1 Phase II/III study initiating in the latefirst quarter or the second quarter of 2005 and the PBT-2 Phase I clinical trialalso commencing in early 2005. Moreover, the Prana science continues to showpromise in the treatment of other diseases, such as Parkinson's disease."About Prana Biotechnology LimitedPrana Biotechnology was established to commercialize research into Alzheimer'sdisease and other major age-related degenerative disorders. The company wasincorporated in 1997 and listed on the Australian Stock Exchange in March 2000and listed on Nasdaq in September 2002. Researchers at prominent internationalinstitutions including the University of Melbourne and Massachusetts GeneralHospital, a teaching hospital of Harvard Medical School, discovered Prana'stechnology.For further information, please visit our web site at http://www.pranabio.com  SOURCE Prana Biotechnology LimitedCONTACT:          Kathy Price, Investor Relations Contact for Prana Biotechnology                  Limited, +1-212-983-1702 ext. 212, kprice@annemcbride.com; or Ivette Almeida,                  Media Relations contact for Prana Biotechnology Limited,                  +1-212-983-1702 ext. 209, ivette.almeida@annemcbride.com URL:              http://www.pranabio.com http://www.prnewswire.comCopyright (C) 2004 PR Newswire.  All rights reserved.KEYWORD:          AustraliaINDUSTRY KEYWORD: HEA                  MTC                  BIO
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Heute riesiges Umsatzvolumen

 
03.12.04 18:19
#49
Das 10fache des sonsitgen Umsatzes!

109000 Stücke. Wow, was ist da im busch.
Schön wer schon investiert. Noch kann man sich günstige einkaufen.


gruß
moneymaker

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Buy, buy

 
03.12.04 19:32
#50
120000 nun schon, was läuft da ab.
Und ichhabe immernochkeinen ECN Zugang. Ich bin am Verzweifeln.

Da geht heute was um so 20000 $ ordervolumen, ist keine Seltenheit.

Egal ich bin schon investiert, aber könnte gerne noch mehr von dem Kuchen haben.
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Entweder News, oder ein Fond hat sich eingekauft

 
03.12.04 20:59
#51
News habe ich im Internet noch keine gefunden,

An der Heimatbörse heute nichts Auffäliges,


Es tut dem Wert nur gut, wenn endlich mal Volumen reinkommt.

Bis jezt über 150 `TSD, das ist das 15 Fache, des früheren Volumens.

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Auszug aus Times und Sales

 
03.12.04 21:04
#52
PRANA BIOTECHNOLOGY LTD - Nasdaq SmallCap Market: PRAN
Führend in Alzheimer Forschung! PRANA Biotech. 1731193
Time & Salesmost recent  next page
Rec. TimeActionPriceVolume
1:18:30 PMBid4.15 10000
1:11:50 PMBid4.15 10100
1:11:48 PMBid4.15 10000
1:11:48 PMBid4.16 100
1:11:48 PMAsk4.2 1000
1:11:26 PMBid4.16 200
1:11:26 PMAsk4.24 100
1:11:16 PMAsk4.25 1000
1:11:16 PMBid4.16 100
1:09:50 PMBid4.16 200
1:09:14 PMBid4.16 100
1:09:14 PMBid4.15 10000
1:09:14 PMBid4.15 10100
1:09:14 PMBid4.17 100
1:09:14 PMBid4.15 10000
1:09:12 PMAsk4.24 100
1:09:12 PMBid4.16 100
1:09:12 PMBid4.15 10000
1:09:00 PMBid4.16 100
1:09:00 PMAsk4.25 1000
1:08:34 PMBid4.16 200
1:06:56 PMAsk4.24 100
1:06:44 PMAsk4.25 1000
1:04:46 PMAsk4.24 100
1:04:46 PMTrade4.2 4000
1:04:46 PMTrade4.2 100
1:04:38 PMBid4.16 100
1:03:14 PMAsk4.25 1000
1:02:08 PMTrade4.25 15000
1:01:42 PMBid4.2 100
1:01:42 PMBid4.15 10000
1:01:42 PMBid4.16 100
12:57:40 PMAsk4.26 200
12:57:36 PMAsk4.28 100
12:56:28 PMAsk4.26 200
12:56:20 PMAsk4.27 100
12:56:20 PMAsk4.27 300
12:56:04 PMTrade4.27 2000
12:55:52 PMAsk4.27 500
12:53:48 PMAsk4.27 300
12:51:18 PMTrade4.25 4900
12:51:18 PMTrade4.25 100
12:49:42 PMAsk4.27 100
12:49:04 PMTrade4.25 900
12:49:04 PMTrade4.25 100
12:49:00 PMTrade4.25 900
12:49:00 PMTrade4.25 100
12:48:58 PMTrade4.25 900
12:48:58 PMTrade4.25 100
12:48:02 PMAsk4.28 100
most recent  next page
3:02:01 PM EST - Friday, December 3, 2004 - data is delayed 15 minutes
Führend in Alzheimer Forschung! PRANA Biotech. 1731193
Führend in Alzheimer Forschung! PRANA Biotech. 1731193
DJIAFührend in Alzheimer Forschung! PRANA Biotech. 173119310,585.50Führend in Alzheimer Forschung! PRANA Biotech. 1731193Führend in Alzheimer Forschung! PRANA Biotech. 1731193Führend in Alzheimer Forschung! PRANA Biotech. 17311930.40
Führend in Alzheimer Forschung! PRANA Biotech. 1731193
NasdaqFührend in Alzheimer Forschung! PRANA Biotech. 17311932,149.23Führend in Alzheimer Forschung! PRANA Biotech. 1731193Führend in Alzheimer Forschung! PRANA Biotech. 1731193Führend in Alzheimer Forschung! PRANA Biotech. 17311935.66
Führend in Alzheimer Forschung! PRANA Biotech. 1731193
S&P 500Führend in Alzheimer Forschung! PRANA Biotech. 17311931,190.48Führend in Alzheimer Forschung! PRANA Biotech. 1731193Führend in Alzheimer Forschung! PRANA Biotech. 1731193Führend in Alzheimer Forschung! PRANA Biotech. 17311930.15
Führend in Alzheimer Forschung! PRANA Biotech. 1731193
30 Yr BondFührend in Alzheimer Forschung! PRANA Biotech. 17311934.94Führend in Alzheimer Forschung! PRANA Biotech. 1731193Führend in Alzheimer Forschung! PRANA Biotech. 1731193Führend in Alzheimer Forschung! PRANA Biotech. 17311930.11
Führend in Alzheimer Forschung! PRANA Biotech. 1731193
10 Yr BondFührend in Alzheimer Forschung! PRANA Biotech. 17311934.27Führend in Alzheimer Forschung! PRANA Biotech. 1731193Führend in Alzheimer Forschung! PRANA Biotech. 1731193Führend in Alzheimer Forschung! PRANA Biotech. 17311930.13
Führend in Alzheimer Forschung! PRANA Biotech. 1731193
Führend in Alzheimer Forschung! PRANA Biotech. 1731193
Führend in Alzheimer Forschung! PRANA Biotech. 1731193
Führend in Alzheimer Forschung! PRANA Biotech. 1731193
Select Time Frame
Specify Time:
       9:30a 9:45a 10:00a 10:15a 10:30a 10:45a 11:00a 11:15a 11:30a 11:45a 12:00a 12:15a 12:30a 12:45a 1:00p 1:15p 1:30p 1:45p 2:00p 2:15p 2:30p 2:45p 3:00p 3:15p 3:30p 3:45p 4:00p  
Or Jump:
fwd 1 min   back 1 min
fwd 5 min   back 5 min
fwd 10 min   back 10 min
fwd 15 min   back 15 min
fwd 30 min   back 30 min
fwd 1 hr   back 1 hr
fwd 2 hrs   back 2 hrs
Führend in Alzheimer Forschung! PRANA Biotech. 1731193
Select Action Type
Trades, Bids, and Asks
Trades only
Führend in Alzheimer Forschung! PRANA Biotech. 1731193
Führend in Alzheimer Forschung! PRANA Biotech. 1731193
Führend in Alzheimer Forschung! PRANA Biotech. 1731193


Exchange market data provided by DTN Market Access. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither FreeRealTime.com nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the FreeRealTime.com site, a member has agreed to the FreeRealTime.com Member Agreement.

Copyright © 1998-2

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Was geht hier ab?

 
04.12.04 03:37
#53
200000 zum Schluß des Tages. Was läuft da ab?

Ein gigantischer Umsatz bis September war der tagesumsatz dieser Aktie Im durchschnitt um die 10.000.

Hauptversammlung war am 17 Nov.




Führend in Alzheimer Forschung! PRANA Biotech. sertralin19
sertralin19:

@geldschneider

 
04.12.04 09:56
#54

Du spekulierts auf Alzheimer-Medikamente?
Dann schau Dir doch auch mal Myriad (WKN 897518) an!

Der PRANA-chart gefällt mir sehr gut! Ich mag Aktien,
die aussehen, als könnten sie bald wachgeküßt werden!
Habe zuvor noch nie was gehört von dem Unternehmen.
Gehe vielleicht mal mit einer ersten Position rein?

Gruß
sertralin19
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

@sertralin Danke

 
06.12.04 18:15
#55
Schau ich mir mal an.

Umsatz heute enttäuschend, warum gab es Freitag so dicke Umsätze?

gruß
gs
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Riesige Umsätze heute wieder

 
16.12.04 19:52
#56

(Printer friendly version)
Prana Biotechnology Raises US$3.7 Million Through Exercise of 9.5 Million Options

MELBOURNE, Australia, Dec 8, 2004 /PRNewswire-FirstCall via COMTEX/ -- PranaBiotechnology Limited (Nasdaq: PRAN; ASX: PBT), today announced that 9.5 millionunlisted options expiring on December 1, 2004 were exercised prior to the expirydate. The options were originally largely owned by certain insiders anddirectors of the company then transferred to new owners, who in turn exercisedthem at a price of A$0.50 per share."We are pleased to receive this vote of confidence in Prana Biotechnology," saidJon Alsenas, CEO. "The US$3.73 million (A$4.75 million) raised will be used asworking capital for general corporate purposes. This includes conducting thepotentially pivotal PLACQUE study of PBT-1 in Alzheimer's disease that is due tostart in the first half of 2005."Prana Biotechnology had 117,384,155 ordinary shares outstanding as of December2, 2004, and this exercise of options increases the total issued shares to126,890,821.About Prana Biotechnology LimitedPrana Biotechnology was established to commercialize research into Alzheimer'sdisease and other major age-related degenerative disorders. The company wasincorporated in 1997 and listed on the Australian Stock Exchange in March 2000and listed on NASDAQ in September 2002. Researchers at prominent internationalinstitutions including the University of Melbourne and Massachusetts GeneralHospital, a teaching hospital of Harvard Medical School, discovered Prana'stechnology.For further information, please visit our web site at http://www.pranabio.com.
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Heute großer Umsatz an der Heimatbörse!News!

 
04.01.05 14:36
#57
523902 Stück, im Vergleich zum 31.12. das 20 fache. 
Prana receives Clinical Trials Authorisation in UK

Sydney, Jan 04, 2005 (RWE via COMTEX) -- (RWE Australian Business News) PranaBiotechnology Ltd has received a Clinical Trials Authorisation from theMedicines and Healthcare Products Regulatory Agency of the UK to initiate the"potentially pivotal" PLACQUE (Progression Limitation in Alzheimer's:ClioQUinol's Efficacy) Phase II/III clinical trial.The PLACQUE trial will be conducted over 52 weeks and will enrol 435 patients inthe UK, Australia and South Africa.The purpose of the study is to assess the efficacy of two dose levels of PBT-1(clioquinol) when added to the current therapy of patients with moderateAlzheimer's disease."Receiving CTA approval is a significant milestone for Prana," said CEO Dr JonAlsenas."When 2004 began, the future of PBT-1 was uncertain due in large part to patentlitigation and other concerns."Now as we begin 2005, the patent litigation with PN Gerolymatos SA is behind usand we are on the cusp of transforming Prana from an early-stage developmentcompany to a late-stage development company with the initiation of thepotentially pivotal PLACQUE trial."The CTA approval allows us to clear the first regulatory hurdle to establishingPBT-1 as the first truly effective therapy for Alzheimer's sufferers."We are extremely hopeful that PBT-1 will be the first drug to target what isbelieved to be the root cause of Alzheimer's disease - the accumulation ofamyloid plaques in the neocortex of the brain."Clioquinol appears to be one of the lead candidates to have a significantimpact on both clinical symptoms and disease progression."Prana shares rose 6c to 60c this morning.RWE Australian Business NewsURL:              rweabn.com.auCopyright 2004 RWEABN
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Erlaubnis in UK für Klin. Phase II/III

 
04.01.05 14:44
#58
Prana Biotechnology Receives Clinical Trials Authorization in UK to Initiate PLACQUE Phase II/III Study

MELBOURNE, Australia, Jan 04, 2005 /PRNewswire-FirstCall via COMTEX/ -- PranaBiotechnology Limited (Nasdaq: PRAN, ASX: PBT), today announced it has receiveda Clinical Trials Authorization (CTA) from the Medicines and Healthcare ProductsRegulatory Agency (MHRA) of the United Kingdom to initiate the potentiallypivotal PLACQUE (Progression Limitation in Alzheimer's: ClioQUinol's Efficacy)Phase II/III clinical trial.-- CTA approval enables company to move forward     -- Study enables Prana to progress to late stage development company     -- Prana meets milestone outlined at Analyst Day     -- PBT-1 may be first drug to modify the progression of Alzheimer's        disease    Study SpecificsThe PLACQUE trial will be conducted over 52-weeks and will enroll 435 patientsin the United Kingdom, Australia and the Republic of South Africa. The purposeof the study is to assess the efficacy of two dose levels of PBT-1 (clioquinol)when added to the current therapy of patients with moderate Alzheimer's disease.The trial will be randomized, double blind and placebo-controlled. The primaryendpoint of the study will be to demonstrate a reduction in the progression ofAlzheimer's as measured by the Alzheimer's Disease Assessment Scale-cognition(ADAS-cog).Significant Milestone"Receiving CTA approval is a significant milestone for Prana," said Jon Alsenas,CEO of Prana. "When 2004 began, the future of PBT-1 was uncertain due in largepart to patent litigation and other concerns. Now as we begin 2005, the patentlitigation with P.N. Gerolymatos, S.A. is behind us and we are on the cusp oftransforming Prana from an early stage development company to a late stagedevelopment company with the initiation of the potentially pivotal PLACQUEtrial. The CTA approval allows us to clear the first regulatory hurdle toestablishing PBT-1 as the first truly effective therapy for Alzheimer'ssufferers."We are extremely hopeful that PBT-1 will be the first drug to target what isbelieved to be the root cause of Alzheimer's disease -- the accumulation ofamyloid plaques in the neocortex of the brain," continued Dr. Alsenas."Clioquinol appears to be one of the lead candidates to have a significantimpact on both clinical symptoms and disease progression."Outlook for 2005Prana expects to have two promising Alzheimer's drugs in the clinic, with thePBT-1 Phase II/III PLACQUE study initiating in the second quarter and the PBT-2Phase I clinical trial also commencing in early 2005. Moreover, Prana continuesto focus upon developing a pipeline of drugs for the treatment of otherdisorders where inappropriate protein aggregation plays a key role, such as inParkinson's disease."The Metal Theory"The prize-winning science behind PBT-1 is based upon what is known as "the metaltheory" of Alzheimer's disease. The theory is based on the premise that keymetals, such as zinc and copper, are required for the inappropriate aggregationof amyloid beta to form the amyloid plaques. These plaques are then thought tocause the neurodegeneration associated with Alzheimer's disease. PBT-1 is thefirst of Prana's Metal-Protein Attenuating Compounds (MPACs) to be studied in apotentially pivotal trial. The metal-mediated aggregation of proteins is alsothought to be a key contributor to the development of a variety of otherdegenerative disorders.About Prana Biotechnology LimitedPrana Biotechnology was established to commercialize research into Alzheimer'sdisease and other major age-related degenerative disorders. The company wasincorporated in 1997 and listed on the Australian Stock Exchange in March 2000and listed on NASDAQ in September 2002. Researchers at prominent internationalinstitutions including the University of Melbourne and Massachusetts GeneralHospital, a teaching hospital of Harvard Medical School, discovered Prana'stechnology.For further information, please visit our web site at http://www.pranabio.com.This press release may contain "forward-looking statements" within the meaningof the Private Securities Litigation Reform Act of 1995 regarding the Company'sbusiness strategy and future plans of operation. Forward-looking statementsinvolve known and unknown risks and uncertainties; both general and specific tothe matters discussed in this press release. These and other important factors,including those mentioned in various Securities and Exchange Commission filingsmade by the Company, may cause the Company's actual results and performance todiffer materially from the future results and performance expressed in orimplied by such forward-looking statements. The forward-looking statementscontained in this press release speak only as of the date hereof and the Companyexpressly disclaims any obligation to provide public updates, revisions oramendments to any forward-looking statements made herein to reflect changes inthe Company's expectations or future events.Contacts:     Investor Relations               Media Relations     Kathy Price                      Ivette Almeida     T: 212-983-1702 ext. 212         T: 212-983-1702 ext. 209SOURCE Prana Biotechnology LimitedCONTACT:          Kathy Price, +1-212-983-1702, ext. 212, or Ivette Almeida, +1-212-983-1702, ext. 209                  both for Prana Biotechnology LimitedURL:              http://www.prnewswire.com                  http://www.pranabio.comwww.prnewswire.comCopyright (C) 2005 PR Newswire. All rights reserved.KEYWORD:          AustraliaINDUSTRY KEYWORD: BIO                  HEA                  MTC

Leider finde ich die Austr. Seite nicht mehr.Sie sollen von 0,06 auf 0,6 heute gestiegen sein.

Kann mir bitte jemand einen Link dazu geben Danke.

Bei ASX, kriege ich den Kurs nicht um die Bohne.

Kürzel ist PBT

 

gruß

gs

 

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Rechne heute mit starkem Anstieg in USA !

 
04.01.05 14:55
#59
In Berlin plus 33 % heute!
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

nun wissen wir warum der Umsatz im dezember

 
04.01.05 14:59
#60
am 16. genau, so stark anstieg, und exakt, da habe ich mich wieder plaziert!!
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Vorböslich im Plus 5 % in USA o. T.

 
04.01.05 15:08
#61
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

8 % vorbörslich! Ran an die Startlöcher! o. T.

 
04.01.05 15:30
#62
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Umsatz fast Tagesdurchschnitt in 1/2 Std. erreicht

 
04.01.05 15:59
#63
und 10 %Plus. Das gibt heute Grund zum Feiern.

gut dass ich dick drin bin.
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Wer kennt Baywick Pty Ltd?

 
04.01.05 19:08
#64
Sind zu 13,5  % beteiligt.

Dann die NRB Developments,ca. 3 %
sowie G. Templer, 0,03 %
und Crystal Triangle zu 0,09 %

George Mihaly, hat am 17. November 83.333 Aktien und 300.000 Optionen und zwar gekauft zu 0,48 Aus.$, je Aktie.
Werde nicht schlau aus dieser Info, dann nochmal bzw. danach hat er 166.000 Aktien
Date of change dann 17.12.04

Weitere Geschäfte könnte ihr dem Link entnehmen. Habe nciht alles ausgedruckt.  
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Da haben sich einige Ges. bzw. onds eingekauft im

 
04.01.05 19:27
#65

Dezember, deshalb die dicken Umsätze. Und dann am 17.12. das Aktien Optionsprogramm.

 

http://www.asx.com.au/asx/research/...ity=&industryGroup=NO#chart

 

 

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Im Aufwärtstrend

 
23.01.05 20:18
#66
PRANA BIOTECHNOLOGY LTD - Nasdaq SmallCap Market: PRAN
Führend in Alzheimer Forschung! PRANA Biotech. 1785644
Chart Options    1 Day2 Day5 Day10 Day1 Month6 Month1 Year2 Year5 Year10 YearMax  BarDotLineMountain  Führend in Alzheimer Forschung! PRANA Biotech. 1785644 Charts provided by Telescan
1 Dy  2 Dy  5 Dy  10 Dy  1 Mo  6 Mo  1 Yr  2 Yr  5 Yr  10 Yr  Max
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Kursziel 12 Euro Outperformer!

 
27.01.05 20:58
#67
 Analyst: Rodman & Renshaw
Rating: Market Outperform
  Kurs: n/A 
KGV: 
  Kursziel: 12 
Update: new coverage
  WKN: 753907 
Führend in Alzheimer Forschung! PRANA Biotech. 1791501
Update Prana Biotechnology Ltd. (Spons. ADRs): Mar
27.01.2005 11:57:28
Führend in Alzheimer Forschung! PRANA Biotech. 1791501
Führend in Alzheimer Forschung! PRANA Biotech. 1791501
Führend in Alzheimer Forschung! PRANA Biotech. 1791501Die Analysten von Rodman & Renshaw bewerten in ihrer Analyse vom Mittwoch, 26. Januar 2005 die Aktie von Prana Biotechnology Ltd. (Spons. ADRs) neu mit dem Rating "Market Outperform". Das Kursziel für die Aktie liegt momentan bei 12 $.
Führend in Alzheimer Forschung! PRANA Biotech. 1791501
-red-
Führend in Alzheimer Forschung! PRANA Biotech. 1791501
Führend in Alzheimer Forschung! PRANA Biotech. 1791501Führend in Alzheimer Forschung! PRANA Biotech. 1791501Führend in Alzheimer Forschung! PRANA Biotech. 1791501Führend in Alzheimer Forschung! PRANA Biotech. 1791501Führend in Alzheimer Forschung! PRANA Biotech. 1791501
    Führend in Alzheimer Forschung! PRANA Biotech. 1791501 Führend in Alzheimer Forschung! PRANA Biotech. 1791501  
Anzeige:
100% Rabatt auf das Agio bei:
Immobilienfonds - Schiffsfonds - LV-Sekundärmarktfonds - Medienfonds - Windfonds - Venture Capital

Führend in Alzheimer Forschung! PRANA Biotech. 1791501Weitere Analysen zu Prana Biotechnology Ltd. (Spons. ADRs):
 27.01.05 11:57Führend in Alzheimer Forschung! PRANA Biotech. 1791501 Update Prana Biotechnology Ltd. (Spons. ADRs): Mar
weiter...
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

die 300 % Cchance

 
27.01.05 21:08
#68
PRANA BIOTECHNOLOGY LTD - Nasdaq SmallCap Market: PRAN
Führend in Alzheimer Forschung! PRANA Biotech. 1791510quotes.freerealtime.com/gra/p.gif" style="max-width:560px" >
Chart Options    1 Day2 Day5 Day10 Day1 Month6 Month1 Year2 Year5 Year10 YearMax  BarDotLineMountain  Führend in Alzheimer Forschung! PRANA Biotech. 1791510host.investortoolbox.com/frti/...4_5_d_d_s_213_14_2_d_d-0.gif" style="max-width:560px" > Charts provided by Telescan
Entferntaste fkunktioniert nicht. kann nichts ändern sorry
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Original Infos aus australien !

 
28.01.05 12:43
#69

 

PRANA BIOTECHNOLOGY LIMITED (PBT)

The Company's business is the development of therapeutic drugs for age-related diseases.

On this page you will find:

Delayed share priceFührend in Alzheimer Forschung! PRANA Biotech. 1792270Company detailsCompany announcementsClosing pricesPrice history chartDividendsExchange Traded OptionsWarrants

Delayed share price

Prices are delayed by at least 20 minutes. Retrieving any price indicates your acceptance of the Conditions.

Code Last % Change Bid Offer Open High Low Vol PBT0.5801.75%0.5700.5900.5700.5900.570119,942<!-- tower ad -->Advertisement <!-- AdSpace -->< iframe marginWidth=0 marginHeight=0 src="http://campaigns.f2.com.au/html.ng/cat=companies&ptype=research&site=asx&adspace=160x600" frameBorder=0 width=160 scrolling=no height=600 BORDERCOLOR="#000000">          < /iframe><!-- AdSpace --><!-- end tower ad -->

PRANA BIOTECHNOLOGY LIMITED details

Please note: ASX relies on third parties to provide the information contained in the company details table, and therefore is unable to assume any responsibility for the accuracy or timeliness of the information.

Issuer CodePBTSecuritiesASX Code, Security Description ------------------------------ PBT, Ordinary Fully Paid Official Listing Date28 March, 2000GICS Industry GroupPharmaceuticals & BiotechnologyExempt Foreign?NoInternet Addresshttp://www.pranabio.com/Registered Office AddressSuite 2 , 1233 High Street , ARMADALE , VICTORIA, AUSTRALIA, 3143 Head Office Telephone(03) 9824 8166 Head Office Fax(03) 9824 8161 Share RegistryCOMPUTERSHARE INVESTOR SERVICES PTY LIMITED
YARRA FALLS , 452 JOHNSTON STREET , ABBOTSFORD , VICTORIA, AUSTRALIA, 3067 Share Registry Telephone1300 787 171 (BKR ONLY) Directors / Senior ManagementDr Jonas Alsenas (Executive Director, CEO)
Mr Phillip Hains (CFO)
Prof. Colin Masters (Executive Director)
Mr Geoffrey Kempler (Executive Chairman)
Dr George Mihaly (Non Exec. Director)
Mr Brian Meltzer (Non Exec. Director)
Dr Ross Murdoch (Chief Op. Officer)
Company SecretaryMr Richard RevelinsPrincipal ActivitiesThe Company's business is the development of therapeutic drugs for age-related diseases.


PRANA BIOTECHNOLOGY LIMITED announcements

How are company announcements published on www.asx.com.au?  quelle: http://www.asx.com.au/asx/research/...lActivity=&industryGroup=NO
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Der Kurs rennt und rennt! 300 % Chance!

 
28.01.05 21:14
#70
PRANA BIOTECHNOLOGY LTD - Nasdaq SmallCap Market: PRAN
Führend in Alzheimer Forschung! PRANA Biotech. 1793030quotes.freerealtime.com/gra/p.gif" style="max-width:560px" >
Chart Options    1 Day2 Day5 Day10 Day1 Month6 Month1 Year2 Year5 Year10 YearMax  BarDotLineMountain  Führend in Alzheimer Forschung! PRANA Biotech. 1793030host.investortoolbox.com/frti/..._d_d_d_d_s_103_d_d_d_d-0.gif" style="max-width:560px" >
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Nerven braucht es, bis man Alzheimer kriegt

 
31.01.05 19:00
#71

wen ich mir den Tageschart von heute ansehe, draucht man sich über die Nervösen nicht zu wundern, die heute als Gewinnmitnahmen kamen, zu billig verkauft haben.

PRANA BIOTECHNOLOGY LTD - Nasdaq SmallCap Market: PRAN
Führend in Alzheimer Forschung! PRANA Biotech. 1795011quotes.freerealtime.com/gra/p.gif" style="max-width:560px" >
Chart Options    1 Day2 Day5 Day10 Day1 Month6 Month1 Year2 Year5 Year10 YearMax  BarDotLineMountain  Führend in Alzheimer Forschung! PRANA Biotech. 1795011host.investortoolbox.com/frti/..._d_d_d_d_s_213_d_d_d_d-0.gif" style="max-width:560px" > Charts provided by Telescan

und just sind wir wieder auf gestrigem Kursniveau!

Führend in Alzheimer Forschung! PRANA Biotech. didl229
didl229:

Nur Test

 
31.01.05 23:19
#72
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Was für ein Zufall!

 
01.02.05 17:37
#73
< script language=JavaScript> function qm_openLookup_1256() {      var w = 450;   var h = 350;   var winl = (screen.width - w) / 2;   var wint = (screen.height - h) / 2;   var winprops = 'height='+h+',width='+w+',top='+wint+',left='+winl+',toolbar=0,location=0,directories=0,status=0,menubar=0,scrollbars=1,resizable=1';   win = window.open("http://app.quotemedia.com/quotetools/clientForward?targetURL=" + escape('http://app.quotemedia.com/quotetools/popups/symbolLookup.jsp') + "&forwardURL=http%3A%2F%2Fwww.otcbb.com%2Fhelp%2Fcms_includes%2Fquote_module.htm", "SymbolLookup", winprops);   if (parseInt(navigator.appVersion) >= 4) {      win.window.focus();   }   } function qm_check_1256() {  fObj = document.qm_navForm_1256;  if(fObj["symbol"].value=="") {              fObj["symbol"].value = 'PRAN';        }   return true; } function qm_forward_1256(newIndex, newAction) {     document.qm_navForm_1256.elements[3].selectedIndex = newIndex;     if (qm_check_1256()) {   document.qm_navForm_1256.submit();  } }< /script>
<!-- top bar of buttons -->
MarketsQuoteDepth/LIIChartsNewsFilingsStreamer
<!-- end top bar -->
<!-- get quote bar -->  
Get Quote:  MarketsDetailed QuoteDepth/Level II Charts News FilingsStreamer Symbol Lookuppowered by
  quotemedia.com
<!-- end get quote bar -->
<!-- section heading -->
Market Depth For Prana Biotechnology Ltd AdsDelayed (11:11 AM EST)
<!-- end heading -->
<!-- first table --><!-- third table --><!-- third table -->
Level II Quotebook
<!-- first table --><!-- second table --><!-- second table -->
TimeMMIDSize Bid
11:07TRAC4.500
10:48RODM10 4.490
10:39NITE4.490 
10:23BTRD4.480 
10:15SCHB4.450 
10:48GSCO4.420
09:24SKYC4.300
09:30CRWN4.300 
08:06MLCO4.200 
08:59TDCM4.120
11:04BRUT3.950
07:30HDSN3.900 
07:30JEFF3.780 
07:30EKNS3.500 
07:30HILL3.300 
07:30SUSQ2.550 
07:30AFCO2.000 
07:30BAMM2.000 
09:30GVRC1.090 
09:25PUGS0.010
07:30ADFN0.000 
07:30NOCI0.000 
07:30NQMO0.000 
10:11SIZE0.000 
 
 
 
 
 
 
AskSize   MMIDTime
 4.56011   SCHB10:15
 4.6101   TRAC11:07
 4.6201   GSCO10:48
 4.7401   TDCM08:59
 4.7501   SKYC09:24
 4.8501   MLCO08:06
4.92010   GVRC09:30
4.9501   NITE10:39
 5.0001   HILL07:30
 5.0001   JEFF07:30
 5.0405   EKNS07:30
 5.3401   SUSQ07:30
 5.5001   HDSN07:30
6.2108   CRWN09:30
 6.4001   BAMM07:30
 6.8001   RODM10:48
 10.0001   AFCO07:30
2,000.0001   PUGS09:25
 0.0000   BRUT11:04
 
 
 
 
 
 
 
 
 
 
 
Time & Sales
PriceSizeTime
4.540100010:39:54
4.540100010:39:54
4.48010010:23:32
4.50010010:23:15
4.56024010:15:03
4.55010010:15:02
4.48090010:11:14
4.50010010:11:13
4.56060010:11:04
4.57010010:03:58
4.560240010:03:58
4.570150010:03:27
4.57050010:03:27
4.63050009:34:47
4.630300009:34:47
4.68010001/31
4.700100001/31
4.70044001/31
4.700100001/31
4.70020001/31
4.69010001/31
4.69050001/31
4.66030001/31
4.660270001/31
4.65010001/31
4.65020001/31
4.62040001/31
4.66060001/31
4.66010001/31
4.66050001/31
<!-- footer  --><!-- end footer  -->

Copyright © 2004 QuoteMedia. All rights reserved. Terms of Use.Data delayed 15-20 min. EPS & PE Ratio are based on rolling 12 month figures. Provided by QuoteMedia, Market Data by NAQ.

<!--   End of Quotemedia.com Multi-Channel QuoteModule Code   -->
Der SCHB Makler steht schon wieder mit einer riesigen Menge zu dem niedrigsten Kurs drin. Heute sind es 1000, damals waren es 5000, als es bergab ging, weil ich bei codi welche zum Verkauf gestellt habe.

Allerdings damals konnte man Orders nicht streichen, ohne GEb. zu haben. Also ließ ich sie drin, das wurde mir zum Verhängnis.

Ich habe es jedenfalls ausdrucken lassen und sende es an die Security, weil ich meine Sache auch noch überprüfen lasssen muß.

Solche Zufälle gibt es nicht.

 

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

So ein Zufall

 
01.02.05 18:24
#74

Die Rechnung auf sinkenden Kurs des Makler SCB  ging erst mal auf, alllerdings wurden zu dem Kurs nur wenige Stücke umgesetzt, prompt stellte sich ob dieses Verkaufsdrucks, die Hälfte des Tagesumsatzes sind 11`K, ein paar Dummies vor den Makler. Und der Kurs gab leider nach bis auf 4,50.

Was für ein Zufall aber, das Angebot, zu 4, 56 vom makler ist weg. und im Ask gibt es momentannichts mehr zu verschenken.

So ists recht!

Market Depth For Prana Biotechnology Ltd AdsDelayed (12:06 PM EST)
<!-- end heading -->
<!-- first table --><!-- third table --><!-- third table -->
Level II Quotebook
<!-- first table --><!-- second table --><!-- second table -->
TimeMMIDSize Bid
12:06RODM4.500
10:39NITE4.490 
10:23BTRD4.480 
11:50SCHB4.450 
12:06GSCO4.350
09:24SKYC4.300
09:30CRWN4.300 
08:06MLCO4.200 
08:59TDCM4.120
12:06BRUT3.950 
07:30HDSN3.900 
07:30JEFF3.780 
07:30EKNS3.500 
07:30HILL3.300 
07:30SUSQ2.550 
07:30AFCO2.000 
07:30BAMM2.000 
11:46GVRC1.090 
09:25PUGS0.010
07:30ADFN0.000 
07:30NOCI0.000 
07:30NQMO0.000 
12:06SIZE0.000 
12:06TRAC0.000
 
 
 
 
 
 
AskSize   MMIDTime
 4.7301   BRUT12:06
 4.7301   TRAC12:06
 4.7401   TDCM08:59
 4.7401   GSCO12:06
 4.7501   SKYC09:24
 4.8501   MLCO08:06
4.92010   GVRC11:46
4.9501   NITE10:39
4.9801   SCHB11:50
 5.0001   HILL07:30
 5.0001   JEFF07:30
 5.0405   EKNS07:30
 5.3401   SUSQ07:30
 5.5001   HDSN07:30
6.2108   CRWN09:30
 6.4001   BAMM07:30
 6.8001   RODM12:06
 10.0001   AFCO07:30
2,000.0001   PUGS09:25
0.0000   SIZE12:06
 
 
 
 
 
 
 
 
 
 
Time & Sales
PriceSizeTime
4.50036011:53:20
4.50010011:53:17
4.50010011:53:16
4.50010011:53:15
4.50010011:53:15
4.50010011:53:14
4.52040011:53:14
4.50010011:53:14
4.50050011:53:08
4.51030011:46:19
4.53020011:46:18
4.540100010:39:54
4.540100010:39:54
4.48010010:23:32
4.50010010:23:15
4.56024010:15:03
4.55010010:15:02
4.48090010:11:14
4.50010010:11:13
4.56060010:11:04
4.57010010:03:58
4.560240010:03:58
4.570150010:03:27
4.57050010:03:27
4.63050009:34:47
4.630300009:34:47
4.68010001/31
4.700100001/31
4.70044001/31
4.700100001/31
<!-- footer  --><!-- end footer  -->

Copyright © 2004 QuoteMedia. All rights reserved. Terms of Use.Data delayed 15-20 min. EPS & PE Ratio are based on rolling 12 month figures. Provided by QuoteMedia, Market Data by NAQ.
<!--   End of Quotemedia.com Multi-Channel QuoteModule Code   -->

 

 

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Preis heute in Australien:

 
10.02.05 15:18
#75
PBT0.5703.64%0.5700.5800.5600.5700.55024,930

 

 

Das wäre in USDollar dann 4,42

zum gestirigen Rückgan auf 4, 10 bringt das heute sicher 10 % Plus. 

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Kursziel 12 $ 200 %

 
19.02.05 18:41
#76

Prana Biotechnology initiated with "market outperform"

Wednesday, January 26, 2005 10:10:11 AM ET
Rodman & Renshaw

NEW YORK, January 26 (newratings.com) - Analysts at Rodman & Renshaw initiate coverage of Prana Biotechnology (ticker: PRAN) with a "market outperform" rating. The target price is set to $12.

Wow, ist da was im busch?


Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Chartsignal steht auf Buy!

 
25.02.05 21:55
#77

                    §
PRAN
PRANA BIOTECHNOLOGY LTD ADR
Daily Commentary

Our system posted a BUY-IF today. The previous SELL recommendation that was confirmed was made on 02.22.2005 (3) days ago, when the stock price was 4.4400. Since then PRAN has fallen -4.48% .

Are you still eager to buy? It is O. K., but patience is also a good virtue. The market is thinking to go up but still hesitant. It is better to get the buy permission from the market. Check first what happened at after hours trading and futures. Then, follow the next session very carefully.

Do you see a gap-up at the market open? Do you see a white candlestick forming with a higher close at the session's end? Shortly, is it a nice bullish day? If so, place your buy orders and open new long positions. The market is now on the bull side.

But, be careful, also. If you see a gap-down when the market opens, or if the session closes with a bearish sentiment producing a black candlestick characterized by a lower close, do not challenge the market. Ignore the BUY-IF alert. Cancel the buy orders and cover any new long positions that you might have opened. Bears are still in control.

[MOTTO OF THE DAY]
Up or down the decision will come soon
Buy when the bulls finally go to the moon


Data provided by:  End of Day Data
          §  
BUY-IF
          §
4.2410
+0.0010 +0.02%
Candlestick Analysis
Today’s Candlestick Patterns:

Doji
          §
Candlestick Pattern


Today a Doji was formed. This shows indecision about the direction of the market and it represents a tug-of-war between buyers and sellers.
For more about this candlestick click here.

Click Here!
          §
 
Stock Quote
Day's Close 4.2410
Previous Close 4.2400
Previous Open 4.2300
Change +0.0010
% Change +0.02%
Volume 6,500
          §  
Stock Activity
Day's Open 4.2400
Day's High 4.2900
Day's Low 4.2200


          §
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Erhöhte Nachfarge bei Pran, Kaufsignal

 
05.03.05 12:50
#78
Gestern war das 3 fache Umsatzvolumen.
Kauf- und Nachkaufgelegenheit.
                    §
                    §
PRAN
PRANA BIOTECHNOLOGY LTD ADR
Daily Commentary

Our system posted a BUY-IF today. The previous SELL recommendation that was confirmed was made on 02.22.2005 (11) days ago, when the stock price was 4.4400. Since then PRAN has fallen -7.66% .

Are you still eager to buy? It is O. K., but patience is also a good virtue. The market is thinking to go up but still hesitant. It is better to get the buy permission from the market. Check first what happened at after hours trading and futures. Then, follow the next session very carefully.

Do you see a gap-up at the market open? Do you see a white candlestick forming with a higher close at the session's end? Shortly, is it a nice bullish day? If so, place your buy orders and open new long positions. The market is now on the bull side.

But, be careful, also. If you see a gap-down when the market opens, or if the session closes with a bearish sentiment producing a black candlestick characterized by a lower close, do not challenge the market. Ignore the BUY-IF alert. Cancel the buy orders and cover any new long positions that you might have opened. Bears are still in control.

[MOTTO OF THE DAY]
Up or down the decision will come soon
Buy when the bulls finally go to the moon


Data provided by:  End of Day Data
          §  
BUY-IF

          §
4.1000
+0.0700 +1.74%
Candlestick Analysis
Today’s Candlestick Patterns:

High Wave
          §
Candlestick Pattern


Today a High Wave was formed. This implies a loss of sense of direction and that there is a great amount of indecision in the market.
For more about this candlestick click here.

Click Here!
          §
 
Stock Quote
Day's Close 4.1000
Previous Close 4.0300
Previous Open 3.8800
Change +0.0700
% Change +1.74%
Volume 28,875
          §  
Stock Activity
Day's Open 4.1300
Day's High 4.4200
Day's Low 3.9700
50-Day Close M.A. 4.2276
200-Day Close M.A. 4.2851
65-Day Volume M.A. 30,694
          §

          §
Two-Year Signal History
Date Price Signal $100 Became
02.22.05 4.440 Sell 225
01.13.05 4.050 Buy 205
11.11.04 4.900 Sell 205
10.04.04 3.700 Buy 155
09.27.04 3.870 Sell 155
08.09.04 3.740 Buy 150
08.05.04 3.910 Sell 150
08.03.04 3.651 Buy 140
06.25.04 4.830 Sell 140
06.18.04 4.650 Buy 135
04.20.04 7.790 Sell 135
03.25.04 3.835 Buy 66
01.30.04 4.300 Buy 74
12.19.03 4.500 Sell 74
12.15.03 4.740 Buy 78
08.18.03 5.850 Buy 97
07.17.03 4.250 Sell 97
07.14.03 4.400 Buy 100
05
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Geldspritze für Prana vom Austr. Staat

 
02.04.05 15:57
#79
10 Firmen erhalten Zuschüsse für ihre forschungen. Prana erhält ca. 10 Mio.

Der Kurs hat sehr gelitten wegen der Biotech krise in USA.

#Deshablb

jedoch erneutes Eisntiegssignal.

die original News könnt ihr im Wallstreetboard nachlesen.

Ich habe sie leider nicht gefunden.

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Hier die ausführliche News:

 
03.04.05 20:42
#80
ABC-News:
Last Update: Friday, April 1, 2005. 12:00pm (AEST)
Companies given $47m R&D funding

The Federal Government has given $47 million to seven Australian pharmaceutical and biotechnology companies.

Federal Industry Minister Ian Macfarlane says the funding is part of a five-year initiative to encourage high-quality research and development.

" There is a tremendous breadth in the successful projects - from research and development in cancer treatments to HIV/AIDS, cardiovascular and central nervous system problems and age-related neurodegenerative conditions," Mr Macfarlane said.

" They are importantly all projects with the potential to improve our lives, just as much as they will build on company bottom lines and this investment will make sure our home-grown research is commercialised in Australia."
Companies

Starpharma has been offered $5.6 million to develop products to fight cancer, HIV and respiratory diseases.

CBio Queensland has been given $6 million to commercialise its treatments for inflammatory and auto-immune disorders.

Prana Biotechnology in Victoria has been given $10 million for research and development of age-related, neurodegenerative disease.

Peplin in Queensland has been given $5.6 million to build on its treatment for non-melanoma skin cancer.

Pfizer Australia has been given $10 million for work in areas including cardiovascular, oncology, the central nervous system and infectious and inflammatory diseases.

Alphapharm in Queensland has been given $1.9 million to further develop their range of more than 550 generic medicines.

Alchemia in Queensland has also been given $7.8 million to develop carbohydrate-based therapeutics for the global market.


gruß
geldschneider
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Trotz guter News,

 
04.04.05 22:56
#81
hat der Kurs sehr nachgelassen.

Nachtrag:

Prana Biotechnology begins clinical trial of PBT2

Sydney, Mar 15, 2005 (RWE via COMTEX) -- (RWE Australian Business News) Prana
Biotechnology Ltd has commenced the Phase I clinical trial of PBT2 with the
dosing of its first subject at a facility associated with the Utrecht University
Hospital in the Netherlands.

This is the first of a planned series of studies examining the safety and
pharmacokinetics of PBT2 in normal human volunteers.

PBT2 is the first completely Prana-discovered compound, and is the successor to
PBT1 for the treatment of Alzheimer's disease.

It is designed to have an improved safety and efficacy profile compared with
PBT1.

The compound has demonstrated significantly greater effectiveness in lowering
plaque in the transgenic mouse model in both pre-clinical in-vitro and in-vivo
testing.

Moreover, it appears to be better than PBT1 at decreasing the toxicity of
plaques through improved peroxide inhibition, and appears to have better
pharmaceutical characteristics, such as improved solubility.

Prana shares traded steady at 50c yesterday.


RWE Australian Business News

URL:              rweabn.com.au


Copyright 2004 RWEABN
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Erneuter Einstieg empfohlen, Kursziel 10 $

 
09.04.05 11:55
#82
Die Aktie hat ihr Allzeittief erreicht. Steht auf Buy.

doch Vorsicht, wer eine Bank hat, die mit dem Makler SCHB handelt, der sollte keine Aufträge in USA über Nacht stehen lassen. Siehe auch Wallstreetboard.
Der Makler SCHB ist der einzige der mit riesigen Mengen handelt, nur seltsamerweise hat der nur ein Ziel, die Kurse zu drücken, was ihm gelingt.  Möglich sind solche Manipulationen, weil die Aktien nicht gerade viel Handel hat, nur 10000 Durchschnitt in USA. Wenn da einer VK orders reinstellt zu dumping Kursen, hat das eine entsprechende Wirkung.  
Deshalb wirklich nur tagesgültige Limits einstellen, bei codi, evtl. Commerzbank, die sollen angeblich das Auslandsgesch. für Codi abwickeln, dann Penson, die Amibank und die deutschen Broker die mit Penson zusammenarbeiten.

Ich handle jetzt nur mehr über ECN trading oder tagesgültig. über Penson.

PRANA BIOTECHNOLOGY LTD ADR
Daily Commentary

Our system posted a BUY   CONFIRMED today. The previous SELL recommendation that was confirmed was made on 03.29.2005 (11) days ago, when the stock price was 3.8000. Since then PRAN has fallen -13.68% .

Were you eager to go long? Well, without doubt, it was the right time to do so. The BUY signal was finally confirmed, and most probably you have called your broker and placed your long orders with no hesitation.

Don't worry if you have missed this buying opportunity. The market may now give you a second chance. You may still find good prices for buying in the next session.

[MOTTO OF THE DAY]
Buying was right in a nice bullish day
Hold your stocks now whatever they say


Data provided by:  End of Day Data
          §  
BUY
CONFIRMED
          §
3.2800
+0.1000 +3.14%
Candlestick Analysis
Today’s Candlestick Patterns:

High Wave
          §
Candlestick Pattern


Today a High Wave was formed. This implies a loss of sense of direction and that there is a great amount of indecision in the market.
For more about this candlestick click here.


Der nächste Widerstand liegt bei 5 $ die sollten demnächst erreicht werden mit weiteren guten News, sollten wir die 10 in diesem Jahr noch sehen.
Führend in Alzheimer Forschung! PRANA Biotech. xpfuture
xpfuture:

Cancels Plans for PLACQUE Clinical Study

 
11.04.05 18:33
#83
Monday April 11, 8:30 am ET

MELBOURNE, Australia, April 11 /PRNewswire-FirstCall/ -- Prana Biotechnology Limited (Nasdaq: PRAN, ASX: PBT), announced today that it will not proceed with supporting the initiation of the PLACQUE study evaluating PBT1 (clioquinol) for Alzheimer's disease and has re-evaluated any further work on the PBT1 program.
ADVERTISEMENT
 
As part of the effort to manufacture GMP grade PBT1 clinical trial material, Prana has characterized the various impurities that occur in the synthetic process and found unacceptably high levels of a di-iodo (toxic) form of PBT1. After further investigation, Prana now believes it is possible that the di-iodo impurity that occurs during PBT1 synthesis could be responsible for an increased risk of side-effects and mutagenicity. While Prana has considered methods to reduce the levels of the di-iodo impurity, it has come to the conclusion that attempts to reduce the impurity to safe levels are not likely to be successful in a timely manner and that further development of PBT1 is not warranted.

PBT2 is a backup compound for Alzheimer's disease that is currently in Phase I clinical testing in Utrecht, the Netherlands. PBT2 has a structure that does not contain iodine and is therefore not capable of forming the di- iodo impurity that has been associated with mutagenicity.

After successfully settling the PBT1 patent litigation with P.N. Gerolymatos, S.A., in the third quarter of 2004, and after successfully achieving a Clinical Trials Authorization (CTA) in the U.K. in the fourth quarter of 2004, Prana made the decision to advance PBT1 into the potentially pivotal Phase II/III PLACQUE trial and attempt to accelerate the development timelines of its MPACs.

As a result of these events, Prana is conducting a strategic review of its development programs.

Das wars erstmal mit Prana -55% bei den Amis!

xpfuture
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Es bleibt noch PBT 2

 
14.04.05 12:48
#84
In clin. Phase I

Dieses Medikament hat nciht die toxischen Eigenschaften wie PBT I.

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

von Market Outperform zu Market Perform

 
14.04.05 18:19
#85
NEW YORK, April 12 (newratings.com) - Analysts at Rodman & Renshaw downgrade Prana Biotech (ticker: PRAN) from "market outperform" to "market perform."

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

zu PBT2

 
14.04.05 18:24
#86
Prana Biotechnology shares have plummeted by close to 30% after the company cancelled its development program for PBT1 in Alzheimer's disease.

12 Apr 2005, 13:33 GMT - As part of the effort to manufacture GMP grade PBT1 (clioquinol) for clinical trials, Prana found unacceptably high levels of a di-iodo (toxic) form of PBT1. After further investigation, the company now believes it is possible that the di-iodo impurity that occurs during PBT1 synthesis could be responsible for an increased risk of side-effects and mutagenicity.

While Prana has considered methods to reduce the levels of the di-iodo impurity, the company said it has come to the conclusion that attempts to reduce the impurity to safe levels are not likely to be successful in a timely manner and that further development of PBT1 is not warranted.

The company does have a backup compound for Alzheimer's disease, PBT2, which is currently in phase I clinical testing in Utrecht, the Netherlands. PBT2 has a structure that does not contain iodine and is therefore not capable of forming the di-iodo impurity that has been associated with mutagenicity.

As a result of these events, Prana is conducting a strategic review of its development programs.
Führend in Alzheimer Forschung! PRANA Biotech. xpfuture
xpfuture:

Heute wieder bei den Amis 10% runter !!

 
14.04.05 18:31
#87
Wieviel haben die eigentlich an Cashreserven? Kommen die noch länger über die Runden, ohne gleich Aktien für die Finanzierung ihre klinischen Tests raus geben zu müssen.

xpfuture
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Aus den austr. Börsenboards

 
14.04.05 19:24
#88
Posted By: Biozone In reply to: 754
Posted on: 12/04/2005 12:11:27 PM Post: 755
      Prev§Post Reply | Back To Board Next

Very hard call to make for Prana. I assume this means that potential income has been delayed by using a fallback product? But how long is the day and does this justify the sell off from 0.52 to 0.18? I would be interested to see if any of the brokers or independent analysts have a view on this.

Voluntary Disclosure: No Position Short Term rating: No Position Long Term Rating: No Position

Posted By: aaron888 In reply to:
Posted on: 12/04/2005 18:22:52 PM Post: 756
      Prev§Post Reply | Back To Board Next

i did not expect or foresee this cancellation of the placque study at all! now that only pbt2 is left, opinions on if this a keeper or not? not having looked at the share price in a few days...i thought i was looking at the wrong share price, over 60% drop ouch!

Posted To:  Shares  |  View Thread  |  Prev  |  Next   Title: bought some pbt earlier today.cash backing around 16 cents  
from my calculations. not for the faint hearted. read all the bad announcement yesterday...


wenig genug über Prana

www.ozestock.com.au/quote.asp?a=quoteSingle&limit=25&symbol=PBT

www.investorweb.com
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

die haben genug Geld!

 
14.04.05 19:30
#89
Die haben von der austr. Regierung Geld bekommen für Ihre Forschungen in Höhe von 10 Mio austr. $.

Die Zittrigen schmeißen weiter die Aktien raus. Es ist schon sehr schlimm der Ausverkauf.

Für die Aktionäre ein bitter Bier, aber besser vor Markteinführung ein Schluß, als nach markteinführung das Problem. Ich gebe es zu, mir wäre es anders lieber.

Zeigt aber doch, dass Prana eine seriöse Firma ist.

Um jedes Risiko auszuschließen, wird die Versuchsphase eingestellt.

Mit diesem Geld können die PBT 2 sehr gut weiter finanzieren. Und möglicherweise weitere produkte, in Angriff nehmen.
Führend in Alzheimer Forschung! PRANA Biotech. xpfuture
xpfuture:

Laut yahoo haben die

 
14.04.05 19:30
#90
23 Mio in Cash. Das bedeutet 1,37/Aktie und das bei einem Kurs von 1,14.

xpfuture
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Die Pipeline von Prana

 
15.04.05 06:41
#91
www.pranabio.com/company_profile/pipeline.asp

sehr übersichtlich:

PBT2 Alzheimer

NG 1 Parkinson

NG 2  Alzheimer

Immunotherapy: Alzheimer

New Science :  Neurogenerative Disease

Schaut doch recht gut aus, die weitere Pipeline.

Und mit dem Cash im Bestand von Prana, kann die Aktie bald wieder steigen.

 
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Kurs notiert unter Wert

 
17.04.05 11:13
#92
Da der Wert undervalued ist,und der Kurs zu starkt meines Erachtens nachgelassen hat,
sollte es in Kürze eine Gegenbewegung geben. entweder jetzt raus und erst wieder rein wenn Gegenbewegung kommt, nur ist man dann meist nicht schnell genug dabei.

In-Depth Analysis
Business: PRANA BIOTECHNOLOGY LTD -ADR, (PRAN) Seeks to commercialize research into Alzheimer's disease and other major age-related degenerative disorders. The company's mission is to develop diagnostic and therapeutic drugs to treat the central disease pathways that cause degeneration of the brain
 
Price: PRAN closed on 4/15/2005 at $1.08 per share  
 
Value: Value is a measure of a stock's current worth.  PRAN has a current Value of $1.92 per share. Therefore, it is undervalued compared to its Price of $1.08 per share.  Value is computed from forecasted earnings per share, forecasted earnings growth, profitability, interest, and inflation rates. Value increases when earnings, earnings growth rate and profitability increase, and when interest and inflation rates decrease. VectorVest advocates the purchase of undervalued stocks. At some point in time, a stock's Price and Value always will converge.  
 
RV (Relative Value): RV is an indicator of long-term price appreciation potential. PRAN has an RV of 1.34, which is very good on a scale of 0.00 to 2.00. This indicator is far superior to a simple comparison of Price and Value because it is computed from an analysis of projected price appreciation three years out, AAA Corporate Bond Rates, and risk. RV solves the riddle of whether it is preferable to buy High growth, High P/E stocks, or Low growth, Low P/E stocks. VectorVest favors the purchase of stocks with RV ratings above 1.00.

 
RS (Relative Safety): RS is an indicator of risk. PRAN has an RS rating of 0.85, which is fair on a scale of 0.00 to 2.00. RS is computed from an analysis of the consistency and predictability of a company's financial performance, debt to equity ratio, sales volume, business longevity, price volatility and other factors. A stock with an RS rating greater than 1.00 is safer and more predictable than the average stock in the VectorVest database. VectorVest favors the purchase of stocks of companies with consistent, predictable financial performance.
 
RT (Relative Timing): RT is a fast, smart, accurate indicator of a stock's price trend. PRAN has a Relative Timing rating of 0.02, which is very poor on a scale of 0.00 to 2.00.  RT is computed from an analysis of the direction, magnitude, and dynamics of a stock's price movements over one day, one week, one quarter and one year time periods. Once a stock's price has established a strong trend, it is expected to continue in that trend for the short-term. If a trend dissipates, RT will gravitate toward 1.00. RT will explode from bottoms, dive from tops, and reflect changes in price momentum. VectorVest favors the purchase of stocks with RT ratings above 1.00.  
 
VST (VST-Vector):  VST is the master indicator for ranking every stock in the VectorVest database. PRAN has a VST rating of 0.86, which is fair on a scale of 0.00 to 2.00. VST is computed from the square root of a weighted sum of the squares of RV, RS, and RT. Stocks with the highest VST ratings have the best combinations of Value, Safety and Timing. These are the stocks to own for above average, long-term capital appreciation. VectorVest advocates the purchase of safe, undervalued stocks rising in price.  
 
CI (Comfort Index): CI is an indicator which reflects a stock's ability to resist severe and/or lengthy price declines. PRAN has a CI rating of 0.48, which is very poor on a scale of 0.00 to 2.00. CI is quite different from RS in that it is based solely upon a stock's long-term price history. VectorVest advocates the purchase of high CI stocks.  
 
GRT (Earnings Growth Rate): GRT reflects a company's one to three year forecasted earnings growth rate in percent per year. PRAN has a forecasted Earnings Growth Rate of 11.00%, which VectorVest considers to be good. GRT is computed from historical, current and forecasted earnings data. It is updated each week for every stock in the VectorVest database. GRT often foretells a stock's future price trend. If a stock's GRT trend is upward, the stock's price will likely rise. If GRT is trending downward, the stock's Price will probably fall. VectorVest favors the purchase of stocks whose GRT is rising and is greater than the sum of current inflation and interest rates, (8.56%).  
 
Recommendation (REC): VectorVest gives a Buy, Sell, Hold recommendation on every stock, every day. PRAN has a Sell recommendation. REC reflects the cumulative effect of all the VectorVest parameters working together. These parameters are designed to help investors buy safe, undervalued stocks rising in price. They also help investors avoid or sell risky, overvalued stocks falling in price. VectorVest recommends that investors buy high VST-Vector, Buy-rated stocks in rising markets.  
 
Stop (Stop-Price): Stop is an indicator of when to sell a long position or cover a short position.  PRAN has a Stop of $2.93 per share. This is $1.85 above PRAN's current closing Price. A stock's Stop is computed from a 13 week moving average of its closing prices, and is fine-tuned according to the stock's fundamentals. High RV, high RS stocks have lower Stops, and low RV, low RS stocks have higher Stops. In the VectorVest system, a stock gets a 'B' or 'H' recommendation if its Price is above its Stop and an 'S' recommendation if its Price is below its Stop.
 
EPS (Earnings per Share):  EPS stands for leading 12 months Earnings Per Share.  PRAN has a forecasted EPS of $-0.39 per share. VectorVest determines this forecast from a combination of recent earnings performance and traditional fiscal and/or calendar year earnings forecasts.  
 
P/E (Price to Earnings Ratio): P/E is a popular measure of stock valuation which shows the dollars required to buy one dollar of earnings.  PRAN has a P/E of -2.77. This ratio may be deemed to be high or low depending upon your frame of reference. The average P/E of all the stocks in the VectorVest database is 28.56. P/E is computed daily using the formula: P/E = Price/EPS.  
 
EY (Earnings Yield): EY reflects earnings per share as a percent of Price. EY is related to P/E via the formula, EY = 100 / (P/E), and may be used in place of P/E as a measure of valuation. EY has the advantages that it is always determinate and can reflect negative earnings. PRAN has an EY of -36.32 percent. This is below the current average of 3.52% for all the stocks in the VectorVest database. EY equals 100 x (EPS/Price).  
 
GPE (Growth to P/E Ratio): GPE is another popular measure of stock valuation. It compares earnings growth rate to P/E ratio. PRAN has a GPE rating of -3.99.  High growth stocks are believed to be able to justify high P/E ratios. A stock is commonly considered to be undervalued when GPE is greater than 1.00 and overvalued when GPE is below 1.00. Unfortunately, this rule of thumb does not take into account the effect of interest rates on P/E ratios. The operative GPE ratio of 1.00 is valid when and only when interest rates equal 10%. With long-term interest rates currently at 5.56%, the operative GPE ratio is 0.31. Therefore, PRAN may be considered to be overvalued.  
 
DIV (Dividend): VectorVest reports annual, regular, cash dividends as indicated by the most recent payments. Special distributions, one-time payments, stock dividends, etc., are not generally included in DIV. PRAN does not pay a dividend.  
 
DY (Dividend Yield): DY reflects earnings per share as a percent of Price. PRAN does not pay a dividend, so it does not have a Dividend Yield rating. . DY equals 100 x (DIV/Price). It is useful to compare DY with EY. If DY is not significantly lower than EY, the dividend payment may be in jeopardy.  
 
DS (Dividend Safety): DS is an indicator of the assurance that regular cash dividends will be declared and paid at current or at higher rates for the foreseeable future. PRAN does not pay a dividend, so it does not have a Dividend Safety rating . Stocks with DS values above 75 typically have RS values well above 1.00 and EY levels that are much higher than DY.

 
DG (Dividend Growth Rate): Dividend Growth is a subtle yet important indicator of a company's financial performance. It also provides some insight into the board's outlook on the company's ability to increase earnings. PRAN does not pay a dividend, so it does not have a Dividend Growth rating .  
 
YSG (YSG-Vector): YSG is an indicator which combines DIV, DY and DG into a single value, and allows direct comparison of all dividend-paying stocks in the database. PRAN does not pay a dividend, so it does not have a YSG rating . Stocks with the highest YSG values have the best combinations of Dividend Yield, Safety and Growth. These are the stocks to buy for above average current income and long-term growth.  
 
Open: PRAN opened trading at a price of $1.10 per share on 4/15/2005.
 
High: PRAN traded at a High price of $1.14 per share on 4/15/2005.
 
Low: PRAN traded at a Low price of $1.07 per share on 4/15/2005
 
Close: PRAN closed trading at price $1.08 per share on 4/15/2005. (Close is also called Price in the VectorVest system)
 
Range: Range reflects the difference between the High and Low prices for the day. PRAN traded with a range of $0.07 per share on 4/15/2005.  
 
$Change: PRAN closed down 0.07 from the prior day's closing Price.  
 
%PRC: PRAN's Price changed -6.09% from the prior day's closing price.
 
Volume: PRAN traded 195,700 shares on 4/15/2005.
 
AvgVol: AvgVol is the 50 day moving average of daily volume as computed by VectorVest. PRAN has an AvgVol of 84,600 shares traded per day.
 
%Vol: %Vol reflects the percent change in today's trading volume as compared to the AvgVol. %Vol equals 100 x (Volume/AvgVol). PRAN had a %Vol of 131.32% on 4/15/2005
 
Sales: PRAN has annual sales of $1,000,000
 
Sales Growth: Sales Growth is the Sales Growth Rate in percent over the last 12 months. PRAN has a Sales Growth of 177.00% per year. This is excellent. Sales Growth is updated each week for every stock. It is often useful to compare Sales Growth to Earnings Growth to gain an insight into a company's operations.  
 
Sales Per Share (SPS): PRAN has annual sales of $0.10 per share. SPS can be used as a measure of valuation when comparing stocks within an Industry Group.  
 
Price to Sales Ratio (P/S): PRAN has a P/S of 10.89. This ratio is also used as a measure of valuation. Here, too, it is useful when comparing stocks within an Industry Group.
 
Shares: PRAN has 11,000,000 shares of stock outstanding.
 
Market Capitalization: PRAN has a Market Capitalization of $12,000,000. Market Capitalization is calculated by multiplying price times shares outstanding.
 
Industry Group: PRAN has been assigned to the Drug (Biomedical\Genetic) Industry Group. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.
 
Business Sector: PRAN has been assigned to the Drug Business Sector. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.
 
The basic strategy of VectorVest is to buy Low risk, High reward stocks. We suggest that Prudent investors buy enough High Relative Value, High Relative Safety stocks to keep the overall RV and RS ratings of their portfolios above 1.00. As you do this, you'll find that your risk will go down and your investment performance will improve.
 
Führend in Alzheimer Forschung! PRANA Biotech. xpfuture
xpfuture:

@geldschneider, das es wohl zu einer

 
17.04.05 20:29
#93
Gegenreaktion kommen wird ist klar - die Frage ist nur wann?

Übrigens wie sieht´s aus mit Verbindlichkeiten? Wäre interessant im Bezug auf die Marktkap. - müßte man doch miteinbezieh´n.

xpfuture
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Buchwert ist mindestens2 x höher als der Kurswert.

 
17.04.05 22:14
#94
Ich gehe allerdings davon aus, dass der Buchwert weit höher ist. Die Analyse bezieht sich auf die letzen Zahlen, die 10 Mio Austr. $ , Zuschuß der Regierung sind in die Zahlen noch nicht eingeflossen.

Auszug aus dem Yahoo Forum:
Why is this stock at $1 US dollar level? This company still has the science and they still have PBT2 is still in progress.. The book value is 2x the current stock price. Who's selling?
Is this company going under?
I found this:
Today's News
Journal of Neuroscience Paper Further Validates Prana Science MELBOURNE, Australia, April 7 2004/PRNewswire-FirstCall/ -- Prana
Biotechnology Ltd. (Nasdaq: PRAN; ASX: PBT), today announced the publication
of a new paper in the current edition of Journal of Neuroscience. The results
further support Prana's theory that metals in the brain, rather than proteins
on their own, are responsible for the pathology of Alzheimer's Disease and
that attenuating the action of these metals may hold the key to effective
therapeutic intervention.
It is known that zinc reacts with amyloid beta to cause the amyloid
plaques around nerve endings in Alzheimer's disease. The role of zinc in the
formation of damaging amyloid plaques in blood vessels supplying the brain has, up to now, not been clear. Amyloid deposits in arteries cause damage to the blood vessel wall resulting in impaired blood flow. If these deposits occur in arteries that supply blood to the brain then this may starve the brain tissue of oxygen
compounding the dementia associated with Alzheimer's Disease. This Journal of Neuroscience article demonstrates that zinc plays a central role in the formation of amyloid plaques not only at the nerves but

also in the blood vessels of the brains of people with Alzheimer's Disease. Prana's scientific consultants produced a mouse model which lacked a protein from nerve endings that transports and mediates the levels of zinc in
the nerves and surrounding tissue. They observed that not only did the blood
vessel walls in the brains of these mice have lower levels of zinc, but with less zinc there is also significantly fewer myloid deposits. These new results show that the same zinc responsible for toxic amyloid deposits around
nerves is also responsible for causing amyloid deposits in blood vessels. Dr. Ashley Bush, chief scientific consultant to Prana, and senior author on the publication explained; "These findings strongly support the suitability of Prana's MPAC* class of drugs for targeting amyloid deposits in Alzheimer's
disease, both in the blood vessels in the brain and in the brain tissue around the nerve endings. "It is yet another piece of evidence that attenuating the interaction of
metals and amyloid protein could be beneficial in treating Alzheimer's Disease," said Dr Bush.
Prana's MPAC technology is designed to attenuate the interaction of zinc and amyloid protein in the brain of patients with Alzheimer's Disease. To view the abstract on the Journal of Neuroscience website please visit:www.jneurosci.org/cgi/content/abstract/24/13/3453

finance.messages.yahoo.com/...9&tid=pran&sid=14187539&mid=1259
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Chartechn. auf Hold -Candlestick Analysis

 
17.04.05 22:16
#95
PRANA BIOTECHNOLOGY LTD ADR
Daily Commentary

Our system posted a HOLD today. The previous BUY recommendation that was confirmed was made on 04.08.2005 (9) days ago, when the stock price was 3.2700. Since then PRAN has fallen -66.97% .

Have you bought this stock when the recent BUY signal was confirmed? If so, it is great. Just relax and wait.

What will you do now? Well, the HOLD tag says all that is to say. Keep on holding your stocks and do not bother yourself with any further buying or selling as long as the HOLD tag stays.

[MOTTO OF THE DAY]
Buying is easy but holding is hard
The winner is who holds them tight


Data provided by:  End of Day Data
          §  
HOLD
          §
1.0800
-0.0700 -6.09%
Candlestick Analysis
Today’s Candlestick Patterns:

High Wave
          §
Candlestick Pattern


Today a High Wave was formed. This implies a loss of sense of direction and that there is a great amount of indecision in the market.
For more about this candlestick click here.  
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

gute Vorgaben aus Australien + 17 %

 
18.04.05 13:19
#96
Last Price   +/-   %   Open   High   Volume
$0.1700 $0.0200 13.3% 0.1400 0.1750 661,650
Bid Ask # Bid # Ask Low Value
0.1600 0.1700 2 2 0.1300 96,730

Nach erstem Kursrückgang auf 0,13, ging der Kurs dann auf 0,17
Jet sollte sichnur mein Devisenrechner von codi öffnen, was er nicht macht.
PBT,2005/04/18,0.1500
10:52:20,0.1400,6000
11:03:30,0.1400,40400
11:08:56,0.1400,12500
11:14:39,0.1400,8000
11:22:34,0.1400,13100
11:41:48,0.1350,26000
11:42:26,0.1350,24000
11:43:59,0.1350,1900
11:53:54,0.1300,40000
11:54:20,0.1300,30000
11:58:32,0.1300,48100
12:00:53,0.1300,36900
12:02:39,0.1300,13100
12:32:50,0.1400,33000
12:46:56,0.1400,18900
14:23:43,0.1450,100000
14:25:21,0.1450,3168
14:55:39,0.1550,29750
14:57:53,0.1750,69000
14:58:25,0.1750,12832
15:19:15,0.1650,11800
15:20:50,0.1650,6000
15:31:57,0.1600,10000
15:32:19,0.1600,17200
15:41:18,0.1700,50000

Hat einer einen guten ? Danke,  Devisenrechner auf Webseite.
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Chartechnik hat wieder recht gehabt.

 
18.04.05 17:53
#97
Auch im Amiland heute wieder Plus, wenn auch nicht viel.

Der Kurs sollte mind. bis 1,30$ heute werden dann ist er gleich zu Australien.

Führend in Alzheimer Forschung! PRANA Biotech. xpfuture
xpfuture:

Schau hier @geldschneider:

 
18.04.05 18:02
#98
waehrungen.onvista.de/

xpfuture
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

@xpfuture danke- News by prana

 
05.05.05 16:21
#99
Online banking hits hip pocket nerve
May 5, 2005 - 2:14PM
Page Tools

   * Email to a friend
   * Printer format
   *
   *

It was supposed to be free, easy and safe.

But online banking is nowadays neither free nor absolutely safe for the eight million Australians who prefer to let their fingers do the walking.

The Australian Federal Police and the banking industry believe online banking fraud is the world's fastest-growing crime.

And with increasingly sophisticated security regimes needed to fight cyber crime, consumers are set to pay more to bank online.

Three of Australia's five biggest banks - the Commonwealth Bank, National Australia Bank (NAB) and Westpac - and a number of smaller financial institutions charge customers internet fees.

Banks say online banking fees are needed to fight cyber criminals.

This week NAB announced it would add an additional layer of security by using mobile phone text message technology for customers completing third party payments.

There are no fee increases related to NAB's initiative.

But last week Commonwealth Bank bumped up its online transaction fees in a $100 million next-generation online services and security overhaul.
AdvertisementAdvertisement

All of the bank's 1.9 million internet bank users would be using the new system - and paying the extra fees - by the end of June.

An international money transfer will cost Commonwealth customers $22 per transfer and to import files, such as payroll details, $2.50 per file.

Under new scheme, the first three third-party payment transactions and scheduled bill payments per calendar month will be free, but after that customers will have to pay 50 cents per transaction.

The fees reflect part of the vast complex array of internet banking fees which most consumers now accept as a fact of life.

But it was not supposed to be.

According to the Australian Consumers Association (ACA) spokeswoman Lisa Tait, consumers had been led to believe internet banking was free.

"The strategy was to get people used to online banking when it was free and once they've developed the habit to charge them for it," Ms Tait said.

"It's an extremely cynical ploy on behalf of the banks.

"But consumers don't need to feel they don't have a choice because they can shop around."

Ms Tait rejects the argument that online banking fees are needed to fight online crime.

"We think it's a bit off actually using internet security as a reason why they have to up their fees," she said.

"What about those banks and credit union who don't charge.

"We think it really has to do with returning profits to shareholders - that's the bottom line."

ACA's website flickyourbank.com.au has listings of all fees charges by banks, building societies and credit unions in Australia.

According to the site, of the five biggest banks only the ANZ and St George don't charge internet transactions fees and say they have no plans to change their minds.

While many institutions don't charge, some do - like wounded bulls.

Citibank charges $2.00 and the University Credit Society $1.00 - but most levy a fee of between 20 and 50 cents a transaction.

Many financial institutions have a certain amount of free internet transactions - for a monthly fee.

For other transaction fees kick in after a certain number of transactions.

NAB's personal banking spokesman Andrew McConville said his bank's online fees online fees were "competitive".

He denied the charge that some banks have pushed online fees by stealth.

"I think we've been very up front and transparent with internet banking for a long time," Mr McConville said.

"Our fees are very competitive especially in flat monthly fees.

"Outside those monthly fees we are also very competitive."

But ANZ spokesman Paul Andrews said the bank was not about to change its no-fee position.

"We've always taken the view that internet banking is one of the lower cost channels in terms of what it costs us to deliver," he said.

"We are very keen to put that as part of our package to customers and ... as a way to build business."

© 2005 AAP
Brought to you by aap

Und schonb geht es aufwärts ein wenig wenigstens mit dem Kurs. Plus 6 % heute
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Link für wallstreetwebcasting:

 
05.05.05 16:42
www.wallstreetwebcasting.com/webcast/rrshq5/pran/

der Ausblick, bzw. die Ausführungen scheinen den Kurs zu beflügeln.
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

sorry Posting 99 ist falsch! Roadshow 4.5.05wars

 
10.05.05 19:41
Prana Biotechnology to Present at Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference

MELBOURNE, Australia, May 4, 2005 /PRNewswire-FirstCall via COMTEX/ -- Prana
Biotechnology Limited (Nasdaq: PRAN, ASX: PBT), today announced that its
founding scientist, Professor Ashley Bush of Harvard Medical School, will
present at the Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference
at the InterContinental Hotel in Paris on Thursday, May 5, 2005, at 12:40 PM
CET.

Professor Bush's presentation will contain a scientific review of the MPAC
(Metal-Protein Attenuating Compounds) theory. A live web cast and replay of the
presentation will be available on the Prana Biotechnology web site:
www.pranabio.com.

To arrange a one-on-one meeting with Professor Bush during the conference,
please contact Kathy Price at The Anne McBride Company, tel. 212-983-1702, ext
212, or kprice@annemcbride.com.

The founding scientists', Professors Rudolph Tanzi and Ashley Bush, theories
concerning the interaction between metals and the protein beta-amyloid in the
brain are the basis of Prana's treatments for Alzheimer's and other
neurodegenerative diseases.

About Prana Biotechnology Limited

Prana Biotechnology was established to commercialize research into Alzheimer's
disease and other major age-related degenerative disorders. The company was
incorporated in 1997 and listed on the Australian Stock Exchange in March 2000
and listed on NASDAQ in September 2002. Researchers at prominent international
institutions including the University of Melbourne and Massachusetts General
Hospital, a teaching hospital of Harvard Medical School, discovered Prana's
technology.



For further information, please visit our web site at

www.pranabio.com.



   Contacts:

   Investor Relations                Media Relations

   Kathy Price                       Ivette Almeida

   T: 212-983-1702 ext. 212          T: 212-983-1702 ext. 209

   E: kprice@annemcbride.com         E: ivette.almeida@annemcbride.com

SOURCE Prana Biotechnology Limited



CONTACT:          Investor Relations
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Und seither gehts wieder aufwärts Im Kurs

 
10.05.05 19:43
Sehr positver Asublick s. # 100 Original webcasting
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

heute wieder plus 5 %

 
10.05.05 20:48
PRANA BIOTECHNOLOGY LTD - Nasdaq SmallCap Market: PRAN (NEW charting help)
Führend in Alzheimer Forschung! PRANA Biotech. 1933594
 {font-weight:bold;color:#ffffff;}.mwExchange {color:#ffffff;}
Enter Symbol or Keyword:Time Frame: 
1-day2 days5 days10 days----------1 month2 months3 months6 monthsYTD1 year2 years3 years4 years5 years1 decadeAll Data Additional chart controls
Führend in Alzheimer Forschung! PRANA Biotech. 1933594
 PRAN - Prana Biotechnology Ltd (NASDAQ SC)1:49 PM ET, 5/10/2005 
Führend in Alzheimer Forschung! PRANA Biotech. 1933594
Führend in Alzheimer Forschung! PRANA Biotech. 1933594
Frequency:Price Display:
Start Date:Führend in Alzheimer Forschung! PRANA Biotech. 1933594End Date:
Size:
1-Minute5-Minute15-MinuteHourly----------DailyWeeklyMonthlyQuarterlyYearly Hide PriceHLCOHLCCandlestickMountainBar ChartsDotCloseLogarithmic StandardLarge
Compare to Index:Compare to Symbol(s):
Moving Average:Days:
<None>SMASMA (2-Line)SMA (3-Line)EMAEMA (2-Line)EMA (3-Line)
Upper Indicator:
<None>DJIANASDAQS&P 500Russell 2000----------InternetBroker/DealersOil & GasGold & SilverUtilitiesTransportationAirlines <None>MA EnvelopesBollinger BandsParabolic SARVolume by PricePrice Channel----------Show SplitsShow EarningsShow DividendsShow All Events----------A/D Line
Lower Indicator 1:Lower Indicator 2:Lower Indicator 3: 
VolumeVolume+RSIMACDOBVFast StochasticSlow StochasticROCWilliams %RMoney FlowDMIVol AccumulationVolatility FastVolatility SlowMomentumUlt Oscillator% Short InterestRolling EPSP/E RatioP/E RangesRolling DividendYield----------Up/Down RatioArms Index (TRIN)A/D Line (Breadth)A/D Line (Daily)----------% Compare <None>VolumeVolume+RSIMACDOBVFast StochasticSlow StochasticROCWilliams %RMoney FlowDMIVol AccumulationVolatility FastVolatility SlowMomentumUlt Oscillator% Short InterestRolling EPSP/E RatioP/E RangesRolling DividendYield----------Up/Down RatioArms Index (TRIN)A/D Line (Breadth)A/D Line (Daily)----------% Compare <None>VolumeVolume+RSIMACDOBVFast StochasticSlow StochasticROCWilliams %RMoney FlowDMIVol AccumulationVolatility FastVolatility SlowMomentumUlt Oscillator% Short InterestRolling EPSP/E RatioP/E RangesRolling DividendYield----------Up/Down RatioArms Index (TRIN)A/D Line (Breadth)A/D Line (Daily)----------% Compare

Copyright © 2005 BigCharts. All rights reserved. Please see our Terms of Use.
MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc.
Intraday data provided by ComStock, an Interactive Data Company and subject to the Terms of Use.
Intraday data is at least 15-minutes delayed. All times are ET.
Historical and current end-of-day data provided by FT Interactive Data.
< script language=JavaScript><!--function mktwrepaint() {if (document.layers) {window.stop();setTimeout("document.location.reload()", 1500);}}function init() {if (document.layers) {setTimeout("window.onresize = mktwrepaint", 1500);     } }init();//-->< /script>
Führend in Alzheimer Forschung! PRANA Biotech. 1933594
Führend in Alzheimer Forschung! PRANA Biotech. 1933594
DJIAFührend in Alzheimer Forschung! PRANA Biotech. 193359410,276.80Führend in Alzheimer Forschung! PRANA Biotech. 1933594Führend in Alzheimer Forschung! PRANA Biotech. 1933594Führend in Alzheimer Forschung! PRANA Biotech. 1933594107.50
Führend in Alzheimer Forschung! PRANA Biotech. 1933594
NasdaqFührend in Alzheimer Forschung! PRANA Biotech. 19335941,961.86Führend in Alzheimer Forschung! PRANA Biotech. 1933594Führend in Alzheimer Forschung! PRANA Biotech. 1933594Führend in Alzheimer Forschung! PRANA Biotech. 193359417.81
Führend in Alzheimer Forschung! PRANA Biotech. 1933594
S&P 500Führend in Alzheimer Forschung! PRANA Biotech. 19335941,166.06Führend in Alzheimer Forschung! PRANA Biotech. 1933594Führend in Alzheimer Forschung! PRANA Biotech. 1933594Führend in Alzheimer Forschung! PRANA Biotech. 193359412.78
Führend in Alzheimer Forschung! PRANA Biotech. 1933594
Russell 2000Führend in Alzheimer Forschung! PRANA Biotech. 1933594595.24Führend in Alzheimer Forschung! PRANA Biotech. 1933594Führend in Alzheimer Forschung! PRANA Biotech. 1933594Führend in Alzheimer Forschung! PRANA Biotech. 19335947.67
Führend in Alzheimer Forschung! PRANA Biotech. 1933594
CBOE VolatilityFührend in Alzheimer Forschung! PRANA Biotech. 193359414.70Führend in Alzheimer Forschung! PRANA Biotech. 1933594Führend in Alzheimer Forschung! PRANA Biotech. 1933594Führend in Alzheimer Forschung! PRANA Biotech. 19335940.95
Führend in Alzheimer Forschung! PRANA Biotech. 1933594
30 Yr BondFührend in Alzheimer Forschung! PRANA Biotech. 19335944.58Führend in Alzheimer Forschung! PRANA Biotech. 1933594Führend in Alzheimer Forschung! PRANA Biotech. 1933594Führend in Alzheimer Forschung! PRANA Biotech. 19335940.03
Führend in Alzheimer Forschung! PRANA Biotech. 1933594
10 Yr BondFührend in Alzheimer Forschung! PRANA Biotech. 19335944.22Führend in Alzheimer Forschung! PRANA Biotech. 1933594Führend in Alzheimer Forschung! PRANA Biotech. 1933594Führend in Alzheimer Forschung! PRANA Biotech. 19335940.06
Führend in Alzheimer Forschung! PRANA Biotech. 1933594
Führend in Alzheimer Forschung! PRANA Biotech. 1933594
Führend in Alzheimer Forschung! PRANA Biotech. 1933594
New flat rate: $7 online market AND limit orders at Scottrade.
Führend in Alzheimer Forschung! PRANA Biotech. 1933594
Führend in Alzheimer Forschung! PRANA Biotech. 1933594
Führend in Alzheimer Forschung! PRANA Biotech. 1933594

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Prana presentiert in Health Care Conference 2005

 
16.05.05 13:58
in Las Vegasim fours Easons Hotel, 19.5.1.20 pm,

die wissenschaflichen Abhandlung von MPAC (Metal-Protein Attenuating Compounds) theor<.

Die Gründungswissenschaftler: Prof. Rudolph Tanzi und Ashley Bush, stellen die _Theorien
vor, bezüglich der Interaction zwischen Metallen und Protein-Beta-amyloid im Gehirn, die die Basis ist von Prana´s Behandlung für Alzheimer und andere neurodegenerativen Geschehnissen.


Melbourne, Australia – May 13, 2005: Prana Biotechnology Limited (NASDAQ: PRAN, ASX: PBT), today announced that its founding scientist, Professor Ashley Bush of Harvard Medical School and the Mental Health Research Institute of Victoria (Australia), will present at the Banc of America Health Care Conference 2005 at the Four Seasons Hotel in Las Vegas on Thursday, May 19, 2005, at 1:20pm PT (May 19, 6:30pm Melbourne time).



Professor Bush’s presentation will contain a scientific review of the MPAC (Metal-Protein Attenuating Compounds) theory.  A live web cast of the presentation will be available on the Prana Biotechnology web site: www.pranabio.com.   A web cast replay of the presentation will be archived on the Prana site through June 3, 2005.



To arrange a one-on-one meeting with Professor Bush during the conference, please contact Kathy Price at The Anne McBride Company, tel. 212-983-1702, ext 212, or kprice@annemcbride.com.



The founding scientists’, Professors Rudolph Tanzi and Ashley Bush, theories concerning the interaction between metals and the protein beta-amyloid in the brain are the basis of Prana’s treatments for Alzheimer's and other neurodegenerative diseases.





About Prana Biotechnology Limited

Prana Biotechnology was established to commercialise research into Alzheimer's disease and other major age-related degenerative disorders. The company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002.  Researchers at prominent international institutions including the University of Melbourne and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, discovered Prana’s technology.



For further information, please visit our web site at www.pranabio.com.



###



Contacts:

Investor Relations and media Relations
Rebecca Piercy

Buchan Consulting

T: 03 9866 4722

E: rpiercy@bcg.com.au





--------------------------------------------------

This message contains confidential information and is for the use of intended recipient(s) only. If you have received this e-mail in error you are notified that disclosing, copying, distributing or taking any action in reliance on the contents of this information is strictly prohibited. E-mail transmission cannot be guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete. The sender krowe@pranabio.com therefore does not accept liability for any errors or omissions in the contents of this message, which arise as a result of e-mail transmission. If verification is required please request a hard-copy version.

Warning: Although the company has taken reasonable precautions to ensure no viruses are present in this email, the company cannot accept responsibility for any loss or damage arising from the use of this email or attachments.

--------------------------------------------------


Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

prana präsentiert sichauf der Needham u.Company...

 
27.05.05 17:31
24 May 2005

Prana Biotechnology to Present at the Needham & Company Fourth Annual Biotechnology Conference
Melbourne, Australia – May 24, 2005 – Prana Biotechnology Limited (NASDAQ: PRAN, ASX: PBT), today announced that its Lead Clinical Advisor, Dr. Craig W. Ritchie of University College London, UK, will present at the Needham & Company Fourth Annual Biotechnology Conference at the New York Palace Hotel in New York City on Thursday, May 26, 2005, at 2:00 p.m. Eastern Time (4:00 am Melbourne time).

Dr. Ritchie’s presentation will contain a scientific review of the MPAC (Metal-Protein Attenuating Compounds) theory. A live web cast of the presentation will be available on the Prana Biotechnology web site: www.pranabio.com. A web cast replay of the presentation will be archived on the Prana site through June 10, 2005.

To arrange a one-on-one meeting with Dr. Ritchie during the conference, please contact Kathy Price at The Anne McBride Company, tel. 212-983-1702, ext 212, or kprice@annemcbride.com.

The founding scientists’, Professors Rudolph Tanzi and Ashley Bush, theories concerning the interaction between metals and the protein beta-amyloid in the brain are the basis of Prana’s treatments for Alzheimer's and other neurodegenerative diseases.

Dr. Ritchie is heavily involved, both clinically and academically, in psychiatric disorders of late life, in particular Alzheimer’s disease, Delirium and Schizophrenia. He leads an international team of investigators developing MPACs for Alzheimer’s disease. He has also worked on several meta-analysis, including one of the current treatments available for Alzheimer’s disease, which was recently published in the American Journal of Geriatric Psychiatry. His interest in conducting and assimilating evidence from clinical trials is based on his clinical background, having worked with elderly patients with dementia for most of his career


About Prana Biotechnology Limited
Prana Biotechnology was established to commercialise research into Alzheimer's disease and other major age-related degenerative disorders. The company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including the University of Melbourne and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, discovered Prana’s technology.

For further information, please visit our web site at www.pranabio.com.

###

Contacts:
Investor and media relations
Rebecca Piercy
Buchan Consulting
T: +61 2 9237 2803
E: rpiercy@bcg.com.au
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Die Biotech Conference findet in London statt

 
28.05.05 04:15
und Prana befindet sich unter bekannten Gesellschaften wie:

Celgene, Antisoma,
Imonogen, Abgenix und
vielen Anderen.
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Was haben die Amis heute aus den über 12 % Plus

 
16.06.05 23:44
in Australien gemacht?

Erst ging es auch fulminant hoch, und nun, plus minus null!

Nach den guten News!




Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Prana vervollständigt Klärung:Entwicklungsprogramm

 
26.07.05 18:18
<!--StartFragment --> 
Prana Completes Review of Development Program - Development and Commercialization of MPAC's for the Treatment of Neurodegenerative Diseases Remains Company's Primary Focus and Goal -

MELBOURNE, Australia, June 16, 2005 /PRNewswire-FirstCall via COMTEX/ -- PranaBiotechnology Limited (Nasdaq: PRAN, ASX: PBT), today announced that it hascompleted the strategic review of the Company's development programs andreaffirmed its commitment to the development of PBT2 for the treatment ofAlzheimer's disease.The Company concluded that:    *  PBT2 continues as the lead candidate for the potential treatment of       Alzheimer's Disease;    *  based on the Company's evaluation, it is confident that PBT2 will not       present the impurity problems that were found in PBT1; and    *  Prana's primary focus and goal continues to be the development and       commercialization of a range of MPAC's (metal-protein attenuating       compounds) for the treatment of neurodegenerative diseases such as       Alzheimer's disease and Parkinson's disease.Prana commenced a series of Phase I clinical trials of PBT2 in March, with thedosing of its first subjects at a facility associated with the UtrechtUniversity Hospital in Utrecht, The Netherlands. The Phase I program, comprisingseveral studies, is expected to continue through the balance of 2005 and wellinto 2006."Prana has made considerable progress in developing PBT2 in the past 12 months,"said Geoffrey Kempler, Executive Chairman and CEO. He further noted:*  "We have completed a comprehensive battery of in vitro and in vivo       tests to characterize the pharmacology and toxicology of the compound       prior to the Phase I trial;    *  PBT2 has successfully passed two (2) in vivo mutagenicity tests;    *  the Company is successfully advancing scaled up manufacturing in       anticipation of GMP production; and    *  Prana commenced the Phase I clinical trial as scheduled."Alzheimer's Disease is a neurodegenerative disorder estimated to affect over 14million people worldwide. There is no effective cure available to patients.About Prana Biotechnology LimitedPrana Biotechnology was established to commercialize research into Alzheimer'sdisease and other major age-related degenerative disorders. The company wasincorporated in 1997 and listed on the Australian Stock Exchange in March 2000and listed on NASDAQ in September 2002. Researchers at prominent internationalinstitutions including the University of Melbourne, the Massachusetts GeneralHospital (a teaching hospital of Harvard Medical School), and the Mental HealthResearch Institute of Victoria (Australia), discovered Prana's technology.For further information, please visit our web site athttp://www.pranabio.com       Contacts:     Investor Relations             Media Relations     Kathy Price                    Ivette Almeida     T: 212-983-1702 ext. 212       T: 212-983-1702 ext. 209     E: kprice@annemcbride.com      E: ivette.almeida@annemcbride.comSOURCE Prana Biotechnology LimitedCONTACT:          Ivette Almeida, +1-212-983-1702 ext. 209, ivette.almeida@annemcbride.com, Investors:                  Kathy Price, +1-212-983-1702 ext. 212, kprice@annemcbride.comURL:              http://www.prnewswire.com                  http://www.pranabio.comwww.prnewswire.comCopyright (C) 2005 PR Newswire. All rights reserved.KEYWORD:          AustraliaINDUSTRY KEYWORD: BIO                  HEA                  MTC
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Pran: Conference on Prevention of Dementia 2005

 
26.07.05 18:47
<!--StartFragment --> Prana's Co-Founding Scientists to Present at the Alzheimer's Association International Conference on Prevention of Dementia 2005
WASHINGTON, June 20, 2005 /PRNewswire-FirstCall via COMTEX/ -- PranaBiotechnology Limited (Nasdaq: PRAN; ASX: PBT), announced today that itsco-founding scientists, Drs. Ashley Bush, MD PhD of Massachusetts GeneralHospital and the Mental Health Research Institute of Victoria (Australia); andRudolph Tanzi, PhD of Harvard Medical School and Massachusetts General Hospitalare scheduled to co-chair and present at the Alzheimer's AssociationInternational Conference on Prevention of Dementia 2005. Both doctors willreside as co-chairmen at separate sessions for the pre-conference meeting onJune 18 called "Clinical Trials Test the "Amyloid Hypothesis": A tutorial onCurrent Approaches and its Mechanisms. The Conference will be held at theMarriott Wardman Park Hotel, Washington DC.Scientists from around the world will present and discuss the findings ofhundreds of studies showcasing the newest advances and steps toward preventionof Alzheimer's disease and related disorders. At the pre-conference, Dr. Tanziwill co-chair the morning session on 'Brain Amyloid-beta Peptide Oligomers asTherapeutic Targets.' This assembly will discuss the potential of amyloidaccumulation in the brain in Alzheimer's disease as a new drug target. Inaddition, Dr. Tanzi will share his view about the genetic basis for amyloidaccumulation in Alzheimer's disease in a lecture called 'Genetic basis ofCerebral Amyloidosis.'In the afternoon session, Dr. Bush will co-chair a discussion on theanti-amyloid drug development that does not directly target amyloid, but thechemistry that interacts with the amyloid (metals) called, 'Anti-amyloidStrategies with Complex Targets.' Dr. Bush also intends to present a lectureentitled 'Antagonists of Metal-dependent Oxidation and Protein Interactions'that will focus on the interaction between metals and the protein beta-amyloid,which leads to the toxicity and accumulation.These insights are the basis of the development of Prana's library of MPAC's(metal protein attenuating compounds), which target neurodegenerative diseases.PBT2, Prana's lead MPAC drug candidate for the potential treatment ofAlzheimer's disease is currently in Phase 1 clinical development.At the conference, nearly 1,000 clinicians, physicians, researchers and policyadvocates will explore how science and technology intersect to open new doorsfor Alzheimer research and care.About Prana Biotechnology LimitedPrana Biotechnology was established to commercialise research into Alzheimer'sdisease and other major age-related degenerative disorders. The company wasincorporated in 1997 and listed on the Australian Stock Exchange in March 2000.Researchers at prominent international institutions including the University ofMelbourne and Massachusetts General Hospital at Harvard Medical Schooldiscovered Prana's technology.This press release contains "forward looking statements" within the meaning ofthe Private Securities Litigation Reform Act of 1995 regarding the Company'sbusiness strategy and future plans of operation. Forward-looking statementsinvolve known and unknown risks and uncertainties; both general and specific tothe matters discussed in this press release. These and other important factors,including those mentioned in various Securities and Exchange Commission filingsmade by the Company, may cause the Company's actual results and performance todiffer materially from the future results and performance expressed in orimplied by such forward-looking statements. The forward-looking statementscontained in this press release speak only as of the date hereof and the Companyexpressly disclaims any obligation to provide public updates, revisions oramendments to any forward-looking statements made herein to reflect changes inthe Company's expectations or future events.For further information, please visit our web site athttp://www.pranabio.com.     Investor                    Media     Kathy Price                 Ivette Almeida     The Anne McBride Company    The Anne McBride Company     212-983-1702 ext. 207       212-983-1702 ext. 209SOURCE Prana Biotechnology LimitedCONTACT:          Investor: Kathy Price, ext. 207, or Media: Ivette Almeida, ext. 209, both of The Ann                  McBride Company, +1-212-983-1702, for Prana Biotechnology LimitedURL:              http://www.prnewswire.com                  http://www.pranabio.comwww.prnewswire.comCopyright (C) 2005 PR Newswire. All rights reserved.
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Wachsende Umsätze wegen dieser News?

 
26.07.05 20:53

<!--StartFragment --> Prana Biotechnology to Present at the Banc of America 2005 Specialty Pharmaceuticals Conference
MELBOURNE, Australia, July 26, 2005 /PRNewswire-FirstCall via COMTEX/ -- PranaBiotechnology Limited (Nasdaq: PRAN, ASX: PBT), today announced that itsfounding scientist, Professor Ashley Bush of Harvard Medical School and theMental Health Research Institute of Victoria (Australia), will present at theBanc of America 2005 Specialty Pharmaceuticals Conference at The Southampton Innin Southampton, NY on Friday, July 29, 2005, at 8:00 a.m. Eastern Time.Professor Bush's presentation will contain a scientific review of the MPAC(Metal-Protein Attenuating Compounds) theory. A live web cast of thepresentation will be available on the Prana Biotechnology web site:http://www.pranabio.com. A web cast replay of the presentation will be archivedon the Prana site through August 12, 2005.To arrange a one-on-one meeting with Professor Bush during the conference,please contact Kathy Price at The Anne McBride Company, tel. 212-983-1702, ext212, or kprice@annemcbride.com.The founding scientists', Professors Rudolph Tanzi and Ashley Bush, theoriesconcerning the interaction between metals and the protein beta- amyloid in thebrain are the basis of Prana's treatments for Alzheimer's and otherneurodegenerative diseases.About Prana Biotechnology LimitedPrana Biotechnology was established to commercialize research into Alzheimer'sdisease and other major age-related degenerative disorders. The company wasincorporated in 1997 and listed on the Australian Stock Exchange in March 2000and listed on NASDAQ in September 2002. Researchers at prominent internationalinstitutions including the University of Melbourne and Massachusetts GeneralHospital, a teaching hospital of Harvard Medical School, discovered Prana'stechnology.For further information, please visit our web site athttp://www.pranabio.com.     Contacts:     Investor Relations     Kathy Price     212-983-1702 ext. 212     kprice@annemcbride.com 

 

gestern der 5- fache Tagesumsatz

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Zum Haare raufen

 
29.07.05 18:31

<!--StartFragment --> Gestern endlich diel lezten verkauft zu 1, 36 und nun zeiht heute der Kurs an!<!--StartFragment --> Exchange Quote

LastChange (%)Trade TimeBid (size)Ask (size)
1.44Führend in Alzheimer Forschung! PRANA Biotech. 2034603 0.09 (6.67)11:341.40 (1)1.46 (63)
Latest TicksPrev CloseOpenLowHigh
+==-1.351.381.331.45
Day VolumeAvg Day VolVWAP52 Wk Low52 Wk High
26,80012,6001.39720.985.05
# of TradesLast SizeAvg Trade SizeP/E RatioMarket Cap (mil)
29200924024
12:03:13 PM EDT - Friday, July 29, 2005- Exchange quote is delayed at least 15 minutes.
Prana Biotechnology Strengthens Board With Non-Executive Appointment

MELBOURNE, Australia, July 29, 2005 /PRNewswire-FirstCall via COMTEX/ -- PranaBiotechnology Limited (Nasdaq: PRAN, ASX: PBT), is pleased to announce theappointment of Peter Marks as a non-executive director. Mr. Marks brings toPrana extensive experience in the areas of corporate finance and advice andventure capital investment, having specialized in capital raisings (for listedand unlisted companies), underwritings and initial public offerings in Londonand Australia.Mr. Marks currently serves as Executive Chairman of Premier Bionics Ltd., aninvestment company focused on investing in later stage Australian-based researchand development projects that demonstrate strong commercial potential. He hasserved as an Associate Director of McIntosh Securities, now Merrill LynchAustralia, as well as held senior corporate finance positions at BaringsSecurities Ltd. and Burdett Buckeridge & Young Ltd. in their Melbourne offices.In his roles with these various financial institutions, he was responsible foradvising a substantial number of listed and unlisted companies on issues rangingfrom corporate and company structure, to valuations, business strategies,acquisitions and international opportunities.In addition, Mr. Marks has served as Head of the Melbourne Companies Departmentat the Australian Stock Exchange; been a founding Director of Momentum FundsManagement Pty Ltd, an Australian venture capital firm; and was employed by KPMGCorporate Finance Ltd (Australia), where he rose to Director and was responsiblefor heading up the equity capital markets group in Melbourne.Geoffrey Kempler, chairman and CEO of Prana, said, "Peter brings invaluable andhighly relevant financial experience to the Board, as well as wise counsel. Hisappointment brings to three the number of non-executives on the Board. Peterwill serve on the Audit Committee, helping to maintain a high level of corporatecompliance."Mr. Marks holds a Bachelor of Economics, Bachelor of Laws and Graduate Diplomain Commercial Law from Monash University in Melbourne, Australia. He completedhis MBA at the Scottish School of Business at the University of Edinburgh.About Prana Biotechnology LimitedPrana Biotechnology was established to commercialize research into Alzheimer'sdisease and other major age-related degenerative disorders. The company wasincorporated in 1997 and listed on the Australian Stock Exchange in March 2000and listed on NASDAQ in September 2002. Researchers at prominent internationalinstitutions including the University of Melbourne and Massachusetts GeneralHospital, a teaching hospital of Harvard Medical School, discovered Prana'stechnology.For further information, please visit our web site athttp://www.pranabio.com.    Contacts:     Investor Relations               Media Relations     Kathy Price                      Ivette Almeida     T: 212-983-1702 ext. 212         T: 212-983-1702 ext. 209     E: kprice@annemcbride.com        E: ivette.almeida@annemcbride.comSOURCE Prana Biotechnology LimitedCONTACT:          Investor Relations: Kathy Price, +1-212-983-1702 ext. 212, kprice@annemcbride.com, or                  Media Relations: Ivette Almeida, +1-212-983-1702 ext. 209,                  ivette.almeida@annemcbride.com; both of Anne McBride for Prana Biotechnology LimitedURL:              http://www.prnewswire.com                  http://www.pranabio.com/www.prnewswire.comCopyright (C) 2005 PR Newswire. All rights reserved.KEYWORD:          AustraliaINDUSTRY KEYWORD: BIO                  HEA                  MTCSUBJECT CODE:     PER

Führend in Alzheimer Forschung! PRANA Biotech. 2034603
Führend in Alzheimer Forschung! PRANA Biotech. 2034603
DJIAFührend in Alzheimer Forschung! PRANA Biotech. 203460310,665.80Führend in Alzheimer Forschung! PRANA Biotech. 2034603Führend in Alzheimer Forschung! PRANA Biotech. 2034603Führend in Alzheimer Forschung! PRANA Biotech. 203460339.70
Führend in Alzheimer Forschung! PRANA Biotech. 2034603
NasdaqFührend in Alzheimer Forschung! PRANA Biotech. 20346032,188.60Führend in Alzheimer Forschung! PRANA Biotech. 2034603Führend in Alzheimer Forschung! PRANA Biotech. 2034603Führend in Alzheimer Forschung! PRANA Biotech. 20346039.84
Führend in Alzheimer Forschung! PRANA Biotech. 2034603
S&P 500Führend in Alzheimer Forschung! PRANA Biotech. 20346031,238.34Führend in Alzheimer Forschung! PRANA Biotech. 2034603Führend in Alzheimer Forschung! PRANA Biotech. 2034603Führend in Alzheimer Forschung! PRANA Biotech. 20346035.38
Führend in Alzheimer Forschung! PRANA Biotech. 2034603
Russell 2000Führend in Alzheimer Forschung! PRANA Biotech. 2034603680.30Führend in Alzheimer Forschung! PRANA Biotech. 2034603Führend in Alzheimer Forschung! PRANA Biotech. 2034603Führend in Alzheimer Forschung! PRANA Biotech. 20346032.74
Führend in Alzheimer Forschung! PRANA Biotech. 2034603
CBOE VolatilityFührend in Alzheimer Forschung! PRANA Biotech. 203460311.29Führend in Alzheimer Forschung! PRANA Biotech. 2034603Führend in Alzheimer Forschung! PRANA Biotech. 2034603Führend in Alzheimer Forschung! PRANA Biotech. 20346030.77
Führend in Alzheimer Forschung! PRANA Biotech. 2034603
30 Yr BondFührend in Alzheimer Forschung! PRANA Biotech. 20346034.41Führend in Alzheimer Forschung! PRANA Biotech. 2034603Führend in Alzheimer Forschung! PRANA Biotech. 2034603Führend in Alzheimer Forschung! PRANA Biotech. 20346030.01
Führend in Alzheimer Forschung! PRANA Biotech. 2034603
10 Yr BondFührend in Alzheimer Forschung! PRANA Biotech. 20346034.26Führend in Alzheimer Forschung! PRANA Biotech. 2034603Führend in Alzheimer Forschung! PRANA Biotech. 2034603Führend in Alzheimer Forschung! PRANA Biotech. 20346030.07
Führend in Alzheimer Forschung! PRANA Biotech. 2034603
Führend in Alzheimer Forschung! PRANA Biotech. 2034603
Führend in Alzheimer Forschung! PRANA Biotech. 2034603
<!-- TF 88x31 JScript code -->
< script language=javascript>');//-->< /script>< script language=javascript src="http://a.tribalfusion.com/j.ad?site=FreeRealTimecom&adSpace=ROS&size=88x31&requestID=16664578370.2343498753099157">< /script>      Führend in Alzheimer Forschung! PRANA Biotech. 2034603
<!-- TF 88x31 JScript code -->
Führend in Alzheimer Forschung! PRANA Biotech. 2034603
Keyword Search
Enter Keyword
  
Führend in Alzheimer Forschung! PRANA Biotech. 2034603
Führend in Alzheimer Forschung! PRANA Biotech. 2034603 Führend in Alzheimer Forschung! PRANA Biotech. 2034603


<!--StartFragment --> Exchange Quote
LastChange (%)Trade TimeBid (size)Ask (size)
1.44Führend in Alzheimer Forschung! PRANA Biotech. 2034603 0.09 (6.67)11:341.40 (1)1.46 (63)
Latest TicksPrev CloseOpenLowHigh
+==-1.351.381.331.45
Day VolumeAvg Day VolVWAP52 Wk Low52 Wk High
26,80012,6001.39720.985.05
# of TradesLast SizeAvg Trade SizeP/E RatioMarket Cap (mil)
29200924024
12:03:13 PM EDT - Friday, July 29, 2005- Exchange quote is delayed at least 15 minutes.

Heute sochn 30.000 Stück umgesetzt, da versthe einer noch die Börse! Die News oben kann es doch nicht sein??

<!--StartFragment --> Und das nach der Vorgabe in der Heimatbörse??? Da brate mir einer einen Storch!  Die News war wohl nach Börsenschluss in Ausstralien rausgekommen?

PBT) PRANA BIOTECHNOLOGY LIMITED

ORDINARY FULLY PAID

29 Jul 2005 19:02Delayed | Live Quote Führend in Alzheimer Forschung! PRANA Biotech. 2034603Führend in Alzheimer Forschung! PRANA Biotech. 2034603
Last Price+/-%OpenHighVolume
$0.1650 Führend in Alzheimer Forschung! PRANA Biotech. 2034603 $-0.0100 Führend in Alzheimer Forschung! PRANA Biotech. 2034603 -5.7% 0.17000.170061,400
BidAsk# Bid# AskLowValue
0.16500.1750110.165010,433

In Australien habe ich die Nachricht erst gar nicht gefunden, und sie ist heute morgen veröffentlich wroden, wieviel Uhr es in Australien war, weis cih nicht.

 

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Konferenz: Originaübertragung

 
29.07.05 19:17

Heute ist die wichtige Konferenz und man kann hören und rechts die Wissenschaftliche Studie ansehen!

http://www.veracast.com/webcasts/bas/sp05/id99201247.cfm

 

Das ist wohl der Grund für den Kursanstieg!

57900 bis jetzt!

 

 

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Cashwert über Kurswert

 
02.08.05 07:08

<?xml:namespace prefix = v ns = "urn:schemas-microsoft-com:vml" /><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />

Friday, July 29, 2005

 

 

 

slide 1 of 21slide 2 of 21slide 3 of 21slide 4 of 21slide 5 of 21slide 6 of 21slide 7 of 21slide 8 of 21slide 9 of 21slide 10 of 21slide 11 of 21slide 12 of 21slide 13 of 21slide 14 of 21slide 15 of 21slide 16 of 21slide 17 of 21slide 18 of 21slide 19 of 21slide 20 of 21slide 21 of 21

 

 

[Click here to open a window to print these slides.]

 


Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

This webcast presentation may contain forward-looking statements that involve risks and uncertainties. Important factors, which could cause actual operating results to differ materially from those in the forward-looking statements, are detailed in filings with the Securities and Exchange Commission made from time to time by the presenting public company, including, without limitation, its quarterly report on Form 10-Q and its annual report on Form 10-K filed with the Securities and Exchange Commission. The presenting company undertakes no obligations to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Banc of America Securities LLC, member NYSE/NASD/SIPC, is a subsidiary of Bank of America Corporation. Copyright © 2005 Banc of America Securities LLC

 

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Prana zieht an 15 % in 2 Tagen!

 
02.08.05 18:53

Erhebliche Umsätze und Interesse seit der Biotechkonferenz s. o.vom 29..7.05.

 

Es decken sich Fonds ein und es gibt Übernahmegerüchte.

 

 <!--StartFragment -->

PRAN - Prana Biotechnology Ltd (NASDAQ SC)12:35 PM ET, 8/2/2005 
Führend in Alzheimer Forschung! PRANA Biotech. 2038919chart.bigcharts.com/custom/frt-com/...ountry=US&rand=8684" style="max-width:560px" border=0>

 

 

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Immer noch keiner interessiert an pran?

 
12.08.05 19:40
könnte auch mal jemand anderer mitposten
habe nicht immer zeit
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

kurze Notiz , erhöhtes Volumen seit Tagen:

 
12.08.05 19:55
BIg block buyers today
by: Send me a message! tyasdfghjkl 08/08/05 02:25 pm
Msg: 1358 of 1359

Schwab took 30k in two 15k blocks and marked it up and MLCO took 15k in. Someone accumulating it for some reason. Anyone know of any upcoming meetings or presentations of any new safety data?


Posted as a reply to: Msg 1357 by techcoat3  

aus dem yahhoo board.
Führend in Alzheimer Forschung! PRANA Biotech. xpfuture
xpfuture:

@geldschneider, die hab ich seit dem

 
12.08.05 19:57
Absturz auf der Watch. Im Moment allerdings noch etwas zu riskant für mich.

xpfuture
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Klassische W-Formation, Einstiegssignal!

 
23.08.05 22:28
<!--StartFragment --> 
PRAN - Prana Biotechnology Ltd (NASDAQ SC)3:59 PM ET, 8/23/2005 
Führend in Alzheimer Forschung! PRANA Biotech. 2070145chart.bigcharts.com/custom/frt-com/...ountry=US&rand=9311" style="max-width:560px" border=0>

War schon wieder draußen und bin bei 1,43 dann wieder rein,  Heute, 1,67.

gruß

gs

 

 

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Erfolgreicher Abschluß Phase I , PBT2

 
07.11.05 01:51

Melbourne, Australia – November 7, 2005: Prana Biotechnology Limited (NASDAQ: PRAN, ASX: PBT), today announced the successful completion of a Phase I trial with its lead compound, PBT2, under development as a therapy for Alzheimer’s Disease.  <?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />

 

The double blind, placebo-controlled single dose escalation study, conducted at a facility in <?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" />Utrecht, The Netherlands on 55 healthy, male volunteers between the ages of 18 and 50, was designed to evaluate the safety, tolerability and pharmacokinetics of PBT2.

 

Data from the study showed PBT2 was well tolerated with little difference in the incidence of adverse events between those receiving PBT2 and those receiving the placebo.  In addition, the pharmacokinetic analysis demonstrated that the drug exposure increased predictably and in a linear manner, both of which are excellent characteristics for a central nervous system (CNS) drug.  Concurrent pre-clinical findings also firmly indicated that PBT2 passes into the brain with more than 20 times greater efficiency than did its predecessor, PBT1.

 

“The clinical and pre-clinical results to date are compelling,” said Ross Murdoch, Chief Operating Officer.  “The trials confirm our laboratory studies showing that PBT2 has great potential for the treatment of Alzheimer’s Disease, which currently affects 4.5 million people in the US and more than 14 million people worldwide.”

 

Prana scientists discovered a common interaction of metals and proteins leading to oxidative damage to the brain that is characteristic of patients with Alzheimer’s Disease, Parkinson’s Disease and other neurodegenerative disorders.  MPAC’s (Metal Protein Attenuating Compounds) target abnormal protein-metal interactions preserving normal metal biochemistry.

 

“Prana MPAC’s, of which PBT2 is the lead compound, take advantage of novel insights into the role of metals and oxidation as the cause of Alzheimer’s Disease, and may be the first ‘plaque busting’ drugs,” added Geoffrey Kempler, Executive Chairman and CEO. “The early results Prana has observed in the trials of PBT2 are extremely exciting and give hope to the battle against Alzheimer’s Disease”.

 

Looking Ahead

Prana has nearly completed a multi-dose escalation safety clinical trial of PBT2 in elderly, healthy, male and female volunteers, having completed three out of four stages of dose escalation.  The company anticipates completing the final dosing stage in December this year.  In addition, the chronic toxicology studies and GMP manufacturing development required for Phase II and Phase III clinical studies are underway concurrently.

 

Prana already has support for PBT2's efficacy via its original ‘proof of concept’ drug, PBT1.  (PBT1 demonstrated benefit for Alzheimer’s Disease patients compared to placebo in a Phase II study.)  PBT2 is a related derivative of PBT1, they are both 8-hydroxyquinolines, but was designed specifically for greater safety, efficacy and brain penetration. 

 

“Given the existing pre-clinical and human clinical performance of PBT2 to date, we hold very high expectations for the drug in Phase II trials,” concluded Mr. Kempler.

 

 

About Prana Biotechnology Limited

Prana Biotechnology was established to commercialise research into Alzheimer's disease and other major age-related degenerative disorders. The company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002.  Researchers at prominent international institutions including the University of Melbourne and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, discovered Prana’s technology.

 

For further information, please visit our web site at www.pranabio.com.

 

###

 

Contacts:

Investor and media relations

Rebecca Piercy

Buchan Consulting

Ph: +61 3 9866 4722

rpiercy@bcg.com.au

 

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Presentaton auf 7. Annual Heahltcare Conference

 
07.11.05 01:54

Melbourne, Australia – November 3, 2005: Prana Biotechnology Limited (NASDAQ: PRAN, <?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" />ASX: PBT), today announced that Geoffrey Kempler, Executive Chairman and Chief Executive Officer, will present at the Rodman & Renshaw Techvest Seventh Annual Healthcare Conference at 3:50 p.m. Eastern Time on Tuesday, November 8 (7.50am Melbourne Time on Wednesday, November 9) at The New York Palace Hotel.  During the presentation, Mr. Kempler will address the current status of Prana’s development program.<?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />

 

The Company’s audio and slide presentation will be web cast live on November 8.  A replay will be available one hour following the presentation and archived on the Company’s web site for 90 days.  To access the live and replay presentations, visit the Prana Biotechnology web site, www.pranabio.com.

 

 

 

About Prana Biotechnology Limited

Prana Biotechnology was established to commercialize research into Alzheimer's disease and other major age-related degenerative disorders. The company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002.  Researchers at prominent international institutions including the University of Melbourne and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, discovered Prana’s technology.

 

For further information, please visit our web site at www.pranabio.com.

 

###

 

Contacts:

Investor Relations                                            Media Relations

Kathy Price                                                       Ivette Almeida

The Global Consulting Group                               The Global Consulting Group

T: 646-284-9430                                                 T: 646-284-9455

E: kprice@hfgcg.com                                         E: ialmeida@hfgcg.com

 

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Seit vorgestern 37 % Plus!!

 
08.11.05 22:38
<!--StartFragment --> 
PRANA BIOTECHNOLOGY LTD - Nasdaq SmallCap Market: PRAN
Real-time ECN Quote*
LastChange (%)After Hours Chg (%)**Trade TimeBidAsk
1.80Führend in Alzheimer Forschung! PRANA Biotech. 2216490 0.3 (20.00)0 (0.00)15:591.50 (25)1.85 (19)
At Scottrade, we listen to our customers and have improved the trading technology serving them. Our online trading is fast, accurate and easy to use.
And, online trades are still just $7. Apply now.

Exchange Quote
LastChange (%)Trade TimeBid (size)Ask (size)
1.80Führend in Alzheimer Forschung! PRANA Biotech. 2216490 0.30 (20.00)15:591.50 (25)1.85 (19)
Latest TicksPrev CloseOpenLowHigh
==-+1.501.521.521.85
Day VolumeAvg Day VolVWAP52 Wk Low52 Wk High
224,7818,6001.72190.984.99
# of TradesLast SizeAvg Trade SizeP/E RatioMarket Cap (mil)
2391,000941023

4:34:24 PM EST - Tuesday, November 8, 2005- Exchange quote is delayed at least 15 minutes.

<!--StartFragment --> PRANA BIOTECHNOLOGY LTD - Nasdaq SmallCap Market: PRAN (NEW charting help)
Führend in Alzheimer Forschung! PRANA Biotech. 2216490
<!--VITALS="app:interactivecharting lic:destination sale:kek web:kjb ops:ccn tech:cdt"-->

Enter Symbol or Keyword:Time Frame: 
1-day2 days5 days10 days----------1 month2 months3 months6 monthsYTD1 year2 years3 years4 years5 years1 decadeAll Data Additional chart controls
Führend in Alzheimer Forschung! PRANA Biotech. 2216490
 PRAN - Prana Biotechnology Ltd (NASDAQ SC)3:59 PM ET, 11/8/2005 
Führend in Alzheimer Forschung! PRANA Biotech. 2216490
Führend in Alzheimer Forschung! PRANA Biotech. 2216490

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Für 1,40 gestern gekauft, verkauft heute für 1,78

 
08.11.05 22:41
Jedenfalls einen Teil davon
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Plus 20 % heute wieder

 
09.11.05 16:53
Führend in Alzheimer Forschung! PRANA Biotech. grace
grace:

PRAN 2.19 kauf stop 1,90 ziel 2,50 in $ o. T.

 
09.11.05 17:10
Führend in Alzheimer Forschung! PRANA Biotech. grace
grace:

geldschneider, das hast du gut recherchiert

 
09.11.05 17:12
hut ab !
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Ob sich das Gap schließen wird?

 
09.11.05 18:42

Könnte sein!! 

PRANA BIOTECHNOLOGY LTD - Nasdaq SmallCap Market: PRAN (NEW charting help)
Führend in Alzheimer Forschung! PRANA Biotech. 2218606

Enter Symbol or Keyword:Time Frame: 
1-day2 days5 days10 days----------1 month2 months3 months6 monthsYTD1 year2 years3 years4 years5 years1 decadeAll Data Additional chart controls
Führend in Alzheimer Forschung! PRANA Biotech. 2218606
 PRAN - Prana Biotechnology Ltd (NASDAQ SC)12:16 PM ET, 11/9/2005 
Führend in Alzheimer Forschung! PRANA Biotech. 2218606
Führend in Alzheimer Forschung! PRANA Biotech. 2218606
Frequency:Price Display:
Start Date:Führend in Alzheimer Forschung! PRANA Biotech. 2218606End Date:
Size:
1-Minute5-Minute15-MinuteHourly----------DailyWeeklyMonthlyQuarterlyYearly Hide PriceHLCOHLCCandlestickMountainBar ChartsDotCloseLogarithmic StandardLarge
Compare to Index:Compare to Symbol(s):
Moving Average:Days:
<None>SMASMA (2-Line)SMA (3-Line)EMAEMA (2-Line)EMA (3-Line)
Upper Indicator:
<None>DJIANASDAQS&P 500Russell 2000----------InternetBroker/DealersOil & GasGold & SilverUtilitiesTransportationAirlines <None>MA EnvelopesBollinger BandsParabolic SARVolume by PricePrice Channel----------Show SplitsShow EarningsShow DividendsShow All Events----------A/D Line
Lower Indicator 1:Lower Indicator 2:Lower Indicator 3: 
VolumeVolume+RSIMACDOBVFast StochasticSlow StochasticROCWilliams %RMoney FlowDMIVol AccumulationVolatility FastVolatility SlowMomentumUlt Oscillator% Short InterestRolling EPSP/E RatioP/E RangesRolling DividendYield----------Up/Down RatioArms Index (TRIN)A/D Line (Breadth)A/D Line (Daily)----------% Compare <None>VolumeVolume+RSIMACDOBVFast StochasticSlow StochasticROCWilliams %RMoney FlowDMIVol AccumulationVolatility FastVolatility SlowMomentumUlt Oscillator% Short InterestRolling EPSP/E RatioP/E RangesRolling DividendYield----------Up/Down RatioArms Index (TRIN)A/D Line (Breadth)A/D Line (Daily)----------% Compare <None>VolumeVolume+RSIMACDOBVFast StochasticSlow StochasticROCWilliams %RMoney FlowDMIVol AccumulationVolatility FastVolatility SlowMomentumUlt Oscillator% Short InterestRolling EPSP/E RatioP/E RangesRolling DividendYield----------Up/Down RatioArms Index (TRIN)A/D Line (Breadth)A/D Line (Daily)----------% Compare

 

Obgleich heute in Australien der Kurs um 9 % zurückging, schneller dieser in USAi weiter hoch. Der Hauptmarkt ist auch dort.

<!--StartFragment -->

PRANA BIOTECHNOLOGY LTD - Nasdaq SmallCap Market: PRAN
Real-time ECN Quote*
LastChange (%)After Hours Chg (%)**Trade TimeBidAsk
2.17Führend in Alzheimer Forschung! PRANA Biotech. 2218606 0.37 (20.56)N/A12:352.12 (1)2.19 (1)

At Scottrade, we listen to our customers and have improved the trading technology serving them. Our online trading is fast, accurate and easy to use.
And, online trades are still just $7. Apply now.

Exchange Quote

LastChange (%)Trade TimeBid (size)Ask (size)
2.19Führend in Alzheimer Forschung! PRANA Biotech. 2218606 0.39 (21.67)12:162.18 (3)2.24 (7)
Latest TicksPrev CloseOpenLowHigh
+-+-1.801.901.782.40
Day VolumeAvg Day VolVWAP52 Wk Low52 Wk High
395,54518,2001.99180.984.99
# of TradesLast SizeAvg Trade SizeP/E RatioMarket Cap (mil)
3621001,093028
12:37:08 PM EST - Wednesday, November 9, 2005- Exchange quote is delayed at least 15 minutes.

Handeslvolumen bis zur halbzeit schon 400 TSD, das ist bei diesem Wert schon was.

Führend in Alzheimer Forschung! PRANA Biotech. xpfuture
xpfuture:

congrats, @geldschneider

 
09.11.05 18:52
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

ja @xpfuture

 
09.11.05 21:23

Schade dass du nicht dabei warst, hatte dir noch rechtzeitig den Tip gegeben.

Ohne Mut, kein Gewinn. Garantie gibt es nie! Bei dem Geschäft,eher Feeling.

Und die Information auch rechtzeitig zu erhalten, gerade dann wach zu sein, mitten in der Nacht kam die nachricht heraus, ist auch ein Glück gewesen.

 

Wie denkst du geht es Charttechnisch weiter?? Sieht nach den Cahrtanalysen gut aus!

<!--StartFragment -->

PRAN - PRANA BIO LTD ADS S1 (NASDAQ)

Date Open High Low Last Change Volume % Change 11/09/051.902.401.782.17+0.37463811+20.56%

< script language=JavaScript> var paid='';  if(paid == '') { document.write(''); bot=13; } < /script>

Composite Indicator   Trend Spotter TMBuy Short Term Indicators   7 Day Average Directional IndicatorBuy   10 - 8 Day Moving Average Hilo ChannelBuy   20 Day Moving Average vs PriceBuy   20 - 50 Day MACD OscillatorSell   20 Day Bollinger BandsBuy Short Term Indicators Average:  60% - Buy20-Day Average Volume - 27790 Medium Term Indicators   40 Day Commodity Channel IndexBuy   50 Day Moving Average vs PriceBuy   20 - 100 Day MACD OscillatorSell   50 Day Parabolic Time/PriceBuy Medium Term Indicators Average:  50% - Buy50-Day Average Volume - 19508 Long Term Indicators   60 Day Commodity Channel IndexBuy   100 Day Moving Average vs PriceBuy   50 - 100 Day MACD OscillatorBuy Long Term Indicators Average:  100% - Buy100-Day Average Volume - 20430 Overall Average:  72% - Buy Price Support Pivot Point Resistance 1.80 1.39 1.72 2.05


Click on the indicator for a graphical interpretation of the result
or visit the Learning Center for more information on the studies

Führend in Alzheimer Forschung! PRANA Biotech. 2218844 Analytics are from close of previous session

Führend in Alzheimer Forschung! PRANA Biotech. xpfuture
xpfuture:

Schau ich mir morgen kurz mal an.

 
09.11.05 22:25
Bin jetzt weg. Wünsch dir noch einen schönen Abend.

xpfuture
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Bellwether Report über Pran

 
10.11.05 23:46
<!--StartFragment --> bellwetherreport.com: Bellwether Report is Following Prana Technology
Nov 08, 2005 (M2 PRESSWIRE via COMTEX) -- Today the Bellwether Report has identified Prana Technology Ltd. (Nasdaq: PRAN), a company that our analysts will be tracking over the ensuing weeks. They recently came out with a significant corporate development this month, causing a positive correction. For a full report on the below mentioned company, and many more, feel free to visit www.bellwetherreport.com for a free 30 day no obligation trial Today November 7, 2005 Prana coming from the Saskrit for "moving force" or "life force" announced the successful completion of a Phase I trial with its lead compound, PBT2, under development as a therapy for Alzheimer's Disease The double blind, placebo-controlled single dose escalation study, conducted at a facility in Utrecht, The Netherlands on 55 healthy, male volunteers between the ages of 18 and 50, was designed to evaluate the safety, tolerability and pharmacokinetics of PBT2.

Trying to get the investment community interested , Nov. 3 Prana Biotechnology Limited announced that Geoffrey Kempler, Executive Chairman and Chief Executive Officer, will present at the Rodman & Renshaw Techvest Seventh Annual Healthcare Conference at 3:50 p.m. Eastern Time on Tuesday, November 8 (07.50 a.m. Melbourne Time on Wednesday, November 9) at The New York Palace Hotel. During the presentation, Mr. Kempler will address the current status of Prana's development program.

Prana Biotechnology Limited, a development stage company, engages in the research and development of therapeutic drugs, which are designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses. The company primarily focuses on Alzheimer's disease, age-related cataracts, Creutzfeldt-Jakob disease, Motor Neuron disease, and Parkinson's disease. Its development stage products include .....

To view the full unbiased report on Prana Technology Ltd. (Nasdaq: PRAN), feel free to visit our site. This article and many more are available for review under the Today's Articles Section. No credit Card Needed!!

The Bellwether Report will continue scanning the markets for true emerging growth opportunities that will show subscribers optimal entry points with profitable exit points. If you are interested in receiving more information on feel free to sign up for a 1 month complimentary subscription to the #1 online investment resource www.bellwetherreport.com.

All material herein was prepared by the Bellwetherreport.com, (Bellwether) based upon information believed to be reliable. The information contained herein is not guaranteed by Bellwether to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Bellwether is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Bellwether may receive compensation in cash or shares from independent third parties or from the companies mentioned.

Bellwether's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Jay Lee.

Bellwether will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Bellwether undertakes no obligation to update such statements.

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web Inquiries to info@m2.com.

(C)1994-2005 M2 COMMUNICATIONS LTD

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

2 Tages-Chart

 
11.11.05 22:54
<!--StartFragment --> PRANA BIOTECHNOLOGY LTD - Nasdaq SmallCap Market: PRAN (NEW charting help)
Führend in Alzheimer Forschung! PRANA Biotech. 2223153
<!--VITALS="app:interactivecharting lic:destination sale:kek web:kjb ops:ccn tech:cdt"-->
Enter Symbol or Keyword:Time Frame: 
1-day2 days5 days10 days----------1 month2 months3 months6 monthsYTD1 year2 years3 years4 years5 years1 decadeAll Data Additional chart controls
Führend in Alzheimer Forschung! PRANA Biotech. 2223153
 PRAN - Prana Biotechnology Ltd (NASDAQ SC)3:59 PM ET, 11/11/2005 
Führend in Alzheimer Forschung! PRANA Biotech. 2223153
Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Ha, ha, wer hat denn verkauft??

 
15.11.05 01:07

Es gab keinen Grund, für das Minus in Deutschland!! Diese Nachricht kam nach Börsenschluß in Australien raus und war noch vor Börsenbeginn , heute morgen bei uns und  in USA.

Die Amis haben die Kurve noch bekommen, erst ging es ins Minus, dann aber gewann die Nachricht doch die Oberhand!

Zeigt, dass viele kaufen bzw. verkaufen, ohne zu wissen warum!

 

Prana Founding Scientist, Professor Ashley Bush, to Present Recent Study Findings at Neuroscience 2005 in Washington, DC - Professor Bush to Announce Results that Confirm the Importance of Oxidative Stress in Causing the Dementia in Alzheimer's Disea
MELBOURNE, Australia, Nov 14, 2005 /PRNewswire-FirstCall via COMTEX/ -- Prana Biotechnology Limited (Nasdaq: PRAN, ASX: PBT), founding scientist, Professor Ashley Bush of Harvard Medical School and the Mental Health Research Institute of Victoria (Australia), is scheduled to present today at Neuroscience 2005, the 35th Annual Meeting of the Society for Neuroscience, in Washington, DC at 3:15 p.m. Eastern Time. During his presentation, Professor Bush will announce the results of a recent study that confirm the importance of oxidative stress in causing the dementia associated with Alzheimer's disease.

The study, conducted in collaboration with Simon Melov, Ph.D. of the Buck Institute in Novato, CA, shows that there is a synergistic interplay between mitochondrial damage and amyloid formation in the brains of transgenic mice (a model for Alzheimer's disease) inducing tau hyperphosphorylation by an oxidative mechanism. Tau hyperphosphorylation is the biochemical event in Alzheimer's disease that leads to tangle formation and ultimately to the actual dementia of Alzheimer's disease. Previous research studies have shown that the accumulation of beta-amyloid precedes tau hyperphosphorylation in mice.

"The Prana MPAC (Metal Protein Attenuating Compound) platform is based on targeting the oxidative chemistry caused by copper binding to beta-amyloid as the major source of oxidative stress in Alzheimer's disease," stated Professor Bush. "We have previously reported in the Journal of Clinical Investigation that the MPAC clioquinol inhibits amyloid deposition and oxidation damage in the brains of transgenic mice. These findings, along with those from the recent collaboration with Dr. Melov, encourage us to believe that targeting the metal on beta-amyloid with an MPAC, such as PBT2 (Prana's lead compound), may prevent the tangle formation in Alzheimer's disease."

The founding scientists', Professors Rudolph Tanzi, Ashley Bush and Colin Masters, theories concerning the interaction between metals and the protein beta-amyloid in the brain are the basis of Prana's treatments for Alzheimer's and other neurodegenerative diseases.

About Neuroscience 2005

At Neuroscience 2005, the Society for Neuroscience will celebrate 35 years as a leading organization for the study of the brain and nervous system. More than 30,000 scientists from across the globe are expected to gather and exchange ideas about the latest discoveries and research on the brain, spinal cord, and nervous system. Nearly 17,000 presentations are scheduled, including 14 special lectures, 28 symposia, and 27 minisymposia, covering research ranging from single molecules to human behavior.

About Prana Biotechnology Limited

Prana Biotechnology was established to commercialize research into Alzheimer's disease and other major age-related degenerative disorders. The company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including the University of Melbourne and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, discovered Prana's technology.

For further information, please visit our web site at www.pranabio.com.

Contacts:

Investor Relations Media Relations

Kathy Price Ivette Almeida

The Global Consulting Group The Global Consulting Group

T: 646-284-9430 T: 646-284-9455

E: kprice@hfgcg.com E: ialmeida@hfgcg.com

SOURCE Prana Biotechnology Limited

CONTACT: Investor Relations - Kathy Price, The Global Consulting Group, +1-646-284-9430,

kprice@hfgcg.com, Media Relations - Ivette Almeida of The Global Consulting Group,

+1-646-284-9455, ialmeida@hfgcg.com

URL: http://www.prnewswire.com

http://www.pranabio.com

www.prnewswire.com

Copyright (C) 2005 PR Newswire. All rights reserved.

good trades

gs

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

Enorm viel Handel heute in den ersten Minuten!

 
16.11.05 15:54
<!--StartFragment --> Exchange Quote
LastChange (%)Trade TimeBid (size)Ask (size)
1.94Führend in Alzheimer Forschung! PRANA Biotech. 2229823quotes.freerealtime.com/gra/uparrow1.gif" style="max-width:560px" > 0.0045 (0.23)09:301.93 (1)2.09 (1)
Latest TicksPrev CloseOpenLowHigh
+--=1.93552.331.942.33
Day VolumeAvg Day VolVWAP52 Wk Low52 Wk High
36,255101,5002.17590.984.99
# of TradesLast SizeAvg Trade SizeP/E RatioMarket Cap (mil)
155002,417025

9:52:05 AM EST - Wednesday, November 16, 2005- Exchange quote is delayed at least 15 minutes.

 

15500 Stück zu 2,33

Führend in Alzheimer Forschung! PRANA Biotech. geldschneider
geldschneider:

2 Monatschart Chart

 
16.11.05 16:03
<!--StartFragment --> PRANA BIOTECHNOLOGY LTD - Nasdaq SmallCap Market: PRAN (NEW charting help)
Führend in Alzheimer Forschung! PRANA Biotech. 2229842
<!--VITALS="app:interactivecharting lic:destination sale:kek web:kjb ops:ccn tech:cdt"-->
Enter Symbol or Keyword:Time Frame: 
1-day2 days5 days10 days----------1 month2 months3 months6 monthsYTD1 year2 years3 years4 years5 years1 decadeAll Data Additional chart controls
Führend in Alzheimer Forschung! PRANA Biotech. 2229842
 PRAN - Prana Biotechnology Ltd (NASDAQ SC)9:42 AM ET, 11/16/2005 
Führend in Alzheimer Forschung! PRANA Biotech. 2229842
Führend in Alzheimer Forschung! PRANA Biotech. 2229842
Führend in Alzheimer Forschung! PRANA Biotech. xpfuture
xpfuture:

Hey Geldschneider, hast schon geseh´n

 
24.07.06 20:23
Prana heute über 70% vorne!!!

xpfuture
Führend in Alzheimer Forschung! PRANA Biotech. Gasman82
Gasman82:

as gaht da ab??????

 
24.03.11 09:53

riesen Umsätze in Sydney....

Führend in Alzheimer Forschung! PRANA Biotech. Balu4u
Balu4u:

Umsätze in Au ziehen heute auch wieder an

 
12.05.11 19:00

-nur zur Info! Ob da was kommt?

Führend in Alzheimer Forschung! PRANA Biotech. gradow
gradow:

hallo wer weiss was

 
29.11.11 20:26

hallo und guten abend

 

bin neu bei prana dabei , gibt es unterschieden zwischen den beiden wkn nr.

ich bin bei dieser hier eingestiegen ,

bin für jede info über prana dankbar

danke vorab und einen netten gruß

Führend in Alzheimer Forschung! PRANA Biotech. Riesenpizza
Riesenpizza:

Warum ist seit Tagen keine Bewegung mehr?

 
18.02.14 09:56
Falls jemand etwas weis bitte kurze Info ins Forum
Führend in Alzheimer Forschung! PRANA Biotech. Lobster2014
Lobster2014:

INFO

 
18.02.14 16:25
www.streetinsider.com/Hot+New+Coverage/...+at+Buy/9182188.html
Führend in Alzheimer Forschung! PRANA Biotech. Riesenpizza
Riesenpizza:

Danke @ Lobster2014

 
19.02.14 09:32
Viele Danke für Ihre Mühe und ein herzliches Dankeschön an Sie!
Führend in Alzheimer Forschung! PRANA Biotech. apfelrücken
apfelrücken:

bin gespannt, wie drüben eröffnet wird

 
05.09.14 14:33
platz nach oben ist genug

www.asx.com.au/asx/research/...o.do?by=asxCode&asxCode=PBT
Jeder ist für sein Handeln selbst verantwortlich. Keine Kaufs-/Verkaufsempfehlung !!!
Im Unterschied zur Straßenbahn wird an der Börse zum Ein- und Aussteigen nicht geklingelt.
Führend in Alzheimer Forschung! PRANA Biotech. apfelrücken
apfelrücken:

prana receives fda orphan drug designation for

 
05.09.14 14:37
pbt2

05.09.2014

www.asx.com.au/asxpdf/20140905/pdf/42s15x0wrsh9nx.pdf
Jeder ist für sein Handeln selbst verantwortlich. Keine Kaufs-/Verkaufsempfehlung !!!
Im Unterschied zur Straßenbahn wird an der Börse zum Ein- und Aussteigen nicht geklingelt.
Führend in Alzheimer Forschung! PRANA Biotech. apfelrücken
apfelrücken:

Kurspotential?

 
05.09.14 14:39
Jeder ist für sein Handeln selbst verantwortlich. Keine Kaufs-/Verkaufsempfehlung !!!
Im Unterschied zur Straßenbahn wird an der Börse zum Ein- und Aussteigen nicht geklingelt.
Führend in Alzheimer Forschung! PRANA Biotech. iTechDachs
iTechDachs:

Inhaltlich durchaus kritisch zu sehen

 
05.09.14 15:57
Adam Feuerstein's biotechnology blog, Biotech Beat, features Adam's opinion and analysis on an array of biotech and pharmaceutical stocks and companies.. Prana Biotechnology Ltd(PRAN)
aber wen kümmert es, wenn der Kurs loszieht.
Aber langfristig?

Meine Meinung - KEIN Empfehlung.
Führend in Alzheimer Forschung! PRANA Biotech. else2
else2:

News

 
04.02.15 08:39
Hallo Leute,

gibt es hier zu Prana irgend etwas Neues?

Wenn ja bitte um eine kurze Info

Danke Gruß Else
Führend in Alzheimer Forschung! PRANA Biotech. Balu4u
Balu4u:

Aktuelle Lage

 
02.04.18 00:56
pranabio.com/research-and-development/#.WsFilMubE1I
www.finanznachrichten.de/...-capsules-for-chronic-pain-200.htm
Führend in Alzheimer Forschung! PRANA Biotech. Androlyt
Androlyt:

Bin seit letzter Woche

 
03.04.18 23:16
auch dabei, bei den Kursen kann man zugreifen..
Führend in Alzheimer Forschung! PRANA Biotech. Vassago
Vassago:

PRAN 1,95$ (+52%)

 
02.01.19 16:15
seekingalpha.com/news/...ogy-plus-84-percent-raising-us-31_4m
Führend in Alzheimer Forschung! PRANA Biotech. Vassago

ATHE 1.41$

 

Prana Bio heißt jetzt Alterity Therapeutics

alteritytherapeutics.com/investor-centre/...-of-company-name/

Diese Nachricht lies den Kurs kurzzeitig von 1,10$ auf in der Spitze ~3,60$ ansteigen:

alteritytherapeutics.com/investor-centre/...erative-diseases/


Seite: Übersicht 1 2 3 4 5 6

Hot-Stocks-Forum - Gesamtforum - Antwort einfügen - zum ersten Beitrag springen

Neueste Beiträge aus dem Prana Biotechnology ADR Forum

Wertung Antworten Thema Verfasser letzter Verfasser letzter Beitrag
3 41 Der Alzheimer Thread! geldschneider maurer0229 03.05.23 14:07
2 107 Die schöne PRANA buran buran 25.04.21 01:09
2 149 Führend in Alzheimer Forschung! PRANA Biotech. geldschneider geldschneider 24.04.21 23:59
  18 Prana Technology (NASDAQ) soros dr.soldberg 24.03.11 16:40
    Mögliche Revolution in der Alzheimer-Forschung? Geselle   15.05.03 17:28

--button_text--